Design and construction of synthetic adhesins driving the specific attachment of Escherichia coli to target surfaces, cells, and tumors by Piñero Lambea, Carlos
  
UNIVERSIDAD AUTÓNOMA DE MADRID 
 
Facultad de Ciencias 
Departamento de Biología Molecular 
 
 
 
Design and construction of synthetic adhesins 
driving the specific attachment of Escherichia 
coli to target surfaces, cells, and tumors 
 
 
 
 
Doctoral Thesis 
 
 
 
Carlos Piñero Lambea 
 
Madrid 2014 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Tesis presentada por D. Carlos Piñero Lambea para optar al grado de 
Doctor en Ciencias por la Universidad Autónoma de Madrid. 
 
 
 
 
 
 
 
 
Directores de la Tesis Doctoral: 
 
Dr. Luis Ángel Fernández Herrero, Investigador Científico del Consejo 
Superior de Investigaciones Científicas. 
 
Dr. Gustavo Bodelón González, Investigador contratado del Consejo 
Superior de Investigaciones Científicas. 
 
 
 
 
 
 
 
 
 
 
Este trabajo ha sido realizado en el Departamento de Biotecnología Microbiana del 
Centro Nacional de Biotecnología del Consejo Superior de Investigaciones Científicas 
(CNB-CSIC), gracias a una beca de formación de personal investigador (BES-2009-
024051) y a la financiación de distintos proyectos de investigación recibida del 
Ministerio de Economía y Competitividad (BIO2011-26689), la Comunidad Autónoma 
de Madrid (S2010-BMD-2312) y el European Research Council (ERC-2012-
ADG_20120314).  
  
 
 
  
  
AGRADECIMIENTOS 
 
Hace casi cinco años desde la primera vez que pise el CNB, han sido unos años increíbles que 
me han permitido crecer tanto en el plano personal como en el científico, y sin duda todo eso 
tengo que agradecérselo a la gente que he tenido la oportunidad de conocer estos años, 
porque sin ellos esta tesis no habría sido posible. 
 
En primer lugar, a mi director de tesis, Luis Ángel Fernández, que confió en mi y me dio la 
oportunidad de trabajar en un proyecto increíble que tardó cinco minutos en “venderme”. Eres 
un científico con ideas brillantes, pero sobre todo eres un gran jefe y una mejor persona, 
siempre con una buena cara y una frase con la que animar. Si algo me llevo de ti es el gusto 
por las cosas bien hechas. Te mereces que todo te vaya muy bien. Muchas gracias por todo. 
 
Evidentemente a mi codirector de tesis, Gustavo Bodelón, al que siempre he considerado un 
compañero. Con él di mis primeros pasos en el laboratorio, y por tanto de él he aprendido la 
inmensa mayoría de lo que sé. La Ciencia necesita de gente como tú, con esa capacidad de 
trabajo y sobre todo esa ilusión y ese optimismo. 
 
A mis compañeros antiguos (Ana, Elvira, Carmen) y actuales (David, Vally, Massiel, Carmen 
Bea y Yago), así como a todos los que transitoriamente han pasado por el 241 (Alberto, 
Lorenza, Ari e Isabel). En el 241 los problemas son de todos, y poder solucionarlos entre todos 
es un lujo. Ha sido un placer compartir estos años y poder aprender de cada uno de vosotros, 
no tengo duda de que cuando salgáis del CNB os espera un gran futuro. 
 
A la gente del laboratorio 280 (Álvaro, Juanjo, Diana, Estel), por su ayuda y por siempre 
sonreír ante la enésima petición de una P24. A la gente del antiguo del 211 (Noelia, Coloma, 
Alexandro, Couce, Claudia, Elva, Jasmina), por tener ese ambiente tan propenso a la 
discusión científica. A Paolo y Cris del 217 y Alejandra del 212, por no quedarse en el 
protocolario saludo de pasillo. 
 
A toda la gente que trabaja en el CNB y hace que todo sea mas fácil (Yolanda, Juancar, 
Angelines etc.). No les agradecemos lo suficiente su predisposición a ayudar y su buena cara. 
Mención aparte merecen Sylvia del servicio de Confocal por su infinita ayuda, y Javi de 
Animalario, siempre dispuesto a echar una mano cuando me veía agobiado. 
 
  
A Luis Álvarez Vallina y todo su equipo del Hospital Puerta de Hierro, en especial a Ángel 
Cuesta y Rodrigo Fernández, porque con ellos di mis primeros pasos en experimentos in vivo y 
fueron grandes maestros. 
 
A Jean-Marc Ghigo y Christophe Beloin, que me dieron la oportunidad de visitar durante tres 
meses su laboratorio en el Institut Pasteur, y aprender como funcionan las cosas mas allá del 
CNB. A toda la gente con la que coincidí allí y me hicieron sentir tan cómodo (Chantal, Fanny, 
Chizu, David, Bianca, Fran, Sylvie y Ashwini). A Marta, Joaquín y Jose, que “me adoptaron”, 
me sacaron del bucle residencia-laboratorio y me enseñaron a disfrutar Paris. 
 
Al servicio de Genómica del CNB, la Genopole del Institut Pasteur y al grupo del Dr. José 
Antonio Bengoechea, por su colaboración en algunos de los experimentos de esta tesis. 
 
A todos mis compañero de carrera (Rincho, Hugo, Pablulu, Manolo, Carol, Ainhoa, Paloma, 
Ana, Paula, Pauli, Isa, Maribel, Almu, Gon, Jaime) y alguno más que seguro me olvido, por ser 
gente entrañable a la que veo menos de lo que me gustaría porque se me van muy lejos. Da 
igual donde estemos, en las casas rurales se seguirán creando esas atmosferas de euforia 
colectiva. De este grupo de compañeros han quedado excluidos intencionadamente Djordje y 
Jero. Tener la oportunidad de trabajar a diez metros de dos de tus mejores amigos es algo que 
todo el mundo debería experimentar, no tiene precio y lo recordaré siempre. 
 
A mis amigos no biólogos (Sara, Irene, Ana, Alba, Carmen, Juanan, Miguel Ángel y Adrián), 
por hacerme ver lo entretenido que es mi trabajo cuando uno pierde la perspectiva. 
 
A mis padres, que siempre han confiado en mi y me han dado la libertad de hacer lo que he 
querido, sin vuestro apoyo esta tesis no habría sido posible. Os admiro y me siento muy 
orgulloso de vosotros. A mi hermano, que siempre ha sido un ejemplo que seguir, me has 
enseñado mas cosas de las que puedas imaginar. A Otto, que ha sufrido como el que más los 
días que llegaba de mal humor porque algo no salía. Al resto de mi familia (tíos/tías, 
primos/primas, yaya), por siempre mostrar interés en eso que estaba haciendo aunque no lo 
entendieran muy bien. 
 
Por ultimo, pero no por ello menos importante, a Alicia, porque esta tesis es mitad mía y mitad 
tuya, porque la hemos sufrido los dos. Gracias por estar siempre a mi lado, ya fuera estando 
en Madrid o en Brescia siempre te sentí muy cerca. Por entenderme mejor de lo que yo mismo 
lo hago. En definitiva gracias por ser tu. No sé que nos depara el futuro, pero contigo cerca no 
puede ser nada malo. 
  
  
TABLE OF CONTENTS 
 
LIST OF FIGURES 1 
LIST OF TABLES 3 
ABREVIATTIONS 4 
SUMMARY 7 
RESUMEN 9 
 
INTRODUCTION 13 
1. Bacteria in biomedical applications. 15 
1.1 Bacteria and their interaction with humans. 15 
1.2 The use of bacteria for the benefit of human health. 16 
1.2.1 Probiotics. 16 
1.2.2 Classic vaccines. 17 
1.2.3 Bacteria as agents to fight cancer. 17 
1.3 The use of modified bacteria for the benefit of human health. 18 
1.3.1 Engineered probiotics. 18 
1.3.2 Engineered bacterial vaccines. 19 
1.3.3 Engineered bacteria as agents to fight cancer. 19 
1.3.4 Engineered bacteria-derived nanoparticles to fight cancer. 21 
2. Designed bacteria and synthetic biology. 22 
2.1 Synthetic biology, genetic parts and modules. 22 
2.2 Synthetic biology for biomedical applications. 23 
3. E. coli adhesion. 24 
3.1 E. coli lifestyle transition. 24 
3.1.1 Non-transcriptional changes upon bacterial adhesion. 25 
3.1.2 Transcriptional changes upon bacterial adhesion. 26 
3.2 E. coli main adhesins. 27 
3.2.1 Fimbrial adhesins. 27 
3.2.2 Non-fimbrial adhesins. 29 
3.2.2.1 Intimins. Structure, secretion and properties. 29 
4. Immunoglobulins and their expression and selection in E. coli. 31 
4.1 Structure of antibodies and heavy-chain-only antibodies. 31 
4.2 Recombinant antibodies and their use in therapy. 32 
4.3 Cell surface display of Igs in E. coli. 33 
 
  
OBJECTIVES 35 
Objectives. 37 
Objetivos (en español). 39 
MATERIALS AND METHODS 41 
1. Bacterial strains and growth conditions. 43 
2. E. coli genome modification and strain construction. 43 
3. Plasmids, DNA constructs and oligonucleotides. 48 
4. In vitro cell culture and plasmid transfection. 57 
5. Flow cytometry analyses. 57 
6. Protein extract preparation, SDS-PAGE and Western blots. 57 
7. Adhesion assays to antigens immobilized on a plastic surface. 58 
8. Bacterial adhesion assays to in vitro HeLa or NIH 3T3 derived cells and 
immunofluorescence microscopy. 58 
9. Bacterial adhesion assays to in vitro cultured NIH 3T3 derived cells to screen 
adhesion-dependent promoters. 59 
10. Minicells adhesion assays to in vitro cultured NIH 3T3 derived cells and 
immunofluorescence microscopy. 60 
11. Double staining protocol to distinguish intra- and extracellular bacteria. 60 
12. Infection of tumor-bearing mice and recovery of bacteria from tissues. 61 
13. Bioluminescence imaging. 62 
14. RNA extraction from adhered or non-adhered bacteria. 62 
15. Transcriptomic profiling by RNAseq. 63 
16. Transcriptomic profiling by DNA microarrays. 63 
17. Isolation and analysis of LPS. 64 
18. Minicells purification. 64 
19. Minicells quantification. 65 
20. Transmission electron microscopy. 65 
21. Statistics. 66 
22. Histology. 66 
RESULTS 67 
Chapter 1: Construction of SAs, expression and validation for driving E. coli  
 adhesion to antigenic surfaces. 69 
1.1. SAs structure and expression from inducible plasmids. 69 
1.2. Adhesion of E. coli expressing SAs to antigen-coated plastic surfaces. 71 
1.3. Marker-less integration of gene cassettes expressing SAs and 
bioluminescent lux reporter in the chromosome of E. coli. 71 
1.4. Constitutive expression of SAs. 73 
  
1.5. Viability and growth rate of engineered strains. 73 
1.6. Stable expression of the introduced gene cassettes. 74 
Chapter 2: The use of SAs to drive the adhesion of engineered strains toward 
mammalian cells expressing cell surface antigens and to characterize  
 the adhesion process. 77 
2.1. Generating stable HeLa cell lines with model antigens on their surface. 77 
2.2. In vitro adhesion assays. 78 
2.3. Bioluminescence as reporter of bacterial adhesion. 80 
2.4. Time-lapse live microscopy analysis of bacterial adhesion mediated by SAs. 81 
2.5. Influence of the flagellum on bacterial adhesion. 81 
2.6. Influence of YcgR protein on bacterial adhesion. 84 
Chapter 3: Improved tissue specificity and tumor colonization by engineered E. coli  
 with SAs. 87 
3.1. Tumor model development. 87 
3.2. Systemic administration of 107 CFU. 87 
3.3. Systemic administration of 105 CFU. 90 
3.4. Lower retention of engineered E. coli in non target tissues. 92 
Chapter 4: Development and validation of a SA against tumor cells expressing EGFR,  
 a therapeutically relevant marker. 93 
4.1. Construction of a SA binding EGFR. 93 
4.2. Specific adhesion of the engineered strain to EGFR positive tumor cells. 93 
Chapter 5: Transcriptional response of E. coli upon adhesion mediated by SAs. 95 
5.1. Experimental design. 95 
5.2. Experimental conditions and samples for the transcriptomic analysis. 97 
5.3. Genes upregulated upon adhesion to target mammalian cells. 97 
5.4. Genes downregulated upon adhesion to target mammalian cells. 100 
5.5. Adhesion-dependent promoters. 103 
Chapter 6: SAs to drive the adhesion of minicells. 107 
6.1. Minicells producer strains generation. 107 
6.2. Purification of minicells and expression of SAs on their surface. 108 
6.3. Adhesion of engineered minicells to target tumor cells. 109  
DISCUSSION 111 
CONCLUSIONS 123 
Conclusions. 125 
Conclusiones (en español). 127 
REFERENCES 129 
ANNEXURES 147 
  
 
 
 
 
  1 
LIST OF FIGURES 
 
Figure 1. Roles of microbiota in human health 16 
Figure 2. Engineered bacteria in cancer therapies 21 
Figure 3. Synthetic bacteria for biomedical applications 24 
Figure 4. Intimin secretion 30 
Figure 5. Antibodies and their fragments 33 
Figure 6. Synthetic adhesins structure 70 
Figure 7. Synthetic Adhesins display on the surface of E. coli. 70 
Figure 8. Specific adhesion of E. coli expressing SAs to antigens immobilized on 
plastic surfaces 
 
71 
Figure 9. Site-specific integration of synthetic adhesin gene in the chromosome of 
E. coli 
 
72 
Figure 10. Display levels of SAs in engineered strains 73 
Figure 11. Effect of SAs expression in bacterial viability and growth rate 74 
Figure 12. Stable expression of SAs and lux gene cassettes 75 
Figure 13. HeLa-GFP-tm and HeLa-TirM-tm cells 78 
Figure 14. Adhesion of E. coli expressing SAs to target mammalian cells 79 
Figure 15. Confocal fluorescence microscopy images of engineered strains targeted 
adhesion 
 
80 
Figure 16. Bioluminescence as reporter of bacterial adhesion to target mammalian 
cells 
 
80 
Figure 17. Display levels of SAgfp in EcM1ΔfliSAgfp and EcM1luxSAgfp strains 82 
Figure 18. Adhesion of E. coli strains with or without flagella and expressing SAs to 
target mammalian cells 
 
82 
Figure 19. Quantification of adhered bacteria for flagellated and non flagellated E. 
coli engineered strains expressing SAs 
 
83 
Figure 20. Swimming motility assay 84 
Figure 21. In vivo colonization of tumors with high doses of E. coli expressing SAs 88 
Figure 22. Expression of SAs and bioluminescence in engineered E. coli recovered 
from colonized tumors 
 
89 
Figure 23. Bacterial distribution in solid HeLa-GFP-tm tumors 90 
Figure 24. In vivo colonization of tumors with low doses of E. coli expressing SAs 91 
Figure 25. Low retention of the engineered E. coli strain in non-target organs 92 
Figure 26. Display levels of the SA against EGFR 93 
  2 
Figure 27. Anti-EGFR SAs drive the specific adhesion of engineered E. coli cells to 
EGFR positive cell lines 
 
94 
Figure 28. Bacterial internalization rate at the conditions determined for RNA 
extraction 
 
96 
Figure 29. Functional categories of genes upregulated upon SAs-mediated 
adhesion to target cells 
 
99 
Figure 30. Functional categories of genes downregulated upon SAs-mediated 
adhesion to target cells 
 
102 
Figure 31. Constructions to test adhesion-dependent promoters 104 
Figure 32. Adhesion-dependent promoters 105 
Figure 33. Mass spectrometry analysis of purified lipid A from EcM1Δfli and 
EcM1Δfli ΔmsbB  strains 
 
108 
Figure 34. Purification of minicells displaying SAs on their surface 109 
Figure 35. TEM images of Mini-WT and Mini-SAgfp minicells 109 
Figure 36. Specific adhesion of minicells expressing SAs to target tumor cells 110 
 
 
 
  3 
LIST OF TABLES 
 
Table M1. E. coli strains used in this study 45 
Table M2. Plasmids used in this study 50 
Table M3. Oligonucleotides used in this study 51-53 
Table 1. List of genes upregulated upon adhesion more than two-fold in at least 
one bacterial strain 
 
98 
Table 2. List of genes upregulated upon adhesion common to both, 
EcM1luxSAega and EcM1luxSAgfp strains 
 
100 
Table 3. List of genes downregulated upon adhesion more than two-fold in at 
least one bacterial strain 
 
101 
Table 4.  List of genes downregulated upon adhesion common to both, 
EcM1luxSAega and EcM1luxSAgfp strains 
 
103 
 
  4 
ABBREVIATIONS 
 5 
ABBREVIATIONS 
 
aa amino-acid 
Ab Antibody 
Ap Ampicillin 
APEx Anchored periplasmic expression 
AT Autotransporter 
BAM β-barrel assembly machinery 
BCA Bicinchoninic acid 
BDEPT Bacterial-directed enzyme prodrug therapy 
bp base pair 
CD Cytosine deaminase 
CDR Complementarity determining region 
CH Constant domain of the heavy chain of an immunoglobulin 
CL Constant domain of the light chain of an immunoglobulin 
Cm Chloramphenicol 
DAPI 4’,6-diamidino-2-fenindol 
DEPC Diethylpyrocarbonate 
DMEM Dulbecco´s modified Eagle´s medium 
DNA Deoxyribonucleic acid 
DNAse DNA ribonuclease 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
EHEC Enterohaemorrhagic Escherichia coli 
ELISA Enzyme-linked immunosorbent assay 
EPEC Enteropathogenic Escherichia coli 
FACS Fluorescence activated cell sorting 
FBS Fetal bovine serum 
Fc Crystallizable constant fragment of Ab 
Fib Human Fibrinogen 
Fv Variable fragment of an Ab 
GFP Green fluorescent protein 
h hour 
HCAb Heavy chain only Ab 
Ig Immunoglobulin 
ABBREVIATIONS 
 6 
IM Inner membrane 
IPTG Isopropylthio-β-D-galactoside 
kDa kiloDalton 
Km Kanamycin 
LB Luria-Bertani medium 
LPS Lipopolysaccharide 
mAb Monoclonal Ab 
mRNA messenger RNA 
µg microgram 
µ l microliter 
µm micrometer 
µM micromolar 
mg milligram 
ml milliliter 
mm millimeter 
mM millimolar 
min minute 
MOI Multiplicity of infection 
nm nanometer 
OD600 Optical density at 600nm 
OMV Outer membrane vesicle 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PG Peptidoglycan 
POD Peroxidase 
RBS Ribosome binding site 
RNA Ribonucleic acid 
RNAse RNA ribonuclease 
rpm revolutions per minute 
rRNA ribosomal RNA 
SA Synthetic adhesin 
scFv single chain fragment variable 
sdAb single domain antibody 
SDS Sodium dodecyl sulphate 
ABBREVIATIONS 
 7 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
T5SS Type V secretion system 
TE Tris-EDTA 
TEM Transmission electron microscopy 
Tir Translocated intimin receptor 
TirM Extracellular domain of Tir 
TK Thymidine kinase 
tm transmembrane 
TNF Tumor necrosis factor 
TRAIL Tumor necrosis factor-related apoptosis-inducing ligand 
tRNA transfer RNA 
VH Variable domain of the heavy chain of an Ig 
VHH Variable domain of the heavy chain of a HCAb, also termed Nanobody 
VL Variable domain of the light chain of an Ig 
WT Wild type 
 
 
 
 
 
 
 
  8 
SUMMARY 
 9 
SUMMARY 
 
One of the aims of genetic engineering and synthetic biology is the design of microorganisms 
with novel capabilities that could be beneficial for humans, including their use of vaccines, 
diagnostic sensors, and therapeutic applications for major diseases such as cancer. In this 
regard, the availability of genetic elements able to program the adhesion of the engineered 
bacterium to different targets would be extremely useful. 
This work reports the development of synthetic adhesins (SAs) that enable to precisely 
program the adhesion properties of Escherichia coli bacteria to different target surfaces, 
including tumor cells. The structural organization of these novel SAs is defined by a domain 
that anchors the SA to the bacterial outer membrane, which is derived from the N-terminal 
fragment of Intimin comprising residues 1-659, and an adhesive domain based on the smallest 
antibody fragments known to date, termed VHHs. This modular organization allows the 
modification of the binding specificity of the SA by the exchange of the VHH sequence. We 
demonstrate that SAs are efficiently displayed on the surface of E. coli and are able to drive 
bacterial adhesion to antigen-coated abiotic surfaces and to target tumor cells expressing on 
their surface the antigen recognized by SAs. SAs are constitutively and stably expressing from 
the chromosome of an engineered E. coli strain lacking a conserved set of natural adhesins (i.e. 
type 1 fimbriae, Antigen 43 and mat fimbriae) and constitutively expressing the lux operon as 
bioluminescent reporter. Using tumor xenograft mouse models we have demonstrated that 
engineered E. coli strains carrying SAs colonize efficiently solid tumors expressing the cognate 
antigen recognized by the SA using two order of magnitude lower doses of systemically 
administered bacteria compared to control strains with SAs binding an unrelated antigen or the 
wild type E. coli strain. In addition, we observed that the engineered strains were cleared faster 
from non-target organs (e.g. liver and spleen) probably due to the deletion of natural adhesins. 
The fast and specific adhesion mediated by SAs was also employed to characterize the 
influence of both, flagella and YcgR protein in the adhesion process, as well as to investigate 
the short-term transcriptional response of E. coli upon adhesion to tumor cells. Our results 
indicate that, whereas active bacterial motility mediated by flagella is important for an efficient 
adhesion to target cells, the lack of YcgR protein does not affect the ability of bacteria to adhere 
to target cells, suggesting that the arrest of bacterial motility upon adhesion is independent of 
YcgR protein. In addition, we analyzed by RNAseq the global transcriptional response of E. coli 
bacteria upon adhesion (15 min) to target tumor cells. Our results indicate a common 
transcriptional response upon adhesion regardless of the cellular receptor recognized. Genes 
involved in sulfur uptake and its metabolism were upregulated upon adhesion, whereas genes 
involved in the transport of intermediates of the tricarboxylic acid cycle and tryptophan 
SUMMARY 
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synthesis were downregulated. We found that the activity of gene fusions between the 
chromosomal yeeE promoter region and the mCherry reporter gene were upregulated in 
response to bacterial adhesion.  
Lastly, we have also demonstrated that SAs can drive the specific adhesion of non-live 
bacterial derived nanoparticles toward target tumor cells expressing a therapeutically relevant 
cell surface receptor (i.e. EGFR).  
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RESUMEN 
 
Uno de los objetivos de la ingeniería genética y de la biología sintética es la creación de 
microorganismos con capacidades no existentes en la naturaleza para su posible aplicación en 
el desarrollo de vacunas, biosensores o en terapias frente a determinadas enfermedades como 
el cáncer. En este contexto, sería extremadamente valiosa la disponibilidad de un sistema que 
permitiese programar la adhesión de bacterias genéticamente modificadas hacia distintas 
dianas con el fin de poder localizar la acción terapéutica de estos microorganismos en un 
determinado punto. Para ello, en esta tesis nos propusimos generar adhesinas sintéticas (SAs 
en sus siglas en inglés) que permitiesen dirigir la adhesión de Escherichia coli (E. coli) hacia 
cualquier superficie o célula deseada. Las SAs tienen una organización estructural inspirada 
en la encontrada en muchas adhesinas naturales de E. coli, consistente en un dominio de 
anclaje a la membrana externa y un dominio adhesivo expuesto en la superficie de la bacteria 
con estructura tipo inmunoglobulina (Ig). Como dominio de anclaje seleccionamos la región N-
terminal de la Intimina (residuos 1-659), una adhesina natural que se encuentra en las cepas 
enterohemorrágicas y enteropatógenas de E. coli (EPEC y EHEC, respectivamente) y que se 
inserta en la membrana externa bacteriana a través de una región plegada como un barril β 
muy estable a la desnaturalización y a la acción de proteasas. Como dominio adhesivo 
seleccionamos los fragmentos de anticuerpo más pequeños conocidos hasta la fecha, 
denominados VHHs o nanobodies (12-14 kDa), que presentan afinidades por sus antígeno 
similares a la de los anticuerpos convencionales y, además, tienen buenas propiedades de 
solubilidad, estabilidad a la desnaturalización y resistencia a proteasas. Los VHHs o 
nanobodies están basados en los únicos dominio variables encontrados en unos anticuerpos 
que sólo contienen cadena pesada encontrados en especies pertenecientes a la familia 
Camelidae (dromedarios, camellos, llamas, alpacas, guanacos y vicuñas). Esta organización 
modular de las SAs permite modificar su especificidad mediante un simple cambio del dominio 
adhesivo que, al estar basado en fragmentos recombinantes VHH, puede dirigirse frente a una 
gran variedad de antígenos seleccionando un clon de VHH con la especificidad deseada desde 
repertorios clonados en E. coli y sus fagos. 
 
La fácil modificación de la especificidad de las SAs queda evidenciada en esta tesis mediante 
el desarrollo de SAs que reconocen cuatro antígenos distintos: La proteína verde fluorescente 
(GFP en sus siglas en inglés) de Aequorea victoria, el Fibrinógeno humano, la región 
extracelular del receptor translocado de Intimina (TirM en sus siglas en inglés) y el domino 
extracelular del receptor para el factor de crecimiento epidérmico humano (EGFR en sus siglas 
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en inglés). Hemos demostrado que las SAs se expresan de manera efectiva en la superficie de 
E. coli y que su expresión permite dirigir la adhesión bacteriana de manera específica hacia 
superficies recubiertas de antígeno (GFP y Fibrinógeno). Una vez evidenciado el potencial de 
las SAs para dirigir la adhesión de E. coli, se empleó un sistema de modificación genética que 
nos permitió reemplazar adhesinas naturales de E. coli por SAs o sistemas de biodetección 
(operón lux), en un solo paso. Esta estrategia hizo posible, no sólo crear cepa bacterianas que 
carecen de un grupo de adhesinas naturales conservadas (fimbrias tipo 1, Antigeno 43 y 
Fimbrias Mat), si no también obtener una expresión constitutiva y no tóxica de los genes de 
interés (SAs y operón lux) que permite su expresión estable durante múltiples generaciones (al 
menos 55) sin necesidad de inductores o antibióticos que ejerzan una presión selectiva. 
Estas cepas modificadas fueron utilizadas para demostrar la eficacia de las SAs en el control 
de la adhesión bacteriana a células tumorales que expresan en su superficie un antígeno (p.ej. 
GFP, TirM o EGFR) que es reconocido por las SAs. La  gran especificidad y efectividad 
observada en los ensayos de adhesión in vitro de estas cepas sobre células tumorales nos 
llevo a investigar la utilidad de las SAs en experimentos de colonización de tumores in vivo, 
dado que la colonización de tumores por bacterias es una de las terapias bacterianas que más 
se está desarrollando en los últimos años. Los resultados de nuestros experimentos con 
ratones con tumores implantados, demuestran que la cepa modificada de E. coli coloniza con 
mayor eficacia tumores sólidos que expresan en la superficie de sus células el antígeno 
reconocido por las SAs de modo más eficiente que las cepas control (cepa sin modificar, y 
cepa que expresa SAs frente a un antígeno no relacionado). Esta mayor eficacia en la 
colonización de tumores permite una reducción significativa (alrededor de dos órdenes de 
magnitud) en la dosis de bacterias necesarias para conseguir la colonización in vivo de los 
tumores sólidos. Además, probablemente debido a la deleción de las adhesinas naturales 
(fimbrias tipo 1, Antígeno 43 y fimbrias Mat), observamos que las cepas modificas de E. coli se 
acumulan en menor medida y por menos tiempo en órganos que no son diana, como el hígado 
o el bazo. Por tanto, en esta tesis se demuestra la utilidad de las SAs en terapias bacterianas 
destinadas al tratamiento de tumores. 
 
La adhesión de E. coli con SAs a las células diana se utilizó para caracterizar la influencia del 
flagelo en el proceso de adhesión bacteriano, así como para investigar la respuesta 
transcripcional que tiene lugar en E. coli inmediatamente después de su adhesión a una célula 
tumoral. Nuestros datos sugieren que, al menos in vitro, la motilidad bacteriana mediada por el 
flagelo es necesaria para obtener una adhesión rápida y eficaz, dado que el número de 
bacterias adheridas a células tumorales a distintos tiempos fue siempre mucho mayor (unas 30 
veces para un tiempo de adhesión de 15 minutos) en el caso de las cepas que expresaba un 
flagelo funcional que en el caso de la cepa que carecía de dos componentes principales del 
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filamento del flagelo (FliC y FliD). Además, estudiamos si la proteína YcgR, que se ha 
propuesto que está implicada en la inhibición de la motilidad bacteriana tras la adhesión a 
superficies, jugaba algún papel en una parada de la motilidad que observábamos en las 
bacterias E. coli con SAs adheridas a sus células diana. Nuestros resultados indican que la 
ausencia de la proteína YcgR no afecta a la capacidad de las bacterias para adherirse a las 
células diana, lo que sugiere que la inhibición de la motilidad bacteriana observada en nuestros 
experimentos es independiente de la acción de YcgR, y que por tanto otros mecanismos 
adicionales deben estar controlando esta transición. 
 
En esta tesis también se ha estudiado la respuesta transcripcional desarrollada por E. coli 
inmediatamente después (15 min) de su adhesión a células tumorales. Estudios anteriores se 
centraban en la adaptación transcripcional llevada a cabo por E. coli tras su adhesión durante 
varias horas o incluso días sobre superficies abióticas durante el proceso de formación de 
biopelículas bacterianas. El rápido fenotipo de adhesión conferido por la expresión de SAs y la 
posibilidad de programarlas frente a antígenos presentes en la superficie de células tumorales 
permitieron, por primera vez, estudiar la respuesta transcripcional llevada a cabo por E. coli 
tras su adhesión a células tumorales y a un tiempo post-adhesión muy corto, nunca estudiado. 
La adaptación transcripcional de E. coli tras la adhesión fue analizada mediante secuenciación 
masiva de RNA (RNAseq) en dos modelos experimentales distintos que implicaban adhesión a 
células tumorales que expresan en su superficie dos marcadores diferentes (EGFR y GFP). 
Nuestros resultados indican que E. coli genera una respuesta transcripcional similar, 
independientemente del receptor reconocido. Entre los genes de E. coli cuya expresión se ve 
incrementada en respuesta a la adhesión encontramos fundamentalmente genes implicados 
en la captación de azufre y su asimilación en forma de aminoácidos (cysD, cysP, yeeE). Por 
otra parte,  encontramos una disminución en la tasa de transcripción de genes relacionados 
con el transporte de carbohidratos (rbsA, ugpE), aminoácidos (mtr) e intermediarios del ciclo 
de Krebs (dctA). Además, los resultados obtenidos por RNAseq fueron confirmados mediante 
una técnica distinta (DNA microarrays). 
 
El hallazgo de que la expresión de ciertos genes de E. coli se ve incrementada en respuesta a 
la adhesión a células tumorales, nos motivó a intentar generar un sistema genético que nos 
permitiese acoplar un estimulo (adhesión) a una respuesta (producción de una proteína con 
fines terapéuticos o de biodetección). Para ello, basándonos en la cepa que expresa SAs 
contra EGFR, se construyeron cepas en las que el gen de la proteína roja fluorescente 
mCherry estaba integrado en el cromosoma bajo control de distintos promotores cuya 
expresión se veía incrementada en respuesta a la adhesión. El resultado de estos 
experimentos reveló que el promotor del gen yeeE actúa como un promotor sensible a la 
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adhesión, incrementando la expresión de mCherry que está bajo su control en bacterias 
adheridas a la célula diana. 
 
Por último, en esta tesis también se ha demostrado la utilidad de las SAs para dirigir la 
adhesión de nanopartículas no vivas (minicélulas) derivadas de E. coli, hacia células tumorales 
que expresan un marcador de relevancia terapéutica, como es EGFR. Además, las minicélulas 
generadas en este trabajo carecen de algunas de las estructuras bacterianas con mayor 
capacidad inmunogénica, como las fimbrias tipo 1, el flagelo y el lípido A hexa-acilado. Estas 
modificaciones adicionales podrían aumentar la bioseguridad de terapias basadas en 
minicélulas cargadas con moléculas terapeúticas.  
 
Por tanto en esta tesis se demuestra el potencial de las SAs para controlar la adhesión de E. 
coli y mejorar de este modo su eficacia para colonizar in vivo tumores sólidos, en cualquier 
caso esta tecnología podría ser muy útil en otras aplicaciones biomédicas como el desarrollo 
de vacunas o la intervención frente a patógenos o incluso en aplicaciones de carácter industrial 
como el desarrollo de biosensores o consorcios microbianos para su uso en biorreactores. 
Además, dado el alto grado de conservación de la maquinaria celular empleada para el 
plegamiento y translocación a la membrana externa de los barriles β como el presente en 
Intimina, es probable que las SAs sean también funcionales en otras bacterias Gram negativas 
ampliamente utilizadas en proyectos de bilogía sintética como por ejemplo Pseudomas putida. 
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1 Bacteria in biomedical applications. 
 
1.1 Bacteria and their interaction with humans. 
 
Some bacterial species are frequently found associated with other living forms such as plants 
or animals. In humans this association is generally considered as detrimental since is 
responsible of bacterial infections such as tuberculosis, cholera or foodborne illness. However, 
most of the interactions between bacteria and human cells do not lead to pathogenic situations. 
Indeed, the human body is colonized by a huge amount of microbes that outnumber human 
cells 10 to 1. This microbial population, mainly conformed by bacteria, is termed microbiota 
and is extensively distributed through the skin and the mucosal surfaces of the human body, 
although it is especially abundant in the gut. Benefits of include harvesting of otherwise 
inaccessible nutrients for the host, competition with pathogens for the colonization of different 
environments and contribution to the proper development of a fully functional immune system 
(Martin et al., 2013) (Fig. 1). Moreover, microbiota has also been proposed as an important 
factor in brain development and behavior (Diaz Heijtz et al., 2011). The impact of microbiota in 
many physiological processes is understood thanks to the study of axenic (germ-free) animals, 
which face many health disorders (Smith et al., 2007).  
Human microbiota is an inherently dynamic population that changes along life (Gerber, 2014). 
Indeed, humans are essentially born germ-free but normally acquire a complex intestinal 
microbiota soon after birth, in a process termed colonization in which bacterial adhesion plays a 
key role. After colonization and along life, microbiota composition changes in response to 
several factors such as diet, age, environment, antibiotic treatments etc (Claesson et al., 2012). 
Sometimes these changes could break the balanced microbial ecosystem leading to a situation 
termed dysbiosis involved in a great variety of different illness. For instance, opportunistic 
pathogens could take advantage of a dysbiosis situation to colonize the gut. Additionally, 
metagenomic studies suggest that diseases like obesity or type 2 diabetes could be influenced 
by prolonged dysbiosis situations (Qin et al., 2012; Turnbaugh et al., 2009). Nevertheless, the 
clearest correlation between dysbiosis and disease has been found in inflammatory bowel 
diseases (IBD), in which the chronic inflammation of the digestive system seems to be related 
with a decreased number of Faecalibacterium prausnitzii bacteria inhabiting the gastrointestinal 
tract (Sokol et al., 2008).  
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Figure 1. Roles of microbiota in human health. Scheme of the different actions that normal microbiota 
inhabiting human gastrointestinal tract carry out. Microbiota is able to harvest otherwise inaccessible 
nutrients for human cells (blue), as well as to induce the secretion of antimicrobial peptides or 
immunoglobulins (green) that contribute to maintain a balanced microbial population in the gut. 
Additionally microbiota mediates pathogen exclusion (purple) by competing either for nutrients or for cell 
receptors. 
 
1.2 The use of bacteria for the benefit of human health. 
 
Beneficial relationships between bacteria and humans do not end with natural microbiota, since 
our current knowledge allows us to actively use bacteria for our benefit. 
 
1.2.1 Probiotics. 
Probiotics are live microorganisms that, when administered in adequate amounts, confer a 
health benefit on the host (World Health Organization definition). Most probiotic strains that are 
currently in use belong to Lactobacillus and Bifidobacterium genera, although some strains of 
Escherichia coli are also being employed (Aureli et al., 2011). 
Probiotics are commonly used to fight or to prevent the great variety of illness that could take 
place because of a dysbiosis state, restoring a balanced bacteria ecosystem either, by 
modulation of the host immunity, and/or by competing against pathogens. For instance, the 
administration of probiotic strain Lactobacillus rhamnosus GG (LGG) alleviate clinical 
symptoms of IBD and atopic dermatitis by enhancing the production of the anti-inflammatory 
cytokine IL-10 (Pessi et al., 2000), while E. coli Nissle 1917 (EcN) strain has been used for IBD 
treatment given its immunomodulatory role (Schultz, 2008), as well as in the prevention of 
traveller’s diarrhea because of its ability to compete for nutrients with enterohaemorrhagic E. 
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coli (EHEC) strains in the gut (Maltby et al., 2013). Thus, probiotics are intended to complement 
the functions that microbiota carry out at the intestine (Fig. 1). 
Recently it has been developed a therapy against recurrent urinary tract infections based on a 
probiotic E. coli strain termed ABU 83972, which was isolated from a patient of asymptomatic 
bacteriuria (Lindberg et al., 1975). Patients that suffer recurrent urinary tract infections are 
intentionally infected with E. coli ABU 83972, to protect against the infection of other bacteria 
that could lead to a pathogenic situation in the urinary tract (Sunden et al., 2006). 
Fecal bacteriotherapies have also attracted the attention of scientific community. These 
therapies involve transplantation of fecal bacteria from healthy individual into a recipient and 
have produced good results combating infections caused by hypervirulent and hyperresistant 
Clostridium difficile strains (van Nood et al., 2013). Additionally, IBD (Anderson et al., 2012) or 
even neurological diseases as multiple sclerosis (Borody and Khoruts, 2012) are susceptible of 
being treated with fecal transplantation therapies. 
 
1.2.2 Classic Vaccines. 
With the development of vaccines, humans understood how to use bacteria to overcome 
bacterial infections. 
Vaccines are based on the intentionally administration of a microorganism or purified subunit(s) 
unable to cause disease but that still retains the antigenic potential needed for inducing a 
protective immune response. Classically, vaccines against bacterial pathogens has been made 
from a chemically or heat-inactivated bacteria, such as the vaccine against Bacillus anthracis, 
the first vaccine against a bacterial infection conceived by Pasteur in 1881, or from a live 
bacteria that naturally does not infect humans but it is related with an human pathogen such as 
BCG vaccine against Mycobacterium tuberculosis.  
 
1.2.3 Bacteria as agents to fight cancer. 
Bacteria also have been used as agents to destroy solid tumors. At the end of XIX century, 
physicians W. Busch and W. Coley reported spontaneous tumor remissions associated with 
erysipelas, upper dermis acute infections caused by Streptococcus pyogenes. Prompted by 
these remissions, Coley started to systematically treat bone and soft tissue sarcoma patients, 
with live Streptococcus pyogenes bacteria first, and with isolated preparations of bacterial 
toxins later (Coley, 1910). However, the variability in clinical outcomes of Coley’s treatment, 
ranging from complete tumor remission to death, reduced clinical attention to his findings. At 
that time, the mechanisms by which bacteria preferentially grow in tumor areas were not 
understood, but currently we have a deeper understanding about why anaerobic bacteria, such 
as Salmonella enterica, E. coli or Clostridium target tumors. It has been proposed that the 
chaotic and leaky newly formed vasculature in tumor areas could enhance bacterial entry into 
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solid tumors, in a phenomenon termed enhanced permeation and retention effect (Forbes et al., 
2003; Maeda, 2013). Additionally, a chemotaxis towards compounds produced by tumors has 
been demonstrated in vitro (Kasinskas and Forbes, 2006). Lastly, the anoxic and immune-
deficient microenvironment present in the tumor favors bacterial replication unimpeded by the 
macrophage and neutrophil clearance mechanisms that normally serve to eliminate them in 
normal organs (Westphal et al., 2008). 
A recent study involving systemic administration of wild type E. coli K-12 strain to tumor-bearing 
mice demonstrated that this strain was not only able to efficiently colonize tumors, but also to 
significantly alter the tumor microenvironment, leading to an increase in the amount of necrotic 
tissue, a change in the expression profile of tumor cells, and even a strong reduction of 
pulmonary metastasic events (Weibel et al., 2008). !
1.3 The use of modified bacteria for the benefit of human health. 
 
Since the development of genetic engineering, researchers have pursued the goal of modifying 
organisms to obtain products of biomedical interest from them, such as the production in E. coli 
of human insulin (Goeddel et al., 1979), followed by the production of interleukins (Taniguchi et 
al., 1983) and antibodies (Cabilly et al., 1984). Alternatively, scientists have also tried to obtain, 
instead of a product, novel beneficial functions from the whole microorganism. 
 
1.3.1 Engineered probiotics. 
Engineered probiotics provide the possibility for in situ delivery on immunomodulatory agents. 
For instance, Lactococcus lactis bacteria have been engineered to in situ secrete IL-10, an 
interleukin that plays a critical role in regulation of the mucosal immune system by preventing 
excessive inflammatory responses toward normal intestinal bacteria. The engineered strain, 
tested in a phase I clinical trial, demonstrated a reduction in Crohn’s disease (a kind of IBD) 
activity mediated by an induction of suppressor Th cells (Braat et al., 2006; Huibregtse et al., 
2012). 
Antibody-derived fragments against TNF-α have been also used as therapeutic molecules 
delivered in situ by L. lactis, achieving a reduction in the inflammation rate of mice suffering 
from induced chronic colitis (Vandenbroucke et al., 2010). In addition to L. lactis, E. coli has 
also been used to in situ secrete immunomodulatory components, such as alpha-defensin 5, or 
beta-defensin 2, antimicrobial peptides whose expression is limited in Crohn’s disease patients 
(Seo et al., 2012). 
Probiotics can be also armed in order to compete with pathogens, for instance Lactobacillus 
jensenii, a microorganism that is part of the normal human vagina flora, has been engineered to 
stably express cyanovirin-N, a cyanobacterial protein with antiviral activity against HIV. Notably, 
the strain tested in rhesus macaques showed that animals challenged with simian HIV showed 
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a 63% reduction in HIV infection rate (Lagenaur et al., 2011). Engineered strain derived from 
EcN also has been used to fight against Vibrio cholera, by interfering with Quorum Sensing 
signaling mechanisms of the pathogen (Duan and March, 2010). Lastly, an engineered E. coli 
strain, with a modified LPS structure that mimics the receptor of Shiga toxin, has been 
demonstrated as 100% effective to protect mice against an otherwise fatal dose of Shiga-toxin 
(Stx)-producing E. coli strains (Paton et al., 2000). 
 
1.3.2 Engineered bacterial vaccines. 
With the development of modern molecular biology, the way in which vaccines were generated 
changed dramatically. Currently, most of the vaccines that are in use are toxoid or conjugated 
vaccines. Toxoid vaccines involve the administration of genetically detoxified toxins that 
maintain immunogenic protein structure but have lost enzymatic activity, such as the detoxified 
pertussis toxin employed in vaccination against whooping cough caused by Bordetella 
pertussis (Pizza et al., 1989). 
Conjugated vaccines are intended to create immunity against bacterial components that do not 
elicit a strong immune response. To do that, bacterial antigens that would not generate an 
immune response are coupled to a carrier protein known by its ability to stimulate the immune 
system (i.e. non-active mutant version of diphtheria toxin). An example of this approach is the 
vaccine against Haemophilus influenzae type b (Kelly et al., 2004).  
There are other experimental vaccination approaches involving living bacteria as vaccination 
agents, such as bacteria that secrete antigens from harmful pathogens (Hess et al., 1996; 
Tzschaschel et al., 1996), bacteria that display on their surface antigens from pathogens (Lee 
et al., 2006) or bacteria that deliver antigen expression vectors into the cytosol of mammalian 
cells (DNA vaccines). Lastly, vaccination strategies involving bacteria-derived vehicles 
(described below) such as, bacterial ghosts (Paukner et al., 2005), minicells (Carleton et al., 
2013) and outer membrane vesicles (OMVs) (Ellis and Kuehn, 2010) have been also 
developed. 
 
1.3.3 Engineered bacteria as agents to fight against cancer. 
The development of genetic engineering also allowed researches to improve bacteria as 
vehicles for anti-cancer therapy. 
One approach has been the generation of gene deletion mutants with improved tumor targeting 
properties. For instance, Salmonella enterica serovar Typhimurium is an interesting vector for 
cancer-therapy since grow under either aerobic or anaerobic conditions, as those that take 
place within solid tumors and it is able to invade and survive within in epithelial and immune 
cells (Pawelek et al., 1997). However, its use is associated with undesired side effects given its 
pathogenic potential. Therefore, mutations on purI and msbB genes involved in biosynthesis of 
INTRODUCTION 
 22 
purines and LPS respectively, were carried out. The resulting strain, termed VNP-20009, 
showed an increased specificity for tumor areas, as a result of its purines synthesis auxotrophy 
and lower toxicity since its pentacylated lipid A of LPS is less immunogenic. VNP-20009 has 
become the reference strain for tumor targeting with Salmonella, and it has been tested in 
clinical trials with modest results (Toso et al., 2002). 
In order to confer new capabilities to bacteria targeting tumors, the expression of heterologous 
genes has been also widely studied (Fig. 2). For instance, bacterial bioluminescent systems 
from different light emitting bacteria have been expressed in tumor targeting-bacteria, providing 
a system to follow bacterial infections in real time by light emission (Min et al., 2008). To 
improve tumor destruction rates, tumor targeting bacteria have been equipped with genes 
encoding for bacterial toxins, such as cytolysin A (Jiang et al., 2010) or genes encoding for pro-
drug converting enzymes like herpes simplex virus thymidine kinase (TK) (Pawelek et al., 1997) 
or E. coli cytosine deaminase (CD) (King et al., 2002), able to convert a non-toxic compound or 
prodrug (i.e. ganciclovir, 5-Fluorocytosine) in a toxic compound or drug (i.e. ganciclovir 
monophosphate, 5-Fluorouracil), resulting in a bacterial-directed enzyme prodrug therapy 
(BDEPT) (Lehouritis et al., 2013) localized in tumor areas. 
Additionally, tumor-targeting bacteria have been engineered to induce apoptosis in tumor cells, 
by secreting tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (Ganai et al., 
2009) and Fas ligand (Loeffler et al., 2008), or to induce an immune response against tumor 
cells by secreting cytokines such as LIGHT, a human TNF-family cytokine known to promote 
tumor rejection (Loeffler et al., 2007). Genetic transfer to tumor cells of genes encoding for 
cytotoxic agents (Fu et al., 2008) anti-angiogenic factors (Lee et al., 2004) or cytokines (Yuhua 
et al., 2001) has been also addressed with tumor-targeting bacteria. Additionally, genetic 
transfer mediated by bacteria has also been employed to silence the expression of genes 
important for tumor development, by a mechanism known as RNA interference (Hannon, 2002). 
One of the approaches involves the transfer to host cells of plasmids encoding for short hairpin 
RNAs (shRNAs). Salmonella has been employed as a vector to transfer plasmids encoding 
shRNAs toward tumor cells to silence the expression of the anti-apoptotic host gene bcl2 (Yang 
et al., 2008), while E. coli has been used to silence the expression of host gene encoding for 
catenin β-1, whose overexpression is involved in several types of cancer (Xiang et al., 2006). 
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Figure 2. Engineered bacteria in cancer therapies. Scheme showing some approaches to improve 
bacteria as agents in cancer therapies. Bacterial accumulation inside tumors is mediated by the leaky 
vasculature of blood vessels found in tumors (red marks in the blood vessel) The scheme includes 
expression of reporter genes to follow infection in real time, generally by light emission (yellow wavy 
lines), localized secretion of bacterial toxins (green dots), Bacterial-directed enzyme prodrug therapy 
(BDEPT) that allows site-specific conversion of prodrugs (yellow molecule) into drugs (red molecule), 
localized secretion of cytokines (orange dots) to stimulate immune cells (grey cells), intracellular 
secretion of pro-apoptotic molecules (blue stars) and release of expression vectors (purple circles) 
coding for different genes or shRNAs. 
 
1.3.4 Engineered bacteria-derived nanoparticles to fight cancer. 
During the last decade, cancer therapies involving chemically-synthesized nanoparticles, have 
attracted the attention of scientists (Malam et al., 2009). These nanosized vehicles are able to 
deeper penetrate in tissues and mediate a controlled drug delivery. Nanocarries obtained from 
biological sources, incluiding bacteria have also been tested for the targeted release of 
therapeutic agents. For instance, minicells (also called nanocells) are bacteria-derived 
anucleate nanoparticles (400 nm), produced as a result of mutations in cell division genes 
(Adler et al., 1967), such as for instance minCD genes.  The products of minCD together with 
minE, whose deletion results lethal for E. coli, form the MinCDE system that inhibits the 
formation of division septum away from midcell (Lutkenhaus, 2007). Minicells produced by 
Salmonella typhimurium ΔminCD strain, have been purified and subsequently loaded in vitro 
with chemotherapeutics (MacDiarmid et al., 2007b), cell cycle inhibitors (MacDiarmid et al., 
2007a) and sh-RNAs encoding plasmids (MacDiarmid et al., 2009). To ensure the specific 
delivery of these compounds to tumor cells, drug-loaded minicells were incubated with 
bispecific monoclonal antibody (Mazor et al.) dimers, in which one mAb recognize a component 
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on the minicell surface (e.g. LPS) and the other a cell surface receptor for the targeted tumor 
cell (e.g. EGFR). 
OMVs are nanosized (20-250 nm) bilayered proteoliposomes that are continuously released 
from the surface of many Gram-negative bacteria, influencing multiple biological processes 
such as secretion, nutrient acquisition or biofilm development (Kulp and Kuehn, 2010). 
Recently, OMVs have been engineered to target tumor cells and specifically deliver small 
interfering RNA (siRNA) against kinesine spindle protein, a microtubule-associated protein 
whose inhibition causes cell cycle arrest (Gujrati et al., 2014). Selective delivery of siRNA was 
achieved by the display on the surface of E. coli bacteria and their derived OMVs of a fusion 
protein, composed of the C-terminal domain of ClyA protein and an engineered version of 
Staphylococcus aureus protein A (i.e. affibody) that binds HER2, a human cell transmembrane 
receptor of the EGFR family with an important role in cell proliferation (Gutierrez and Schiff, 
2011). 
 
2 Designed bacteria and synthetic biology. 
 
2.1 Synthetic biology, genetic parts and modules. 
 
During the last years the idea of using a rational design to generate completely new 
microorganisms for specific applications, rather than modifying pre-existing ones, has gained 
pace promoted by the rise of synthetic biology. Synthetic biology is an emergent area of 
research that aims to design and produce biological components or systems that do not already 
exist in the natural world, or to redesign the previously existing natural biological systems 
(http://syntheticbiology.org).  
These ideas are supported by recent reports on the creation, by chemical synthesis, of whole 
bacterial chromosome (Gibson et al., 2008), and the successful transfer of this synthetic 
chromosome to a receptive cytoplasm (Gibson et al., 2010). Notably, similar technology 
allowed the creation of a synthetic chromosome from Saccharomyces cerevisiae (Annaluru et 
al., 2014). Paradoxically, success in synthetizing synthetic chromosomes has highlight our 
inability to de novo design a genome, meaning that although writing a new genome is the long-
term objective of synthetic biology, our current limited knowledge, just allow us to copy and edit 
an existing genome (Porcar et al., 2011). 
However, what synthetic biology is currently doing is to create genetic parts and modules that 
could be ideally assembled in a de novo synthesized genome in the future. An example of this 
way of thinking the Registry of Standard Biological Parts (http://parts.igem.org/Catalog), a 
standardized collection of biological parts such as promoters, ribosome binding sites (RBS), 
transcriptional terminators etc. designed to have a modular architecture, allowing easy 
INTRODUCTION 
 25 
combination of the biological parts. Moreover, ideally these biological parts should be selected 
from repertoires that would cover all the functionality landscape, to in that way allow a fine-
tuning of gene expression. To this end, libraries of promoters (Blount et al., 2012), RBS 
sequences (Egbert and Klavins, 2012) and transcriptional terminators (Chen et al., 2013) of 
variable strengths have been constructed. Combination of genetic parts leads to the generation 
of genetic modules or devices with predictable behaviors. 
 
2.2 Synthetic biology for biomedical applications. 
 
One of the aims of synthetic biology is the rational design of microorganisms for biomedical 
applications (Hasty, 2012) (Fig. 3). This requires the availability of genetic modules with 
predictable phenotype that could be integrated into complex cellular assemblies, without 
perturbing or being perturbed by other cellular functions (i.e. orthogonal behavior in synthetic 
biology jargon). These modules should also be stably inherited through cell generations (Porcar 
et al., 2011). Some useful modules have already been designed. For instance, it is possible to 
reprogram E. coli chemotaxis toward areas in which a pathogen such as Pseudomonas 
aeruginosa is present and induce the secretion of microcine S and DNaseI, for pathogen killing 
and biofilm degradation, respectively (Hwang et al., 2013). 
Also it has been designed a module allowing bacteria to sense their location inside a vacuole 
and induce a lysin (Huh et al., 2013), which could be useful for the selective delivery of 
therapeutic compounds inside targeted cells. An additional genetic module regulates the 
expression of desired bacterial genes, in response to environmental conditions found inside 
solid tumors (i.e. hypoxia) (Arrach et al., 2008). In this regard, a genetic module able to 
program E. coli adhesion to different targets could be extremely useful to improve current 
bacterial therapies (e.g. probiotics, vaccines, tumor targeting bacteria etc). 
 
These and other modules must be integrated in a genetic context that provides the essential 
functions needed to keep a cell alive (i.e. chassis in synthetic biology jargon). Since we are not 
yet able to synthesize de novo a genome, currently available bacterial chassis are obtained by 
genome reduction (Csorgo et al., 2012; Martinez-Garcia and de Lorenzo, 2011).  
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Figure 3. Synthetic bacteria for biomedical applications. Scheme of a nanomachine based on 
bacterial chassis (grey) carrying some of the genetic modules that would be interesting for bacterial 
therapies. A chemotaxis module (light blue) could control bacterial migration in response to 
chemoatractant signals (orange molecules). Selective attachment of bacteria could be mediated by the 
adhesion module (green) and monitored through the reporter module (orange). A sensory module 
(purple) could detect environmental signals and response by activating the transcription of the payload 
module (yellow). Product of the payload module (yellow molecules) could be secreted outside bacteria 
through the delivery module (pink) to exert a therapeutic effect. 
 
 
3  E. coli adhesion. 
 
To engineer a genetic module to program E. coli adhesion, it is important to understand how 
bacteria adhere to surfaces and host tissues and which bacterial structures have evolved to 
mediate bacterial adhesion. 
!
3.1 E. coli lifestyle transition. 
!
Although usually motile, most bacteria in nature are also able to attach to and live in close 
association with surfaces (biotic or abiotic). E. coli is a motile unicellular microorganism that 
frequently inhabits the GIT of several vertebrates, being associated with host tissues rather 
than in a motile unicellular lifestyle within the host body. Both, pathogenic and beneficial 
associations are mainly determined by the ability of bacteria to adhere to host cells, in order to 
withstand natural fluxes and perturbations. The molecules that mediate bacterial adhesion to 
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host cells or abiotic surfaces are proteinaceous appendages that stick out from bacterial 
membrane termed adhesins (see below). In general bacterial adhesion is a two-step process. 
First, proteinaceous adhesins mediates an initial attachment, recognizing molecular structures 
found on the biotic or abiotic surface and later, the production of polysaccharides by bacteria, 
generates a matrix around them that facilitates a tighten attachment of bacteria to the surface. 
The community formed by adhered bacteria embedded in that matrix mainly conformed by 
polysaccharides is termed biofilm (Beloin et al., 2008). Biofilms have a tremendous impact in 
several medical and industrial areas, since they are extremely resistant to disinfectants (Bridier 
et al., 2011) or antibiotics (Hoiby et al., 2010). 
Transition between planktonic (motile) to sessile (adhered) lifestyle is associated with both, 
transcriptional and non-transcriptional changes in bacteria, although the molecular mechanisms 
underlying the sensing and development of this transition are not fully understood (Kirkpatrick 
and Viollier, 2012). 
 
3.1.1 Non-transcriptional changes upon bacterial adhesion. 
In first term adhesion requires a reduced activity of flagellar propellers, to avoid the disruption 
of proteinaceous adhesins and cell receptors interaction. This immediate adaptation to the 
sessile lifestyle is mediated by post-translational mechanisms, rather than a transcriptional or 
translational regulation, whose effects would take longer time to being effective. 
The cyclic di-nucleotide c-di-GMP is a soluble molecule that acts as second-messenger in 
bacteria being involved in many signaling processes in bacteria, among them the transition 
between motile to sessile life styles (Hengge, 2009). Steady-state levels of c-di-GMP are 
maintained by a balanced activity of diguanylate cyclases (DCGs) that synthesize c-di-GMP, 
and phospodiesterases (PDEs) that degrade it. Although the nature of the signals that regulate 
DCGs and PDEs activities is not fully characterized, it is known that many PDEs and DCGs 
contain one or more transmembrane helices, allowing the placement of sensory domains of 
these proteins in the periplasm, where they can perceive oxygen and redox conditions, among 
others (Jenal and Malone, 2006). The genome of E. coli encodes for 19 predicted DCGs and 
13 PDEs (Romling et al., 2005).  Deletion of a single PDE termed YhjH leads to an increase of 
c-di-GMP levels that impairs bacterial motility, although this phenotype can be supressed by an 
additional mutation in the gene encoding for the c-di-GMP binding protein YcgR (Ryjenkov et 
al., 2006). These findings prompted to hypothesize that YcgR could be involved in the transition 
between motile and sessile lifestyles by interfering with flagellar apparatus in a c-di-GMP 
dependent-manner (Wolfe and Visick, 2008). 
In fact, different groups have demonstrated the interaction of YcgR with several components of 
the flagellar apparatus (i.e. FliG, FliM, MotA) (Boehm et al., 2010; Fang and Gomelsky, 2010; 
Paul et al., 2010), and remarkably, some studies suggest that YcgR may be positioned to 
INTRODUCTION 
 28 
associate with the flagellar switch complex prior to c-di-GMP binding, allowing a fast c-di-GMP 
dependent regulation of flagellar motility (Fang and Gomelsky, 2010; Paul et al., 2010). 
 
3.1.2 Transcriptional changes upon bacterial adhesion. 
Several studies have tried to unravel the transcriptional changes associated with biofilm 
development. For E. coli bacteria several comprehensive DNA microarray studies have been 
performed. The change in transcriptional pattern has been analyzed for (a) E. coli K-12 
reference strain MG1655 upon 32 h growth on a glass slide (Schembri et al., 2003); (b) E. coli 
K-12 substrain TG1 upon 5 to 8 days biofilm development in microfermenters (Beloin et al., 
2003); (c) E. coli K-12 substrain JM109 upon 7 h growth on glass wool (Ren et al., 2004); (d) E. 
coli ABU 83972 and VR50 strains after 42 h growth on petri dishes filled wit human urine 
(Hancock and Klemm, 2007); and (e) E. coli K-12 substrain BW25113 after shorter periods of 
biofilm formation on glass (from 4 to 24 hours) (Domka et al., 2007). Unfortunately, all these 
transcriptome analyses showed modest overlapping in their results, suggesting that even for 
the same bacteria (i.e. E. coli), each experimental condition leads to a different biofilm, resulting 
in a different transcriptional profile.  
Strikingly, although adhesion is the first step for biofilm development, fewer studies have 
focused on the transcriptional changes that bacteria suffer immediately upon adhesion. Early 
studies using differential display PCR showed individual genes whose expression was 
upregulated in adhered bacteria. For instance, the expression of kpsD gene, involved in K 
capsular antigen biosynthesis, was found upregulated in the uropathogenic E. coli strain NU149 
adhered by Type 1 fimbriae to mannose-coated Sepharose beads for 90 minutes (Schwan et 
al., 2005), whereas the expression of barA, which encodes a sensor histidine protein kinase 
essential for iron starvation response, was upregulated in the uropathogenic E. coli strain DS17 
adhered to human red blood cells by PapG adhesin for 30 minutes (Zhang and Normark, 1996). 
CpxRA signal transduction system was upregulated in E. coli K-12 substrain MC4100, after 1 
hour adhesion to glass beads (Otto and Silhavy, 2002). More recently, a comprehensive 
transcriptome analysis, based on DNA microarray technology, measured the transcriptional 
changes of hyperfimbriated E. coli CSH50 strain upon adhesion to mannose-coated agarose 
beads for 1 hour (Bhomkar et al., 2010). Genes related with removal of reactive oxygen species 
(e.g. grxA, marA) assimilatory sulfate reduction (e.g. cysD, cysJ), and some with unknown 
function (e.g. yeeE, ygaD) were among the most upregulated genes upon adhesion, whereas 
genes encoding for flagellar components (e.g. fliM, flgB) and tricarboxilic acid (TCA) cycle 
enzymes (i.e. sdhC) were downregulated in response to adhesion. 
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3.2 E. coli main adhesins. 
!
The molecular composition of bacterial cell surface determines the ability of bacteria to interact 
with the environment, but in Gram-negative bacteria such as E. coli, surface display of proteins 
involves translocation across both, inner (IM) and outer membranes (OM). In E. coli, 
translocation of adhesins to OM occurs by different protein secretion systems (Gerlach and 
Hensel, 2007). This variety of systems to translocate adhesins, together with the remarkable 
array of adhesins encoded in E. coli genome, highlight the importance of being associated with 
abiotic and host surfaces for E. coli. 
Adhesins can be subdivided by their assembly mechanism and structure into two major 
classes: fimbrial adhesins, and non-fimbrial adhesins.  
 
3.2.1 Fimbrial adhesins. 
Fimbrial adhesins constitute a group of filamentous fibers anchored in the OM that are 
composed of hundreds to thousands subunits. Type 1 fimbriae, P fimbriae and Curli are the 
fimbrial adhesins that have been clasically studied, associated to uropathogenic E. coli (UPEC) 
strains. However, Mat fimbriae, also termed E. coli common pilus, is the most common fimbrial 
structure among both, commensal and pathogenic strains (Rendon et al., 2007). In addition, 
genome analysis of E. coli K-12 and some pathogenic E. coli strains showed the presence of 
multiple operons encoding for putative fimbriae (Blattner, 1997; Perna et al., 2001; Welch et al., 
2002), suggesting the existence of an armory of fimbrial adhesins with different roles and 
specificities in E. coli (Korea et al., 2011). 
Except for Curli, the general structure of fimbrial adhesins and the secretion pathway employed 
is quite conserved. Operons encoding for fimbrial adhesins strains contain all the genes 
needed for the adhesin formation and also for its translocation across the OM through the 
chaperone/usher pathway, also termed type VII secretion system (Desvaux et al., 2009). In this 
pathway, pilus subunits associate with a dedicated periplasmic chaperone immediately after 
crossing the IM through the Sec translocon. The periplasmic chaperone binds to pilus subunits 
to prevent their aggregation in the periplasm, and transport them to the OM usher, a fimbrial 
assembly platform and translocon. Surface exposed pilus subunits, which vary in number and 
relative abundance between different fimbrial adhesins, are translocated to the outer space by 
the usher in an ordered way, which involves donor strand complementation between the 
incoming subunits, in order to complete the characteristic Ig-like fold of pilus components 
(Sauer et al., 2002). This ordered assembly allows the placement the pilus adhesin at the tip of 
the filament.  
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On the other hand, Curli fimbriae are secreted to the OM through the nucleation/precipitation 
pathway, which has also been defined as Type VIII Secretion System (T8SS) (Desvaux et al., 
2009).  
Given their variety, it is obvious that fimbrial adhesins play different roles in different E. coli 
strains. Type 1 fimbriae expression through the fim operon is widely distributed among different 
E. coli strains, and mediates the binding to mannose residues present on the surface of host 
cells through the FimH adhesin subunit. Surprisingly, whereas commensal and laboratory 
strains display FimH variants that bind with high affinity trimannose residues, UPEC strains 
present FimH molecules that exhibit higher affinity for monomannose residues, more prevalent 
in cells of the urinary tract, suggesting and environmental adaptation mechanism (Hommais et 
al., 2003). P fimbriae, encoded by the pap operon, are mainly expressed by UPEC strains and 
bind through the PapG adhesin subunit to the α-D-galactopyranosyl-(1-4)-β-D-
galactopyranoside moiety of glycolipids of upper urinary tract cells and erythrocytes (Leffler). As 
for FimH, there are PapG variants that recognize related versions of their host cell receptors, 
meaning that expression of different PapG variants drives tissue and host specificity (Pizarro-
Cerda and Cossart, 2006). Curli fibers lack a clear ligand-binding specificity, since they have 
been proposed to mediate bacterial attachment to a wide variety of proteins such as fibronectin, 
laminin, plasminogen and class I major histocompatibility complex (Olsen et al., 1998). Curli 
fibers also have a role in biofilm formation on abiotic surfaces, promoting both, bacterium-
surface and bacterium-bacterium interactions (Uhlich et al., 2006). Curli expression only takes 
place at room temperature, however some UPEC strains also express Curli fimbriae at 37ºC 
suggesting a role in pathogenicity (Bian et al., 2000).  
Mat fimbriae were originally reported as fimbrial structures expressed by meningitis associated 
pathogroups grown at low temperatures (Pouttu et al., 2001). In spite of this, recent studies 
have demonstrated the ubiquitous expression of Mat fimbriae in both, commensal and 
pathogenic groups, in a temperature independent fashion, at least for EHEC strains (Rendon et 
al., 2007). Expression of Mat fimbriae is involved in early biofilm development (Lehti et al., 
2010) and host cell recognition (Garnett et al., 2012; Rendon et al., 2007; Saldana et al., 2009) 
although the exact nature of the moieties recognized by Mat fimbriae on the surface of 
mammalian cells has not been determined yet. Despite that mat operon structure in E. coli K-12 
seems to be functional, expression of Mat fimbriae has never been detected in this strain. 
However, given the conservation of mat genes across E. coli species, it is likely that Mat 
fimbriae belong to the group of cryptic E. coli adhesins (Korea et al., 2010) that could be 
expressed under very specific conditions encountered, for instance, in in vivo situations (van 
Diemen et al., 2005). 
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3.2.2 Non-fimbrial adhesins. 
Contrary to fimbrial adhesins, in which different subunits conform the shaft and the adhesive 
domains, non-fimbrial adhesins contain these domains in a single polypeptide. As outer 
membrane proteins (Pulido et al.), non-fimbrial adhesins should be translocated across the OM, 
following the Type V secretion system (T5SS) also termed autotransporter pathway 
(Henderson et al., 2004). In this secretion system, the polypeptide with a N-terminal signal 
peptide crosses the IM through the Sec translocon. Once in the periplasm, a domain of the 
polypeptide, with a β-barrel structure, is inserted in the OM with the mediation of the β-barrel 
assembly machinery (BAM) complex Bam complex, allowing the translocation of the remaining 
polypeptide, termed passenger domain, toward the bacterial surface. Many non-fimbrial 
adhesins, such as Antigen 43, are members of the classical autotransporter (AT) family, which 
contains the β-barrel domain at the C-terminal region of the polypeptide, and has N-terminal 
passenger domains on the bacterial surface folded as long rods of parallel β-helix structure. 
Antigen 43, encoded by flu gene, is a non-fimbrial adhesin conserved in most E. coli strains 
that is involved in biofilm formation and bacterial self-aggregation. However, given the strong 
sequence similarity between Antigen 43 and other AT adhesins (e.g. AIDA-I) recognizing 
glicoproteins on the surface of mammalian cells, a role in host-cell recognition for Antigen 43 
cannot be rule out (van der Woude and Henderson, 2008). 
 
3.2.2.1 Intimins. Structure, secretion and properties. 
Intimins are non-fimbrial adhesins, encoded by eae gene, found in bacterial pathogens such as 
enteropathogenic and enterohaemorrhagic E. coli (EPEC and EHEC) strains and Citrobacter 
spp., which cause a characteristic intimate adhesion to enterocytes and the effacement of 
brush border microvilli (i.e. the attaching and effacing lesion). Intimins are highly homologous to 
Invasins from Yersinia spp., constituting together a subfamily of the T5SS with an opposite 
topology to classical ATs, having N-terminal β-barrel domains and C-terminal surface-exposed 
passengers (Leo et al., 2012). Structure of Intimin from EPEC and EHEC strains is defined by 
an OM anchoring domain composed of a 12-stranded β-barrel, and four surface-exposed 
globular domains showing either, immunoglobulin (Ig)-like fold (e.g. D0 D1 and D2 domains) or 
lectin-like fold (e.g. D3 domain) (Fairman et al., 2012). Translocation of Intimin to the OM 
involves its translocation to the periplasm, DsbA-dependent formation of a disulfide bond in the 
D3 lectin-like domain, and interaction with SurA, and in a lesser extent with with Skp and DegP 
chaperones, to assist its transport to the BAM complex for OM insertion (Fig. 4) (Bodelon et al., 
2009). Intimin is an extremely stable OMP, resistant to strong denaturants such as SDS and 
urea. Moreover, Intimin was found to be highly resistant to the action of extracellularly added 
proteases (Bodelon et al., 2009).  
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Intimin takes part of an original “velcro-like” bacterial adhesion system in which bacteria provide 
both, the ligand (i.e. Intimin) and the receptor for the adhesion (El Hamidi et al.). The 
translocated intimin receptor (El Hamidi et al.) is an effector molecule of the Type III secretion 
system present in EPEC and EHEC strains that allows the direct injection of proteins into the 
cytoplasm of mammalian cells, through a bacterial OM needle-like structure termed the 
injectisome (Coburn et al., 2007). Once translocated inside the host cell, Tir is inserted into the 
host cell membrane leaving an extracellular domain called TirM accessible for the interaction 
with Intimin D3 domain (Kenny et al., 1997). 
 
 
Figure 4. Intimin secretion. Schematic view of Intimin structure, folding and translocation to the OM in 
E. coli. Intimin polypeptide crosses the IM through the Sec complex to reach the periplasm where DsbA 
protein catalizes the formation of a disulfide bond in the D3 lectin-like domain of Intimin. In addition, SurA 
chaperone and, in a lesser extent, DegP and Skp chaperones are involved in periplasmic transport and 
folding of the N-terminal domain of Intimin, which is subsequently inserted in the OM in a process 
mediated by Bam complex, leading to the translocation of D0 D1 D2 and D3 domains of Intimin to the 
extracellular side of OM. 
 
Interestingly, many fimbrial and non-fimbrial adhesins contain Ig-like domains in their structure. 
Although Ig-domains are widespread in nature, they are especially recognized for their role in 
proteins of the immune system of vertebrates (i.e. antibodies). It is not clear if the existence of 
Ig-like folding structures, in molecules so phylogenetically distant as bacterial adhesins and 
vertebrate antibodies, constitutes a case of evolution from a common ancestor or alternatively, 
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a mechanism of convergent evolution towards an energetically favorable folding (Bodelon et al., 
2012). In either case, it is surprising how bacteria (i.e. adhesins) and vertebrates (i.e. 
antibodies) have maintained or evolved the same protein folding to face a common problem: 
specific ligand recognition. 
 
 
4 Immunoglobulins!and!their!expression!and!selection!in!E.#coli.!!
 
Antibodies (Abs), also known as immunoglobulins (Ig), are large polypeptides produced by the 
immune system of vertebrates that are able to specifically recognize foreign molecular 
structures  (i.e. antigens) that are not part of the host (Fanning et al., 1996; Schroeder and 
Cavacini, 2010).  
The extreme ligand specificity showed by antibodies together with the possibility of targeting 
virtually any molecule with them, has turned antibodies into valued molecules for medical and 
biotechnological purposes. 
 
4.1 Structure of antibodies and heavy-chain-only antibodies. 
 
Conventional Abs are large heterotetetrameric protein complexes with Y shape consisting in 
two 2 large polypeptidic chains termed heavy (H) chains and two smaller polipeptides known as 
light (L) chains. Both chains are organized in autonomously folding functional units termed Ig 
domains, which are composed of around 120 aminoacids folded as two sandwiched β-pleated 
sheets joined by one disulfide bond between conserved cysteine residues (canonical disulfide 
bond). Pairing of the N-terminal Ig domains of L and H chains constitute the antigen-binding 
site, meaning that each Ab has two antigen-binding sites. These Ig-domains responsible of 
antigen binding have a more variable primary sequence and are termed as variable (V) 
domains, as opposed to the other Ig domains of the H and L chains, which are referred as 
constant (C) domains. Each V domain contains three hypervariable regions or complementary 
determining regions (CDRs) that define antigen specificity of antibodies (Fig. 5). 
Interestingly, members of the family Camelidae (i.e. dromedaries, camels, llamas, alpacas, 
vicuñas and guanacos), in addition to conventional Abs with H and L chains, also produce Ab 
molecules that naturally lack L chains, named as heavy-chain-only Abs (HCAbs) (Fig. 5) 
(Hamers-Casterman et al., 1993). As a result of this L chain absence, the antigen-binding site 
of HCAbs is formed by a single domain termed VHH (VH of HCAbs). In addition, HCAbs also 
lack the constant domain CH1, providing a possible explanation to the absence of associated 
light chains, since this domain mediates association between heavy and light chains.  
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4.2 Recombinant antibodies and their use in therapy. 
 
Currently over 40 different antibodies have received the approval from the Food and Drug 
Administration (FDA) (http://www.antibodysociety.org/news/approved_mabs.php). Approved 
antibodies are designed for the treatment of several diseases such as cancer, autoimmune 
disorders or rare diseases (Dimitrov and Marks, 2009). Most recent Abs being approved and 
entering in clinical trials are completely based on human sequences. These human monoclonal 
antibodies (named with suffix –umab) are obtained either from transgenic mice that produce 
human antibodies (Green et al., 1994; Lee et al., 2014; Macdonald et al., 2014; Murphy et al., 
2014), or from libraries of human V domains (i.e. antibody fragments, see below) that are 
screened by phage display (McCafferty et al., 1990), ribosome display (He and Khan, 2005), 
yeast display (Chao et al., 2006) or bacterial display (Li et al., 2013) against the desired antigen. 
Selected V-domains of both heavy and light chains are cloned in a genetic scaffold encoding 
constant domains of human antibodies leading to the generation of fully human antibody 
molecules with antigen binding sites selected from libraries. 
 
Despite the widespread use of full-length Ab molecules (e.g. IgG) for therapy, small antibody 
fragments that retain full antigen binding capacity have some advantages compared to full-
length antibodies. Their simplified structure allows their expression in microorganisms like 
bacteria (Fernandez, 2004) or yeast (Feldhaus and Siegel, 2004) that have been essential for 
the screening of antibody fragments libraries. Additionally, small antibody fragments could be 
valuable molecules by it self, since the smaller size of fragments allows a better penetration 
into certain tissues such as tumors (Yokota et al., 1992). On the other hand, small Ab-
fragments are rapidly degraded in humans and have short circulating half-lifes (Nelson, 2010). 
Fab molecules are the oldest class of monoclonal antibody fragments developed (Better et al., 
1988), composed of two polypeptides (VL-CL and VH-CH1) joined by a disulfide bond (Fig. 5). 
Next smaller Ab fragments were developed based on a single polypeptide chain (single chain 
Fv or scFv) containing the VH and VL domains joined with a short linker peptide (Fig. 5) (Bird 
and Walker, 1991). Although the stability of scFvs is lower than that of Fabs, they are 
commonly used since expression of a single polypeptide represents a clear advantage for 
correct folding.  
Lastly, the discovery of HCAbs led to the expression of single domain VHH sequences that 
have high similarity with human sequences of the VH3 family, which make them suitable for 
human therapy. VHH fragments, also known as nanobodies, are the smallest recombinant Ab 
fragments generated to date (ca. 12-14 kDa) (Fig. 5). Despite their small size, antigen affinity of 
VHHs is similar to that of conventional antibodies, with equilibrium dissociation constants in the 
range of nano- or even picomolar concentrations (Muyldermans, 2013). In addition, VHH 
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molecules have been demonstrated as extremely resistant to chemical or thermal denaturation 
(van der Linden et al., 1999). Lastly, probably because of their naturally evolved single chain 
and monodomain structure, VHH molecules show higher solubility than other Ab fragments 
such as scFvs (Veiga et al., 2004).  
 
 
Figure 5. Antibodies and their fragments. Schematic representation of conventional and heavy-chain-
only antibodies and their fragments. Conventional Abs (e.g. IgG) are composed of two heavy (H) chains 
and two light (L) chains, and the antigen-biding site is determined by the joining of the variable (V) 
domain of both, H and L chains. Fab fragments are devoid of the constant region (Fc), whereas scFvs 
are composed only by the VH and VL joined by a short linker peptide (shown in yellow). HCAbs lack L 
chains, as well as the CH1 domain, and their antigen-binding site is determined by a single domain, 
termed VHH or Nanobody. 
 
4.3 Cell surface display of Igs in E. coli. 
 
E. coli has been used to produce libraries of either, Ab fragments (Fernandez, 2004) or full-
length Abs (Mazor et al., 2007) and to select desired clones from these libraries, using phage 
display (Smith, 1985) and anchored-periplasmic expression (APEx) systems (Harvey et al., 
2004), respectively. The expression strategies for these systems involves the secretion of Ab 
molecules to the periplasm, since the reducing conditions found in the cytoplasm of wild-type E. 
coli strains impede the formation of disulfide bonds required for the proper folding of Ab 
molecules (Jurado et al., 2006; Jurado et al., 2002). In addition, it has been demonstrated that 
periplasmic chaperones (e.g. FkpA, Skp) and disulfide bond forming and isomerization 
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enzymes (e.g. DsbA, DsbC) assist correct folding of aglycosilated Abs in the periplasm of E. 
coli (Bodelon et al., 2012). 
In order to facilitate the selection of desired clones from libraries, direct display of Ab molecules 
on the bacterial surface has been also attempted. However, the presence of the OM in E. coli 
has hindered the development of effective cell surface display methods for Ab selection, since 
in order to be displayed on the surface, polypeptides produced in the cytoplasm should traverse 
the IM, the periplasm, and be inserted into the OM. In addition display of heterologous proteins 
on the surface of E. coli often affects cell physiology, resulting in growth arrest, cell lysis and 
poor display performance. Thus, OM proteins native to the organism have served as 
convenient targeting and anchoring portions and are generally used for display, though 
heterologous anchor proteins have also been evaluated. For instance, scFvs have been 
displayed on the surface of E. coli using a tripartite fusion protein comprising de secretion 
signal of Lpp protein a fragment of OmpA protein and the scFv fragment (Francisco et al., 
1993). Unfortunately, the expression of heterologous proteins on the surface of E. coli mediated 
by lipoprotein fusions severely disturbs the integrity of OM causing significant leakiness and 
toxicity (Georgiou et al., 1996). Furthermore, since Lpp-OmpA fusions are based on a truncated 
fragment of the native 8-stranded β-barrel structure of OmpA, they probably lack the 
characteristic stability of native β-barrels found in most OM proteins (Fairman et al., 2011). Our 
group previously reported that that scFv and VHH clones could be displayed on the surface of 
E. coli fused to different autotransporter proteins, such as the IgA protease from Neisseria 
gonorrhoeae (Veiga et al., 2004), or the EhaA adhesin from EHEC (Marin et al., 2010). This 
autotransporter display technology reduce bacterial toxicity found in lipoproteins display system, 
although a significant amount of the heterologous protein is found in culture media, since 
autotransporters are prone to proteolysis as part of their secretion mechanism (Leyton et al., 
2012). More recently, our group also reported an effective E. coli display system for VHHs 
based on the β-domain of Intimin from EHEC, which allowed the screening of VHH libraries for 
the selection of high-affinity clones (Salema et al., 2013). Intimin-VHH fusions were also shown 
to be resistant to the action of proteases and denaturing agents, turning this display system into 
an attractive technology to modify the adhesion properties of E. coli.  
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6 To investigate whether fusion proteins composed of the outer membrane anchoring 
domain of Intimin and the adhesive domain based on VHH single domain antibodies  
could act as synthetic adhesins, driving the specific adhesion of E. coli bacteria to target 
antigenic surfaces. 
 
6 To engineer constitutive and stable expression of the adhesion module based on 
synthetic adhesins from the chromosome of an E. coli chassis strain lacking a 
conserved set of natural adhesins.  
 
6 To demonstrate that engineered E. coli strains constitutively expressing synthetic 
adhesins specifically attach to target tumor cells and to characterize the adhesion 
process.  
 
6 To demonstrate the functionality of synthetic adhesins in vivo and their ability to improve 
the efficiency of solid tumor colonization by engineered E. coli bacteria.  
 
6 To investigate short-term transcriptional response of engineered E. coli strains upon 
specific adhesion to tumor target cells mediated by synthetic adhesins.  
 
6 To generate non-live bacterial-derived nanoparticles devoid of chromosomal DNA 
maintaining the expression of synthetic adhesins against antigens present on the 
surface of tumor cells. 
 
 
 
 
 
 
 
 
 !!!!
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6 Investigar si la proteínas de fusión generadas mediante la combinación del dominio de 
anclaje a membrana externa de Intimina y de los dominios de adhesión basados en 
anticuerpos monodominio VHH, podrían actuar como adhesinas sintéticas que dirijan la 
adhesión específica de bacterias E. coli hacia superficies antigénicas diana. 
 
6 Diseñar un módulo de adhesión basado en adhesinas sintéticas que se exprese de 
manera estable y constitutiva desde el cromosoma de una cepa "chasis" de E. coli 
carente de un conjunto de adhesinas naturales conservadas. 
 
6 Demostrar que las cepas modificadas de E. coli que expresan de modo constitutivo 
adhesinas sintéticas se unen específicamente a células tumorales diana, y caracterizar 
dicho proceso de adhesión. 
 
6 Demostrar la funcionalidad de las adhesinas sintéticas en experimentos in vivo y su 
capacidad para mejorar la eficiencia de E. coli para colonizar tumores sólidos. 
 
6 Investigar la respuesta transcripcional de las cepas modificadas de E. coli 
inmediatamente después de su adhesión mediada por adhesinas sintéticas a células 
tumorales diana. 
 
6 Generar nanopartículas derivadas de bacterias, carentes de ADN cromosómico y por 
tanto no vivas, que mantengan la expresión de adhesinas sintéticas frente a antígenos 
presentes en la superficie de células tumorales. 
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1. Bacterial strains and growth conditions. 
The E. coli strains used in the experiments described in this work are listed in Table M1. 
Bacteria were grown in Luria-Bertani (LB) liquid medium and agar-plates (1.5% w/v), at 37°C, 
unless otherwise indicated.  When needed for plasmid or strain selection, antibiotics were 
added to the media at the following concentrations: chloramphenicol (Cm) at 30 µg/ml, 
kanamycin (Km) at 50 µg/ml and ampicillin (Ap) at 150 µg/ml, except for minicells-producer 
strains with Ap resistance gene in their chromosome that were selected with Ap at 75 µg/ml. E. 
coli DH10B-T1R strain was used as host for cloning and   propagation of plasmids with a pBR 
origin of replication (e.g. pAK-Not, pNV-derivatives). For cloning and propagation of suicide 
pGE-plasmid derivatives, containing the conditional pi-dependent R6K origin of replication 
(Stalker et al., 1982), the E. coli strains BW25141 or CC118-λpir were used. For inducible 
expression of the SAs from plasmid vectors with plac promoter (i.e. pNVfib, pNVgfp), EcM1 
bacteria bearing the corresponding plasmid, were grown in LB-Cm at 30°C and 0.05 mM 
isopropyl-thio-β-D-galactoside (IPTG) was added at an optical density 600 nm (OD600) of 0.5. 
The cultures were further grown for 2 h at 30°C with agitation (160 rpm). Bacteria with 
constitutive expression of the synthetic adhesins and the lux operon from the chromosome 
were always grown statically at 37°C in LB, except for analysis of their growth curve in which 
cultures were grown at 37°C with agitation (160 rpm), and except for minicells-producer 
bacterial strains that were also grown at 37°C with agitation (160 rpm). Bioluminescence of 
bacterial colonies grown on LB plates were monitored in a Chemi-doc XRS+ (Bio-Rad). 
 
2. E. coli genome modification and strain construction.  
The E. coli strains generated in this work are listed in Table M1. Site-specific deletions and 
insertions in the chromosome of E. coli were done with the marker-less strategy of genome 
edition based on expression of I-SceI endonuclease (Posfai et al., 1999; Posfai et al., 2006).  
Briefly, the E. coli strain to be modified was initially transformed with plasmid pACBSR (CmR) 
(Herring et al., 2003), expressing I-SceI and λ Red proteins under the control of PBAD promoter 
(inducible with L-arabinose), and subsequently electroporated with the corresponding pGE-
based suicide vector (KmR). Cointegrants were selected on LB-Cm-Km plates incubated at 
37°C. Individual colonies were isolated and grown for 6 h in LB-Cm liquid medium containing L-
arabinose 0.4% (w/v) with agitation (160 rpm). After this period, a ~1 µl sample of these 
cultures was streaked on LB-Cm plates using an inoculating loop and incubated overnight.  
Individual colonies were replicated in LB-Cm and LB-Cm-Km plates to screen for Km-sensitive 
colonies that have performed resolution of the cointegrant vector after I-SceI induction.  
Individual Km-sensitive colonies were screened by PCR with specific oligonucleotides to 
identify those with the desired modification in their chromosome (i.e. deletion, insertion, 
substitution).  Plasmid pACBSR was cured from the final strains by growth in liquid LB and 
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streaking on LB-plates. Individual colonies were replicated in LB and LB-Cm plates to screen 
for Cm-sensitive colonies. Minicells producer-strains were obtained through substitution of 
minCD genes by an Ap resistance gene cassette (bla gene) flanked by Flippase Recognition 
Target (FRT) sites. To excise bla gene, minicells producer strains were transformed with 
plasmid pCP20 (CmR) (Cherepanov and Wackernagel, 1995), a thermosensitive plasmid that 
expresses Flp recombinase under thermal induction. Individual colonies carrying pCP20 were 
grown for 6 h in LB liquid medium at 42º C with agitation (160 rpm). After thermal induction of 
Flp recombinase, individual Ap-sensitive colonies were screened by PCR to further confirm 
genome modification. 
Construction details of individual E. coli strains are described below. 
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EcM1SAgfp: The EcM1 strain carrying pACBSR (CmR) was transformed with pGEflu-SAgfp 
(KmR) and cointegrants were selected on LB-Km-Cm plates. Cointegrants were resolved by I-
SceI expression and individual Km sensitive colonies were checked by PCR with primer pairs: 
VHH-Sfi2 and VHH-Not for VHH detection; Yoe1 and NeaeR1 for checking upstream 
integration site; Neae4 / YeeR2 for checking downstream integration site. 
EcM1SAtir: The EcM1 strain carrying pACBSR (CmR) was transformed with pGEflu-SAtir 
(KmR) and cointegrants were selected on LB-Km-Cm plates. Cointegrants were resolved by I-
SceI expression and individual Km sensitive colonies were checked by PCR with primer pairs: 
VHH-Sfi2 and VHH-Not for VHH detection; Yoe1 and NeaeR1 for checking upstream 
integration site; Neae4 / YeeR2 for checking downstream integration site. 
EcM1lux Δflu: The EcM1 strain carrying pACBSR (CmR) was transformed with pGEflu (KmR), 
and cointegrants were selected on LB-Km-Cm plates. Cointegrants were resolved by I-SceI 
expression and individual Km sensitive colonies were checked by PCR with primers Yoe1 and 
YeeR2 to confirm the flu gene deletion. Subsequently, EcM1Δflu strain bearing pACBSR was 
transformed with pGEmat-lux (KmR). Cointegrants were resolved by I-SceI expression and 
individual Km sensitive colonies were tested for light emission. To ensure site specific 
integration of the lux operon, the bioluminescent colonies were checked by PCR primer pairs: 
ykgL-For and LuxC-Rev for upstream integration site and LuxE-For and yagX-Rev for 
downstream integration site. 
EcM1luxSAgfp: The EcM1SAgfp strain carrying pACBSR (CmR) was transformed with 
pGEmat-lux suicide plasmid (KmR). Cointegrants and individual bioluminescent colonies were 
selected and screened as described above for strain EcM1luxΔflu. 
EcM1luxSAtir: The EcM1SAtir strain carrying pACBSR (CmR) was transformed with pGEmat-
lux suicide plasmid (KmR). Cointegrants and individual bioluminescent colonies were selected 
and screened as described above for strain EcM1luxΔflu. 
EcM1luxSAega: The EcM1luxSAgfp strain carrying pACBSR (CmR) was transformed with 
pGEflu-SAega (KmR). Cointegrants were resolved by I-SceI expression and individual Km 
sensitive colonies were checked by PCR with primer pairs: VHH-Sfi2 and Ega CDR3 to confirm 
VHH exchange; Yoe1 and NeaeR1 for checking upstream integration site; Neae4 / YeeR2 for 
checking downstream integration site. 
EcM1ΔfliSAgfp: The EcM1∆fli strain carrying pACBSR (CmR) was transformed with pGEflu-
SAgfp (KmR) and cointegrants were selected on LB-Km-Cm plates. Cointegrants were resolved 
by I-SceI expression and individual Km sensitive colonies were checked by PCR with primer 
pairs: VHH-Sfi2 and VHH-Not for VHH detection; Yoe1 and NeaeR1 for checking upstream 
integration site; Neae4 / YeeR2 for checking downstream integration site. 
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EcM1luxSAgfp-ΔycgR: The EcM1luxSAgfp strain carrying pACBSR (CmR) was transformed 
with pGEycgR suicide plasmid (KmR). Cointegrants were resolved by I-SceI expression and 
individual Km sensitive colonies were checked by PCR with primer pairs XhoI HR1 ycgR / SphI 
HR2 ycgR to confirm ycgR gene deletion. 
EcM1luxSAega-PcysPCherry: The EcM1luxSAega strain was transformed with 
pGEPcysPCherryT0 suicide plasmid (KmR). Cointegrants were selected on Kanamycin plates 
and analyzed by PCR with primer pairs: cysP ups check / SpeI Cherry for checking upstream 
integration site; and NotI-RBS-Cherry / cysP down check for checking downstream integration 
site. 
EcM1luxSAega-PcysDCherry: The EcM1luxSAega strain was transformed with 
pGEPcysDCherryT0 suicide plasmid (KmR). Cointegrants were selected on Kanamycin plates 
and analyzed by PCR with primer pairs: cysD ups check / SpeI Cherry for checking upstream 
integration site; and NotI-RBS-Cherry / cysD down check for checking downstream integration 
site. 
EcM1luxSAega-PyeeECherry: The EcM1luxSAega strain was transformed with 
pGEPyeeECherryT0 suicide plasmid (KmR). Cointegrants were selected on Kanamycin plates 
and analyzed by PCR with primer pairs: yeeE ups check / SpeI Cherry for checking upstream 
integration site; and NotI-RBS-Cherry / yeeE down check for checking downstream integration 
site. 
EcM1luxSAega-PydjNCherry: The EcM1luxSAega strain was transformed with 
pGEPydjNCherryT0 suicide plasmid (KmR). Cointegrants were selected on Kanamycin plates 
and analyzed by PCR with primer pairs: ydjN ups check / SpeI Cherry for checking upstream 
integration site; and NotI-RBS-Cherry / ydjN down check for checking downstream integration 
site. 
EcM1luxSAega-PldhACherry: The EcM1luxSAega strain was transformed with 
pGEPldhACherryT0 suicide plasmid (KmR). Cointegrants were selected on Kanamycin plates 
and analyzed by PCR with primer pairs: ldhA ups check / SpeI Cherry for checking upstream 
integration site; and NotI-RBS-Cherry / ldhA down check for checking downstream integration 
site. 
EcM1luxSAega-PfruBCherry: The EcM1luxSAega strain was transformed with 
pGEPfruBCherryT0 suicide plasmid (KmR). Cointegrants were selected on Kanamycin plates 
and analyzed by PCR with primer pairs: fruB ups check / SpeI Cherry for checking upstream 
integration site; and NotI-RBS-Cherry / fruB down check for checking downstream integration 
site. 
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EcM1Δfli ΔmsbB: The EcM1Δfli strain carrying pACBSR (CmR) was transformed with 
pGEmsbB suicide plasmid (KmR). Cointegrants were resolved by I-SceI expression and 
individual Km sensitive colonies were checked by PCR with primer pairs XbaI HR1 msbB / SphI 
HR2 msbB to confirm msbB gene deletion. 
EcMini: The EcM1Δfli ΔmsbB strain carrying pACBSR (CmR) was transformed with 
pGEminCD-AmpFRT suicide plasmid (KmR). Cointegrants were resolved by I-SceI expression 
and individual Km sensitive colonies were checked by PCR with primer pairs XbaI minE / SphI 
minC to confirm minCD gene deletion. Subsequently pCP20 (CmR) was transformed and the 
strain carrying this plasmid was grown at 42ºC for six hours to induce FLP recombinase 
expression, which mediates excision of FRT flanked Ampicillin resistance gene. Bacterial 
growth at 42ºC also leads to pCP20 plasmid curing. Amp sensitive colonies were checked by 
PCR with primer pairs XbaI minE / SphI minC to confirm AmpR gene cassette excision. 
EcMini-WT: The E. coli K-12 MG1655 strain carrying pACBSR (CmR) was transformed with 
pGEminCD-AmpFRT suicide plasmid (KmR). Cointegrants were resolved by I-SceI expression 
and individual Km sensitive colonies were checked by PCR with primer pairs XbaI minE / SphI 
minC to confirm minCD gene deletion. Subsequently pCP20 (CmR) was transformed and the 
strain carrying this plasmid was grown at 42ºC for six hours to induce FLP recombinase 
expression, which mediates excision of FRT flanked Ampicillin resistance gene. Bacterial 
growth at 42ºC also leads to pCP20 plasmid curing. Amp sensitive colonies were checked by 
PCR with primer pairs XbaI minE / SphI minC to confirm AmpR gene cassette excision. 
EcMini-SAgfp: The EcMini strain carrying pACBSR (CmR) was transformed with pGEflu-SAgfp 
(KmR).  Cointegrants were resolved by I-SceI expression and individual Km sensitive colonies 
were checked by PCR with primer pairs: VHH-Sfi2 and VHH-Not for VHH detection; Yoe1 and 
NeaeR1 for checking upstream integration site; Neae4 / YeeR2 for checking downstream 
integration site. 
EcMini-SAega: The EcMini strain carrying pACBSR (CmR) was transformed with pGEflu-
SAega (KmR).  Cointegrants were resolved by I-SceI expression and individual Km sensitive 
colonies were checked by PCR with primer pairs: VHH-Sfi2 and VHH-Not for VHH detection; 
Yoe1 and NeaeR1 for checking upstream integration site; Neae4 / YeeR2 for checking 
downstream integration site. 
 
3. Plasmids, DNA constructs, and oligonucleotides.  
The plasmids constructed and used in this study are summarized in Table M2. Oligonucleotides 
were synthesized by Sigma Genosys and are listed in Table M3. PCRs were performed with 
Taq DNA polymerase for standard amplifications in screenings and with proof-reading DNA 
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polymerases, Vent DNA polymerase (New England Biolabs) and High-expand fidelity (Roche) 
for cloning purposes. All plasmid constructs were fully sequenced (Secugen). Details of plasmid 
constructions are described below. 
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Table M2. Plasmids used in this study 
Reference 
(Salema et al., 2013)!
(Bodelon et al., 2009)!
(Salema et al., 2013)!
(Salema et al., 2013)!
This work!
(Salema et al., 2013)!
This work!
Life technologies!
(Han et al., 2004)!
This work!
This work!
This work!
This work!
This work!
This work!
This work!
(Herring et al., 2003)!
(Cherepanov and 
Wackernagel, 1995)!
This work!
This work!
This work!
This work!
This work!
This work!
This work!
This work 
This work 
Relevant properties 
(CmR), lacIq-Plac promoter, pBR322 ori!
pAK-Not-derivative;  Neae polypeptide [IntiminEHEC (1-659)-E-His-tag]!
pAK-Not-derivative; Neae-myc polypeptide [IntiminEHEC (1-659)-E-His-myc-tag]!
pNeae2-derivative; VHH anti-GFP fused to Neae2 [IntiminEHEC (1-659)-E-Vgfp-myc-tag]!
pNeae2-derivative; VHH anti-human Fibrinogen fused to Neae2 [IntiminEHEC (1-659)-E-Vfib-myc-tag]!
pNeae2-derivative; VHH anti-TirM fused to Neae2 [IntiminEHEC (1-659)-E-Vfib-myc-tag]!
pNeae2-derivative; VHH anti-human EGFR fused to Neae2 [IntiminEHEC (1-659)-E-Vfib-myc-tag]!
(AmpR, G418R) PCMV-IgK signal peptide-HA-polylinker-myc tag-PDGFR transmembrane domain!
pDisplay derivative; GFP-tm fusion (display of GFP)!
pDisplay derivative; TirM-tm fusion (display of TirMEHEC and mWasabi)!
(KmR), R6K-ori, polylinker flanked by two I-SceI restriction sites!
pGE derivative; with homology regions flanking the flu gene of E. coli K-12!
pGEflu derivative; PN25-SAgfp (constitutive expression of SA binding GFP)!
pGEflu derivative; PN25-SAtir (constitutive expression of SA binding TirM)!
pGEflu derivative; PN25-SAega (constitutive expression of SA binding hEGFR)!
pGE derivative;  P2-luxCDABE with homology regions flanking the matB gene of E. coli K-12!
(CmR), p15A-ori, PBAD promoter, I-SceI endonuclease,  λ Red!
(AmpR, CmR) rep101ts, Flippase expression under thermal induction!
pGE derivative; with homology regions flanking the ycgR gene of E. coli K-12!
pGE derivative; E. coli K-12 cysP promoter, mCherry, T0 transcriptional terminator!
pGE derivative; E. coli K-12 cysD promoter, mCherry, T0 transcriptional terminator!
pGE derivative; E. coli K-12 yeeE promoter, mCherry, T0 transcriptional terminator!
pGE derivative; E. coli K-12 ydjN promoter, mCherry, T0 transcriptional terminator!
pGE derivative; E. coli K-12 ldhA promoter, mCherry, T0 transcriptional terminator!
pGE derivative; E. coli K-12 fruB promoter, mCherry, T0 transcriptional terminator!
pGE derivative; with homology regions flanking the msbB of E. coli K-12 
pGE derivative; with homology regions flanking the minCD genes of E. coli K-12 and the bla gene 
(AmpR) flanked by two FRT sites inserted between homology regions. 
Name 
pAK-Not 
pNeae 
pNeae2 
pNVgfp 
pNVfib 
pNVtir 
pNVega 
pDisplay 
pDisplay-GFP-tm 
pDisplay-TirM-tm 
pGE 
pGEflu 
pGEflu-SAgfp 
pGEflu-SAtir 
pGEflu-SAega 
pGEmat-lux 
pACBSR 
pCP20 
pGEycgr 
pGEPcysPCherryT0 
pGEPcysDCherryT0!
pGEPyeeECherryT0!
pGEPydjNCherryT0!
pGEPldhACherryT0!
pGEPfruBCherryT0 
pGEmsbB 
pGEminCD-AmpFRT!
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pNVfib: A DNA fragment encoding a VHH binding human fibrinogen (Campuzano et al., 2014) 
was cloned between SfiI and NotI sites of pNeae2. 
pNVega: a DNA fragment encoding a VHH binding human EGFR (Roovers et al., 2007) was 
cloned between SfiI and NotI sites of pNeae2. 
pDisplay-TirM-tm: the DNA sequence corresponding to amino acid residues 252 to 360 of the 
translocated intimin receptor  of EHEC was amplified by PCR from pET28a-TirMEHEC (Salema 
et al., 2013) template with oligonucleotide primers Sfi-TirM-For and TirM-Xma-Rev. The 
amplified fragment was digested with SfiI and XmaI and cloned into the same sites of pDisplay 
vector. Subsequently, a DNA fragment encoding mWasabi (GeneBank Accession Number 
EU024648) was synthesized (GeneArt, Life Technologies) with flanking SmaI and SacII 
restriction sites and cloned into pDisplay. 
pGE: This 1436 bp KmR-suicide plasmid contains two I-SceI sites flanking a multiple cloning 
site (MCS) with the following restriction sites: XmaI, XhoI, BsaI, SacI, NdeI, XbaI, HindIII, SpeI, 
AvrII, SphI and XmaI. This plasmid was constructed ligating three DNA fragments, one 
encompassing the R6K origin of replication, a Km resistance cassette and the MCS. A DNA 
fragment of 424 bp corresponding to R6K origin of replication was PCR amplified from plasmid 
pEMG (Martinez-Garcia and de Lorenzo, 2011) with R6K1 and R6K2 primers. This PCR 
product has XmaI and I-SceI sites at its 5'-end and an AscI site at its 3'-end. The Km resistance 
cassette was amplified by PCR from pEMG with Km1 and Km2 primers. This PCR product of 
958 bp has an AscI site at its 5'-end and I-SceI and XmaI sites at its 3'-end. The MCS was 
obtained annealing oligonucleotides MCS1 and MCS2 generating a DNA fragment of 74 bp 
with XmaI cohesive ends. PCR fragments of R6K and Km were digested with XmaI and AscI, 
and ligated to the MCS. 
pGEflu: This suicide plasmid is a pGE-derivative with two homology regions (HR) of ca. 500 bp 
flanking the flu gene that were amplified by PCR from the chromosomal DNA of E. coli K-12 
MG1655. The 5'-HR was amplified with oligos XhoI-yeeP and SacI-yeeP and cloned between 
XhoI-SacI sites of pGE. The 3'-HR was amplified with oligonucleotides Ang43-Spe and and 
Ang43-Sph and cloned into SpeI and SphI restriction sites of pGE vector backbone. 
pGEflu-SAgfp: The sequence encoding NVgfp fusion was obtained by digesting pNVgfp 
(Salema et al., 2013) with XbaI and HindIII and cloned into same sites of pGEflu. Promoter PN25 
sequence, obtained by hybridizing oligonucleotides PN25-Sac-Xba1 and PN25-Sac-Xba2, was 
cloned upstream NVgfp between SacI and XbaI sites.  
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pGEflu-SAtir: The sequence encoding the VHH anti-TirM and C-terminal myc-tag was 
obtained by digestion of pNVtir (Salema et al., 2013) with NcoI and HindIII and cloned into the 
same sites of pGEflu-SAgfp replacing the VHH anti-GFP and myc-tag of SAgfp.  
pGEmat-lux: This suicide plasmid is a pGE-derivative contains the luxCDABE operon with P2 
constitutive promoter and two homology regions (HR) of ca. 500 bp flanking the matB gene of E. 
coli K-12 MG1655. The 5'-HR was amplified by PCR using primers matA-XhoI and matA-SacI 
and cloned between XhoI and SacI sites of pGE. The 3'-HR was amplified by PCR using 
primers matBC-SpeI and matBC-SphI and cloned into SpeI and SphI sites of pGE. The 
luxCDABE operon was obtained by HindIII and SpeI digestion of pSEVA226 (Silva-Rocha et al., 
2013) and cloned into the same sites of pGE vector backbone. The P2 promoter sequence was 
cloned between SacI and HindIII sites of pGE. The constitutive P2 promoter is a synthetic 
tandem promoter based on PA1 and Ptac promoters (Brunner and Bujard, 1987) with the 
following sequence (5’-TTATCAAAAAGAGTATTGGCTTAAAGTCTAACCTATAGGATACTT 
ACAGCCATCGAGAGGGACACGGCGAATCTAGAGTCGACCTGCAGGCATGCAAGCTCTTC
TGAAATGAGCTGTTGACAATTAATCATGGGCTCGTATAATAGATTCAT-3’)  
pGEycgR: This suicide plasmid is a pGE-derivative with two homology regions (HR) of ca. 500 
bp flanking the ycgR gene that were amplified by PCR from the chromosomal DNA of E. coli K-
12 MG1655. The 5'-HR was amplified with oligos XhoI HR1 ycgR and XbaI HR1 ycgR. The 3’-
HR was amplified with oligos XbaI HR2 ycgR and SphI HR2 ycgR. pGE vector was digested 
with XhoI and Sph I restriction enzymes, the 5’ HR was digested with XhoI and XbaI and the 3’ 
HR was digested with XbaI and SphI restriction enzymes. The pGEycgR plasmid was 
constructed ligating these 3 DNA fragments at the same time.  
pGEflu-SAega: The sequence encoding the VHH anti-ega and C-terminal myc-tag was 
obtained by digestion of pNVega with NcoI and HindIII and cloned into the same sites of 
pGEflu-SAgfp replacing the VHH anti-GFP and myc-tag of SAgfp.  
pGEPcysPCherryT0: This suicide plasmid is a pGE-derivative contains the mCherry gene  
with PcysP promoter ( i.e. 500 pb upstream the start codon of cysP gene) and the lambda T0 
derived transcriptional terminator sequence. mCherry gene was amplified from pP35mCherry 
plasmid (a gift from Jean-Marc Ghigo and Christophe Beloin) with oligos NotI-RBS-Cherry and 
SpeI Cherry. PcysP promoter was amplified by PCR from the chromosomal DNA of E. coli K-12 
MG1655 with oligos XhoI cysP Prom and NotI cysP Prom. T0 transcriptional terminator was 
amplified from pSEVA226 (Silva-Rocha et al., 2013) with oligos SpeI terminator and SphI 
terminator. The 3 fragments were digested and cloned into their respective sites present in 
pGEyeeJPtetGFP plasmid, leading to the substitution of GFP coding gene by mCherry coding 
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gene, Ptet promoter and yeeJ 5’ HR by PcysP promoter sequence, and yeeJ 3’ HR by T0 
transcriptional terminator.  
pGEPcysDCherryT0: The PcysD promoter sequence (i.e. 500 pb upstream the start codon of 
cysD gene) was amplified by PCR from the chromosomal DNA of E. coli K-12 MG1655 with 
oligos XhoI cysD Prom and NotI cysD Prom, and cloned into XhoI and NotI sites of 
pGEPcysPCherryT0, replacing PcysP promoter by PcysD promoter. 
pGEPyeeECherryT0: The PyeeE promoter sequence (i.e. 500 pb upstream the start codon of 
yeeE gene) was amplified by PCR from the chromosomal DNA of E. coli K-12 MG1655 with 
oligos XhoI yeeE Prom and NotI yeeE Prom, and cloned into XhoI and NotI sites of 
pGEPcysPCherryT0, replacing PcysP promoter by PyeeE promoter. 
pGEPydjNCherryT0: The PydjN promoter sequence (i.e. 500 pb upstream the start codon of 
ydjN gene) was amplified by PCR from the chromosomal DNA of E. coli K-12 MG1655 with 
oligos XhoI ydjN Prom and NotI ydjN Prom, and cloned into XhoI and NotI sites of 
pGEPcysPCherryT0, replacing PcysP promoter by PydjN promoter. 
pGEPldhACherryT0: The PldhA promoter sequence (i.e. 500 pb upstream the start codon of 
ldhA gene) was amplified by PCR from the chromosomal DNA of E. coli K-12 MG1655 with 
oligos XhoI ldhA Prom and NotI ldhA Prom, and cloned into XhoI and NotI sites of 
pGEPcysPCherryT0, replacing PcysP promoter by PldhA promoter. 
pGEPfruBCherryT0: The PfruB promoter sequence (i.e. 500 pb upstream the start codon of 
fruB gene) was amplified by PCR from the chromosomal DNA of E. coli K-12 MG1655 with 
oligos XhoI fruB Prom and NotI fruB Prom, and cloned into XhoI and NotI sites of 
pGEPcysPCherryT0, replacing PcysP promoter by PfruB promoter. 
pGEmsbB: This suicide plasmid is a pGE-derivative with two homology regions (HR) of ca. 500 
bp flanking the msbB gene that were amplified by PCR from the chromosomal DNA of E. coli K-
12 MG1655. The 5'-HR was amplified with oligos XbaI HR1 msbB and SpeI HR1 msbB. The 3’-
HR was amplified with oligos SpeI HR2 msbB and SphI HR2 msbB. The pGE vector was 
digested with XbaI and SphI restriction enzymes, the 5’ HR was digested with XbaI and SpeI 
and the 3’ HR was digested with SpeI and SphI restriction enzymes. The pGEycgR plasmid 
was constructed ligating these 3 DNA fragments at the same time. 
pGEminCD-AmpFRT: This suicide plasmid is a pGE-derivative with two homology regions (HR) 
of ca. 500 bp flanking the 3’ end of minC gene and the 5’ end of minD gene. In addition 
between the two HRs, an Ampicillin resistance gene cassette flanked by two Flippase 
Recognized target (FRT) sites, was cloned. HRs were amplified by PCR from the chromosomal 
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DNA of E. coli K-12 MG1655 using oligos XbaI-minE and HindIII-minD for 5’ HR and SpeI-minC 
and SphI-minC for 3’ HR. The 5’ HR was digested with XbaI and HindIII, whereas the 3’ HR 
was digested with SpeI and SphI and both fragments were cloned into their respective sites in 
pGE vector. The Ampicillin resistance gene was amplified by PCR from pUC18 plasmid (Vieira 
and Messing, 1982) with oligos HindIII-FRT-bla and SpeI-FRT-bla that included FRT sites at 
both ends of the fragment. The PCR product was digested with HindIII and SpeI enzymes and 
cloned into the same sites of pGE vector backbone. 
 
4. In vitro cell culture and plasmid transfection. 
 The human epithelial tumor cell line HeLa (ATCC, CCL-2) was grown as monolayer in 
Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum 
(FBS) and 2 mM glutamine (complete DMEM), at 37°C with 5% CO2. For transfection, HeLa 
cells were seeded in 24-well tissue culture plates (BD Falcon) (~105 cells/well), grown for 20 h 
at 37°C with 5% CO2, and transfected with 0.6 µg/well of plasmids pDisplay-GFP-tm or 
pDisplay-TirM-tm following the calcium phosphate method (Jordan et al., 1996). After 22 h 
incubation at 37°C with 5% CO2, the medium was removed, wells were washed three times 
with phosphate-buffered saline (PBS) and filled with complete DMEM medium containing G418 
(0.5 mg/ml, Invitrogen, Life Technologies). After 24 h incubation, cells were passed to T75 flask 
(BD Falcon) with the same medium and further grown.  G418-resistant HeLa cells expressing 
GFP or mWasabi fusion proteins were selected from these cultures by fluorescence activated 
cell sorting (FACS) using Epics-Altra Cell Sorter (Beckman Coulter). HeLa-GFP-tm and HeLa-
TirM-tm positive cells populations were expanded on complete DMEM medium. 
 
5. Flow cytometry analyses.  
Bacteria (equivalent to a final OD600 of 1.0) were harvested from cultures by centrifugation 
(4000 xg, 3 min), washed with PBS and resuspended in 1 ml of PBS containing 10% (v/v) goat 
serum (Sigma).  An aliquot sample of 200 µl was incubated for 1 h on ice with anti-myc mAb 
clone 9B11 (1:200; Cell Signaling Technology). Next, bacteria were washed in PBS, 
resuspended in 500 µl of PBS containing 10% (v/v) goat serum, and stained for 40 min in the 
dark with Alexa 488-conjugated anti-mouse IgGs (1:500; Molecular Probes, Life Technologies). 
Bacteria were finally washed and resuspended in a final volume of 1 ml of PBS, and analyzed 
in a flow cytometer (Gallios, Beckman Coulter). 
 
6. Protein extract preparation, SDS-PAGE, and Western blots. 
Whole-cell protein extracts were prepared in urea-SDS sample buffer as described previously 
(Bodelon et al., 2009). SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotting 
conditions to polyvinylidene difluoride membrane (PVDF, Immobilon-P; Millipore) have been 
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reported (Bodelon et al., 2009; Salema et al., 2013). For immunodetection, the PVDF-
membranes were incubated with anti-myc mAb clone 9B11 (1:2000; Cell Signaling Technology) 
to detect myc-tagged SAs and anti-mouse IgG-peroxidase (POD) conjugate (1:5000; Sigma) as 
secondary antibody. GroEL was detected with anti-GroEL MAb-POD conjugate (1:5000; 
Sigma). Membranes were developed by chemiluminescence using a mixture in 100 mM Tris-
HCl (pH 8.0) containing 1.25 mM luminol (Sigma), 0.22 mM cumaric acid (Sigma), and 
0.0075% (v/v) H2O2 (Sigma), and exposed to an X-ray film (Curix, Agfa).  
 
7. Adhesion assays to antigens immobilized on a plastic surface. 
Purified GFP (Upstate, Millipore) or human fibrinogen (Enzyme Research Laboratories) as 
indicated, were diluted in PBS to 10 µg/ml and 100 µl were adsorbed onto ELISA plates 
(Maxisorb, Nunc) overnight at 4°C. Antigen-coated plates were washed with PBS and blocked 
for 1 h at room temperature with PBS containing 3% (w/v) skimmed milk. Next, a bacterial 
suspension (100 µl) of the indicated strain was added at an OD600 of 3.0 in PBS and incubated 
for an additional hour. The plates were then washed with PBS three times, and the presence of 
bound bacteria was visualized by light microscopy and macroscopically detected by staining 
with crystal violet solution (Sigma).  
 
8. Bacterial adhesion assays to in vitro cultured HeLa or NIH 3T3 derived cells and 
immunofluorescence microscopy.  
Bacteria from the indicated E. coli strain were harvested by centrifugation (4000 xg, 3 min) from 
static liquid LB cultures grown overnight at 37 oC. An OD600 of 1.0 from these cultures grown 
statically was determined to contain ~3x108 CFU/ml by plating in LB-agar. Bacteria were 
washed in PBS and resuspended at 3x107 CFU/ml in PBS or DMEM.  For an infection at MOI 
300:1, a 1 ml sample of this bacterial suspension was added to a single well of a 24-well tissue 
culture plate having the indicated HeLa or NIH 3T3 derived cell line (~105 cells/well). HeLa or 
NIH 3T3 derived cells were grown on sterile coverslips (13 mm diameter, VWR international) 
placed at the bottom of the well. After 1 h infection at 37 oC, the wells were aspirated and 
washed five times with 1 ml PBS at room temperature.  The coverslips were fixed for 20 min at 
room temperature with 0. 5 ml of a paraformaldehyde 4% (w/v) solution in PBS and washed 
three times with 1 ml of PBS. Coverslips were blocked and stained for 1 h at room temperature 
in a wet chamber with 50 µl of PBS-10% goat serum solution, having a rabbit polyclonal serum 
anti-E. coli O and K antigenic serotypes (1:1000; Biodesign) for HeLa cells 
immunofluorescences, or having rabbit polyclonal serum anti-E. coli O and K antigenic 
serotypes (1:1000; Biodesign) and mouse mAb anti-EGFR (1:500; Calbiochem) for NIH 3T3 
derived cell lines immunofluorescences . The coverslips were washed by immersion 15 times in 
a large volume of PBS (100 ml), placed again the wet chamber and incubated for 40 min at 
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room temperature with 50 µl of PBS-10% goat serum solution, having a goat anti-rabbit IgG-
Alexa 594 conjugated secondary antibody (1:500; Molecular Probes, Life Technologies) and 
DAPI (1:500; Sigma) for HeLa cells immunofluorescences, and having goat anti-rabbit IgG-
Alexa 594 conjugated secondary antibody (1:500; Molecular Probes, Life Technologies), goat 
anti-mouse IgG-Alexa 488 (1:500; Molecular Probes, Life Technologies) and DAPI (1:500; 
Sigma) for NIH 3T3 derived cells immunofluorescences. Next, the coverslips were washed with 
PBS as above, the excess of liquid was removed touching a kimwipe with the edge of the 
coverslip, and mounted with 2 µl of Prolong (Invitrogen) on glass slides. The samples were 
examined by epifluorescence microscopy (Zeiss Axio imager microscope) or by confocal 
microscopy (Leica TCS SP5 multispectral confocal system). For time-lapse live cell video 
microscospy, HeLa-GFP-tm cell, grown on 24-well tissue culture plates, were infected with 
1x107 CFU of EcM1luxSAgfp in a final volume ~0.3 ml/well (MOI 100:1) and monitored using an 
Olympus IX71 microscope equipped with an Olympus cell^R motorized TIRF system. 
 
9. Bacterial adhesion assays to in vitro cultured NIH 3T3 derived cells to screen 
adhesion-dependent promoters.  
The indicated bacterial strains expressing SAs against hEGFR and the mCherry protein under 
the control of different promoters were harvested by centrifugation (4000 xg, 3 min) from static 
liquid LB cultures grown overnight at 37 oC. An OD600 of 1.0 from these cultures grown statically 
was determined to contain ~3x108 CFU/ml by plating in LB-agar. Bacteria were washed in PBS 
and resuspended at 4x107 CFU/ml in DMEM. For the infections at MOI 100:1, a 250 µl sample 
of this bacterial suspension was added to a single well of a 24-well tissue culture plate having 
3T3#2.2 or Her14 cells (~105 cells/well) growing over sterile coverslips (13 mm diameter, VWR 
international), placed at the bottom of the well. After 15 minutes of infection at 37 oC, the wells 
of tissue culture plates containing Her14 cells were aspirated and washed three times with 1 ml 
of pre-heated DMEM to remove unbound bacteria. After that, plates were placed again at the 
incubator for two additional hours to allow mCherry protein translation, maturation and 
accumulation. Lastly, coverslips were fixed for 20 min at room temperature with 0. 5 ml of a 
paraformaldehyde 4% (w/v) solution in PBS and washed three times with 1 ml of PBS before 
mount them with 2 µl of Prolong (Invitrogen) on glass slides. On the other hand, tissue culture 
plates containing 3T3#2.2 cells were infected with the indicated bacterial strains for 2 hours, but 
after 1 hour of infection 0,5 ml of pre-heated fresh DMEM was added to each well in order to 
maintain a bacterial density similar to the one of Her14 infected cells. After 2 hours of infection, 
the medium in which the infection took place (0,75 ml) containing the non-adhered bacteria was 
collected and centrifuged (4000g, 3 min). Bacterial pellet was fixed for 20 min at room 
temperature with 0. 5 ml of a paraformaldehyde 4% (w/v) solution in PBS and washed three 
times with 1 ml of PBS. After fixation, 100 µl of the bacterial suspension were placed over Poly-
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L-Lysine (SantaCruz Biotechnology) coated coverslips and incubated for 20 minutes. Lastly, 
the excess of liquid was removed touching a kimwipe with the edge of the coverslip before 
mount them with 2 µl of Prolong (Invitrogen) on glass slides. All samples were examined by 
epifluorescence microscopy (Zeiss Axio imager microscope) 
 
10. Minicells adhesion assays to in vitro cultured NIH 3T3 derived cells and 
immunofluorescence microscopy.  
Minicells with the desired SA specificity were harvested by centrifugation (4000g, 20 min), from 
minicells purifications stored at 4 ºC in OptiPrepTM solution at 4% (w/v) in water, and 
resuspended at 4x108 minicells/ml in DMEM. For a minicell-mammalian cell co-incubation at 
MOI 1000:1, a 250 µl sample of this minicell suspension was added to a single well of a 24-well 
tissue culture plate having the indicated or NIH 3T3 derived cell line (~105 cells/well) that were 
grown on sterile coverslips (13 mm diameter, VWR international) placed at the bottom of the 
well. After four hours of coincubation at 37 oC, the coverslips were washed by immersion 15 
times in a large volume of PBS (100 ml) to remove unbound minicells. Subsequently, the 
coverslips were treated as in NIH 3T3 derived cell lines immunofluorescences carried out in 
bacterial adhesion assays and examined by confocal microscopy (Leica TCS SP5 multispectral 
confocal system) 
 
11. Double staining protocol to distinguish intra- and extracellular bacteria.  
Bacteria from the indicated E. coli strain were harvested by centrifugation (4000 xg, 3 min) from 
static liquid LB cultures grown overnight at 37 oC. An OD600 of 1.0 from these cultures grown 
statically was determined to contain ~3x108 CFU/ml by plating in LB-agar. Bacteria were 
washed in PBS and resuspended at 4x107 CFU/ml in DMEM. For the infections at MOI 100:1, a 
250 µl  sample of this bacterial suspension was added to a single well of a 24-well tissue 
culture plate having HeLa-GFP-tm or Her14 cells (~105 cells/well) growing over sterile 
coverslips (13 mm diameter, VWR international), placed at the bottom of the well. After 15 
minutes of infection at 37 oC, the wells were aspirated and washed five times with 1 ml PBS at 
room temperature. Coverslips were blocked and stained for 30 minutes at 4 ºC in a wet 
chamber with 50 µl of PBS-10% goat serum solution, having a rabbit polyclonal serum anti-E. 
coli O and K antigenic serotypes (1:500; Biodesign) for HeLa-GFP-tm cells 
immunofluorescences, or having rabbit polyclonal serum anti-E. coli O and K antigenic 
serotypes (1:500; Biodesign) and mouse mAb anti-EGFR (1:250; Calbiochem) for Her14 cells 
immunofluorescences. After this staining, coverslips were washed by immersion 15 times in a 
large volume of PBS (100 ml) and fixed for 20 min at room temperature with 0. 5 ml of a 
paraformaldehyde 4% (w/v) solution in PBS, which was washed three times with 1 ml of PBS. 
Subsequently, coverslips were placed again the wet chamber and incubated for 40 min at room 
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temperature with 50 µl of PBS-10% goat serum solution, having a goat anti-rabbit IgG-Alexa 
546 conjugated secondary antibody (1:500; Molecular Probes, Life Technologies) for HeLa-
GFP-tm cells immunofluorescences, and having goat anti-rabbit IgG-Alexa 594 conjugated 
secondary antibody (1:500; Molecular Probes, Life Technologies), and goat anti-mouse IgG-
Alexa 647 (1:500; Molecular Probes, Life Technologies) for Her14 cells immunofluorescences.  
After extracellular bacteria staining, cells were permeabilized for 10 min at room temperature 
with 0. 5 ml of a Triton X-100 0,2% (v/v) solution in PBS, which was washed four times with 1 
ml of PBS. After cell permeablization, both extra- and intracellular bacteria were stained 
following the same procedure that the one used before permeablization, but using as 
secondary antibodies anti-rabbit IgG-Alexa 647 conjugated  antibody (1:500; Molecular Probes, 
Life Technologies) for HeLa-GFP-tm cells immunofluorescences, and anti-rabbit IgG-Alexa 488 
conjugated  antibody (1:500; Molecular Probes, Life Technologies) for Her14 cells 
immunofluorescences. After stainining, samples were mounted with 2 µl of Prolong (Invitrogen) 
on glass slides, and examined by confocal microscopy (Leica TCS SP5 multispectral confocal 
system) 
 
12. Infection of tumor-bearing mice and recovery of bacteria from tissues.  
All animal experiments were done in accordance with protocols approved by the CNB Ethics 
Committee for Animal Experimentation (ref 11034) and by the Hospital Universitario Puerta de 
Hierro Animal Care and Use Committee, in compliance with Spanish and European Union 
legislation. Five-week-old athymic female Hsd:Athymic Nude-Foxn1nu were obtained from 
Harlan (Harlan Ibérica). Tumor-bearing mice were generated by subcutaneous injection of 
~1x106 HeLa-GFP-tm or HeLa cells, as indicated, in 100 µl PBS containing 20% (v/v) Matrigel 
(BD Biosciences), into the abdominal right flank of 6-week-old Nude mice. Tumor volumes were 
estimated with calipers according to the formula: width2×length×0.52. When tumors reached a 
volume between 200-400 mm3, the mice were randomly divided into experimental groups. 
Bacteria were grown and harvested as described above for the in vitro adhesion assays, and 
resuspended in sterile PBS at 1x108 CFU/ml. For each independent experiment the number of 
CFU in this bacterial suspension was determined, showing an experimental error below 10%. 
This bacterial stock was directly used for systemic inoculation of mice receiving a dose of 1x107 
CFU by injection of 100 µl into the lateral tail vein using a 0.5 ml syringe with a 29G needle 
(Becton Dickinson). Alternatively, for mice receiving a dose of 1x105 CFU, the original bacterial 
stock was diluted in PBS to 1x106 CFU/ml and 100 µl were injected per mouse as above.  
These bacterial doses did not cause any apparent disease symptoms in the animals, which 
showed normal phenotype throughout the entire experiment (i.e. mobility, weight, feeding 
behavior). For determination of bacterial CFU per gram (CFU/g) of tumors, livers and spleens, 
animals were euthanized and tumors and organs were excised, placed individually into (pre-
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weighed) sterile tubes containing 5 ml of PBS and weighed. Samples were then transferred to 
sterile sampling bags (VWR) and Triton X-100 (Sigma) was added to a final concentration of 
0.2% (v/v).  Samples were homogenized by soft mechanical squeezing.  Next, a 100-µl sample 
of the homogenates was serially diluted in LB, plated in LB-agar and incubated overnight at 37 
oC to determine CFU. Bacterial titers were expressed as CFU/g of tissue. For statistical 
analysis a minimal bacterial titer of 50 CFU/g, corresponding to the detection limit of the assay, 
was considered in those cases in which no bacteria were detected by plating. 
 
13. Bioluminescence imaging.  
Bacterial light emission from LB plates or from tissue culture plates was captured using a 
ChemiDoc XRS system (Bio-Rad). For live imaging of bioluminescent bacteria in tumor-bearing 
mice, animals were anesthetized with 4% Isoflurane (Forene, Abbott) and maintained under 1% 
Isoflurane in a thermostated chamber with a high-resolution charge-coupled-device (CCD) 
cooled digital camera ORCA-2BT (Hamamatsu Photonics). Imaging analysis was done with the 
Hokawo software (Hamamatsu Photonics).  
 
14. RNA extraction from adhered or non-adhered bacteria. 
Bacteria from the indicated E. coli strain were harvested by centrifugation (4000 xg, 3 min) from 
static liquid LB cultures grown overnight at 37 oC. An OD600 of 1.0 from these cultures grown 
statically was determined to contain ~3x108 CFU/ml by plating in LB-agar. Bacteria were 
washed in PBS and resuspended at 108 CFU/ml in DMEM.  For an infection at MOI 100:1, a 9 
ml sample of this bacterial suspension was added to a 150 cm2 cell culture dish (BD Falcon) 
containing approximately 9x106 cells of the indicated HeLa or NIH 3T3 derived cell line. For 
RNA extraction a DEPC (Sigma)- treated water solution containing 1% (v/v) Acid Phenol 
(Sigma), 19% (v/v) Ethanol and 0,2% (w/v) SDS (Sigma), termed lysis buffer was prepared. 
After 15 minutes of infection at 37 ºC, infection media of cell culture dishes containing HeLa or 
3T3#2.2 cells (non-adhered bacteria) was collected and mixed with an equal volume of pre-
cooled 2X lysis buffer. On the other hand, after 15 minutes of infection at 37 ºC, cell culture 
dishes containing Hela-GFP-tm or Her14cells (adhered bacteria) were washed 3 times with 
pre-heated DMEM to remove unbound bacteria, and treated with pre-cooled 1X lysis buffer 
containing DNAse I RNAse free (Roche). Both, adhered and non-adhered bacteria were 
incubated with 1X or 2X lysis buffer for 30 minutes at 4 ºC. Subsequently lysis buffers 
containing bacteria were centrifuged for 1 hour at 7200g and bacterial pellets were washed 2 
additional times with pre-cooled 1X lysis buffer to ensure mammalian cell lysis. After that, 
bacterial pellets were resuspended in a TE solution (Tris-HCl pH 8; EDTA 1mM) containing 
Lysozyme (Sigma) at 2 mg/ml, and incubated for 5 minutes at room temperature to break 
bacterial cell wall. Bacterial RNA was isolated using Trizol (Life Technologies) following 
MATERIALS AND METHODS 
 65 
manufacturer’s recommendations, adding two additional Chloroform washing steps to avoid 
any phenol contamination. The resulting aqueous phase from Trizol-mediated RNA isolation 
was precipitated with Isopropanol (Merck) and 20 µg of glycogen (Roche) for 1h at 4ºC. Lastly, 
bacterial RNA was treated with turbo DNA free kit (Life Technologies) for complete digestion of 
DNA and cleaned-up with RNAeasy kit (Quiagen) to remove DNAse. Quality and concentration 
of isolated bacterial RNA was determined using Bioanalyzer 2100 (Agilent), obtaining RNA 
Integrity Numbers (RIN) ranging from 8.6 to 9.8. 
 
15. Transcriptomic profiling by RNAseq.  
RNA preparations were treated with the rRNA capture hybridization approach from the 
MicrobExpress kit (Ambion) according to manufacturer’s instructions. Non directional cDNA 
libraries were prepared from enriched fragmented mRNA using the TruSeq RNA sample 
preparation V2 kit set A (Illumina). Fragments of cDNA (ca. 150 bp), ligated with Illumina 
adapters and amplified per PCR, were purified from each library. Quality was confirmed on a 
Bioanalyzer (Agilent) and quantification done using a Qubit® dsDNA HS Assay Kit (Invitrogen). 
Sequencing of 49 bases was performed in single-end mode, using an Illumina HiSeq2000 
instrument (Illumina). Samples were multiplexed on two lines on the flowcell (eight per line). 
Sequences shorter than 25 nucleotides, of poor quality, and those corresponding to adapters 
were discarded for further analysis. Bowtie software (Langmead et al., 2009) was employed to 
align the reads to the E. coli genome.  
Statistical analysis were carried out with R software and the DESeq package (Anders and 
Huber, 2010). For each strain the count data were normalized according to DESeq procedure 
with the default parameter. A p-value reflecting the significance of the biological effect (i.e. 
adhesion to target cells) was then computed and adjusted according to the Benjamini and 
Hochsberg (BH) procedure for each gene (Benjamini). Genes with an adjusted p-value below 
0,05 were considered differentially expressed. 
 
16. Trancriptomic profiling by DNA microarrays.  
RNA preparations were transformed to cDNA and fluorescently labeled with either Cy3 or Cy5 
using the SuperScript Indirect cDNA Labeling System (Invitrogen). The labeled cDNAs 
corresponding to the adhered and non-adhered conditions from EcM1luxSAega strain were 
mixed and used to hybridize a oligonucleotide-based E. coli genome-wide DNA microarray 
(Agilent Microarray Design ID 020097). Four hybridizations, corresponding to four independent 
experiments (biological replicas), were used. The results for each replica (median intensity for 
each spot) were normalized and statistically analyzed as described using the LIMMA software 
package (Smyth, 2004), which deduces the differential expression values of the genes in the 
microarray using linear models and moderated t-statistics using the empirical Bayes approach. 
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The probability values obtained (p-values) were adjusted for multiple testing to control the false 
discovery rate (Benjamini). Genes with an adjusted p-value below 0,05 were considered 
differentially expressed. 
 
17. Isolation and analysis of LPS.  
Samples of LPS from the indicated stains were extracted using an ammonium hydroxide-
isobutyric acid method and subjected to negative-ion matrix-assisted laser desorption 
ionization-time of flight (MALDI-TOF) mass spectrometry analysis, as previously described (El 
Hamidi et al., 2005; Perez-Gutierrez et al., 2010) Briefly, lyophilized crude cells (10 mg) were 
resuspended in 400 µl isobutyric acid-1 M ammonium hydroxide (5:3, v/v) and were incubated 
in a screw-cap test tube at 100°C for 2 h with occasional subjection to a vortex. Samples were 
cooled in ice water and centrifuged at 2000g for 15 min. The supernatant was transferred into a 
new tube, diluted with an equal volume of water, and lyophilized. The sample was then washed 
twice with 400 µl methanol and centrifuged at 2000g for 15 min. The insoluble lipid A was 
solubilized in 100 to 200 µl chloroform-methanol-water mixture (3:1.5:0.25, v/v/v). Analyses 
were performed with a Bruker Autoflex II MALDI-TOF mass spectrometer (Bruker Daltonics, 
Inc.) in negative reflective mode with delayed extraction. Each spectrum was an average of 300 
shots. The ion-accelerating voltage was set at 20 kV. Dihydroxybenzoic acid (Sigma) was used 
as a matrix. A sample of a few microliters of a lipid A suspension (1 mg/ml) was desalted with a 
few grains of ion-exchange resin (Dowex 50W-X8; H+) in an Eppendorf tube. A 1-µl aliquot of 
the suspension (50 to 100 µl) was deposited onto the target and covered with the same amount 
of the matrix suspended at 10 mg/ml in a 0.1 M solution of citric acid. A peptide calibration 
standard (Bruker Daltonics) was used to calibrate the MALDI-TOF mass spectrometer.  
 
18. Minicells purification.  
A 10-ml LB pre-inocolum of the minicell producer strain was grown during 8 hours at 37 ºC with 
agitation (160rpm), after that, pre-inocolum was transferred to a flask containing one liter of 
fresh LB that was grown overnight at 37 ºC with agitation (160rpm). A culture of one liter of 
minCD- mutant bacteria was subjected to initial differential centrifugation at 550g for 40 minutes 
at 4 ºC to decrease the bulk of the bacterial burden. The resulting bacterial cell/minicell 
supernatant was centrifuged at 4000g for 20 min at 4 ºC to harvest the bacteria/minicell content, 
which was resuspended in Optiprep solution at 4% (w/v) (see below) and subjected to two 
sequential density gradient centrifugation steps using a isotonic biologically compatible medium 
(OptiPrepTM, Axis-Shield PLC, Scotland), which is a sterile 60% (w/v) solution of iodixanol in 
water. Gradients were performed with OptiPrep solutions ranging from 20% to 6% (w/v). After 
both density gradient centrifugations minicells were found in a low-density band, whereas 
bacteria were found in the pellet. The enriched minicell fraction still contained some residual 
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bacterial cells that were eliminated after incubating the suspension in LB liquid media for 30 
min at 37 ºC and shaking to reactivate any residual bacterial cell and then for 90 minutes in LB 
liquid media containing gentamycin (100 µg/ml) at 37 ºC with agitation to kill any live bacterial 
cell. Lastly, the antibiotic treated minicell enriched fraction, was centrifuged at 4000g for 20 min 
at 4 ºC and resuspended in 4% (w/v) OptiPrep solution and subjected to an additional density 
gradient centrifugation step to eliminate any dead bacterial cell.  
 
19. Minicells quantification. A method based on minicell protein content determination was 
developed to quantify minicells. A volume equivalent to 6x108 CFU was collected from an 
overnight culture of EcM1luxSAega grown statically at 37 ºC, centrifuged at 4000g for 3 
minutes, resuspended in 200 µl of PBS, sonicated (LabSonic B, Braun) for 40 seconds to 
release protein content and serially diluted using 2 as the dilution factor. Protein content in all 
dilutions was determined with bicinchoninic acid (BCA) protein assay kit (ThermoScientific) 
providing an equation that correlates CFU and protein content. A 100-µl fraction of the purified 
minicells solution was treated in the same way to obtain a BCA-based protein content 
estimation in minicells. The equation that correlates protein content and CFU enable to 
determine the number of minicells from the data of protein content estimated for them, including 
a correction factor of five given the size difference between bacteria (2 µm) and minicells (0,4 
µm). A yield of approximately 1010 minicells was routinely obtained from a 1 liter culture of 
minCD-mutant bacteria. Acuraccy of this quantification method was confirmed by determining 
the number of minicells in a standard purification with Nanosight’s NS300 device (Nanosight 
Ltd.), an alternative method that allows visualization, counting and tracking of nanoparticles in 
liquid media. 
 
20. Transmission electron microscopy.  
Aliquots of five µl from the indicated purified minicells were applied to collodion-coated copper 
grids and incubated for two minutes at room temperature. After that, grids were washed three 
times with MilliQ water to remove excess of sample and the excess of MilliQ water was 
removed touching a kimwipe with the edge of the grid. For negative staining, samples were 
incubated with Phosphotungstic Acid (PTA) 2% (w/v) solution in MilliQ water for three minutes. 
Excess of PTA solution was removed touching a kimwipe with the edge of the grid. Images 
were taken with JEOL 1200EX-II electron microscope operated at 100 kV and recorded at a 
nominal magnification of 50000X. 
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21. Statistics.  
Statistical analyses comparing the ratio of colonized tumors between experimental groups were 
conducted with Fisher's exact test to determine two-tailed P values using Prism 5.0 (GraphPad 
software Inc).  Data were considered significantly different when P <0.05. 
 
 
22. Histology.  
For ex vivo histological analyses, resected tumors were fixed with 4% (w/v) paraformladehyde 
in PBS for 16 h at 4 oC and embedded in paraffin. Serial 6 mm sections were cut at the tumor 
center with a microtome (Leica RM2155) and placed onto glass slides. The samples were 
deparaffinized with xylene and ethanol solutions, re-hydrated in PBS, and incubated with 1 M 
citrate buffer (pH 6.0) and PBS-Tween (PBS, 0.1 % Tween 20) to unmask antigens. Tissue 
sections were blocked with 10% goat serum in PBS-Tween, and incubated with anti-E. coli 
polyclonal serum (1:100) 1 h at room temperature in the same buffer. Next, samples were 
washed with PBS-Tween and incubated with goat anti-rabbit IgG-Alexa 594 conjugated 
secondary antibody (1:500) in PBS-Tween with 10% goat serum for 1 h at room temperature. 
Samples were mounted in Vectashield media (Vector Labs) and images were obtained with a 
fluorescence microscope (Leica DMI6000B fluorescence system with Orca R2 digital camera 
from Hamamatsu).  
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Chapter 1: Construction of Synthetic Adhesins, expression and validation for driving E. 
coli adhesion to antigenic surfaces. 
 
1.1 Synthetic adhesins structure and expression from inducible plasmids. 
We hypothesized that synthetic adhesins (SAs) for E. coli could be based on two distinct 
structural and functional domains, one having the specific adhesion function, and a second for 
anchoring and displaying the protein on the surface of the bacterium. Excellent candidates for 
the adhesion module were sdAbs from camelids (VHHs or nanobodies) given their superior 
binding, small size, high solubility and stability properties (see Introduction section 4.2) 
Previous work of our group assessed the possibility of display VHHs on the surface of E. coli 
with different β-domains from members of the T5SS, a large family of proteins with “self-
translocation-capacity” (Marin et al., 2010; Veiga et al., 2004) (see Introduction section 4.3). 
Recently, it was found that the the β-domains of EhaA autotransporter and Intimin from EHEC 
mediate the effective display of VHHs on the surface of E. coli, allowing the selection of high-
affinity clones from immune libraries (Salema et al., 2013). However, the antigen-binding 
activity of VHHs was higher when displayed with Intimin β-domain than with EhaA β-domain 
(Salema et al., 2013). In addition, preliminary experiments displaying model VHHs with EhaA β-
domain on E. coli showed weak bacterial adhesion to plastic surfaces coated with the antigen 
recognized by the VHH (data not shown). These initial observations, together with the high 
resistance of Intimin β-domain to the action of denaturing agents (e.g. SDS, urea) and 
proteases (Bodelon et al., 2009), prompted us to investigate whether VHHs displayed with this 
OM-anchoring and transport domain could drive the effective adhesion of E. coli to target 
antigenic surfaces.  
The β-domain of Intimin used for the display of VHHs corresponds to the first 659 amino acids 
of EHEC Intimin (also referred to as Neae fragment) (Bodelon et al., 2009). This region 
comprises the N-terminal signal peptide (SP), the periplasmic LysM domain for peptidoglycan 
binding, a 12-stranded β-barrel domain for OM insertion, and the first surface-exposed Ig-like 
domain (named D0), which does not interact with Tir (Bodelon et al., 2009; Fairman et al., 
2012). 
The Neae polypeptide (ca. 69 kDa) can be fused to a VHH domain (ca. 13kDa) of the desired 
specificity flanked by short epitopes (E- and myc-tags) for immunodetection, generating a 
fusion protein termed NVHH or SA with a total mass of ca. 84 kDa. Thus, using as template a 
natural adhesin of E. coli such as Intimin (Fig. 6A) we were able to create SAs of defined 
specificity (Fig. 6B).  
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Figure 6. Intimin and synthetic adhesins structure. (A) Scheme of the primary structure of Intimin 
(left) showing the signal peptide (SP), the OM anchored region comprising LysM and the β-domain, and 
the secreted region comprising the Ig-like domains (D0, D1 and D2) and the lectin like domain (D3). 
Structural model of intimin (right) on the bacterial outer membrane (OM) showing the LysM domain in the 
periplasm (yellow sphere), the β-barrel embedded in the OM and the D0, D1, D2 and D3 domains 
exposed to the the extracellular milieu. (B) Scheme of the primary structure of SAs (left) showing the N-
terminal domain of Intimin (Neae), comprising the signal peptide (SP), LysM, β-domain and D0 Ig-like 
domain, fused to a variable Ig domain from heavy-chain-only antibodies (VHH). The E-tag and myc-tag 
epitopes flanking the VHH domain are also indicated. Structural model of a SA fusion protein (right) in 
the bacterial outer membrane (OM) showing the LysM domain in the periplasm (yellow sphere), the β-
barrel of Intimin embedded in the OM, and the D0 and VHH Ig-domains exposed to the extracellular 
milieu. !
We constructed two different NVHH fusions binding GFP (NVgfp) and human fibrinogen (NVfib) 
and expressed them in in E. coli K-12 strain EcM1 (MG1655 ΔfimA-H; Table M1). This strain 
has a deletion of the operon encoding encoding Type 1 fimbriae, a major adhesin found in most 
E. coli strains (Connell et al., 1996; Munera et al., 2008) (see Introduction section 3.2.1). 
Cultures of EcM1 bacteria bearing plasmids encoding NVgfp, NVfib, and the control 
polypeptide, lacking the myc-tag, Neae (Table M2), were induced with IPTG and the display of 
the corresponding NVHH fusion on the surface of E. coli was confirmed by 
immunofluorescence and by flow cytometry with anti-myc mAb (Fig. 7). 
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Figure 7. Synthetic Adhesins display on the surface of E. coli. (A) Fluorescence and light 
microscopy images of IPTG-induced cultures of EcM1 bacteria expressing Neae polypeptide control 
(pNeae), lacking myc-tag, or synthetic adhesins against human Fibrinogen (pNVfib) or GFP (pNVgfp) 
stained with anti-myc mAb and secondary anti-mouse IgG-Alexa 594 (B) Same cultures than in A were 
analyzed by flow cytometry. Histograms show the fluorescence intensity of bacteria stained with anti-myc 
mAb and secondary anti-mouse IgG-Alexa 488. 
 
1.2 Adhesion of E. coli expressing SAs to antigen-coated plastic surfaces. 
To investigate whether NVHH fusions could modify the adhesion properties of E. coli, we first 
examined the specific adhesion of bacteria to abiotic surfaces coated with the antigen 
recognized by the VHH. To this end, IPTG-induced EcM1 bacteria transformed with pNeae, 
pNVgfp or pNVfib were incubated with GFP- or Fibrinogen (Fib)-coated plastic surfaces, 
washed with PBS and either, stained with crystal violet (Fig. 8A) or subjected to light 
microscopy (Fig. 8B). This experiment revealed that, whereas control bacteria expressing Neae 
control polypeptide did not bind to GFP- or Fib-coated wells, bacteria expressing NVgfp or 
NVfib bound specifically to their respective antigens. These results demonstrated that NVHH 
fusions could act as actual SAs, driving the adhesion of E. coli bacteria to a target surface. 
 
 
Figure 8. Specific adhesion of E. coli expressing SAs to antigens immobilized on plastic surfaces. 
Induced E. coli EcM1 bacteria expressing the Neae polypeptide control (pNeae), or SAs binding GFP 
(pNVgfp) or human fibrinogen (pNVfib), were incubated with plastic surfaces coated with GFP or human 
fibrinogen (Fib), as indicated. After 1 hour unbound bacteria were removed by rinsing the wells with PBS 
and bacterial adhesion was assessed by crystal violet staining (A) and light microscopy (B). 
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1.3 Marker-less integration of gene cassettes encoding SAs and bioluminescent lux 
reporter in the chromosome of E. coli. 
To further investigate E. coli adhesion mediated by SAs, we developed constitutive gene 
expression cassettes that can be integrated as a single copy in the chromosome of E. coli. This 
strategy would allow constant expression of SAs in the absence of any exogenous inducer or 
antibiotic for plasmid maintenance. For site-specific integration in the chromosome of E. coli, 
we adapted the marker-less gene deletion system employed for E. coli genome reduction 
(Posfai et al., 2006), which enables sequential manipulation of multiple gene loci leaving no 
antibiotic resistance or vector sequences (Posfai et al., 1999). This technology is based on the 
insertion of a suicide plasmid bearing homology regions (HRs) of the targeted gene and a 
restriction site for I-SceI endonuclease. Subsequent expression of I-SceI generates double-
strand breaks that are repaired by homologous recombination, resulting in the specific 
modification of the targeted gene (e.g. gene insertion/deletion). For this genome edition, a 
suicide vector named pGE (Table 1) was constructed, as well as its derivatives pGEflu-SAgfp 
and pGEflu-SAtir for site-specific integration of SAs having VHHs against GFP and TirM, 
respectively. TirM is the extracellular domain (amino acids 252-360) of the translocated intimin 
receptor of EHEC (Frankel et al., 2001). In these plasmids the expression of the SAs is driven 
by the constitutive promoter PN25. The expression cassette (PN25 and SA) is flanked by HRs of 
the flu gene in E. coli K-12 strain MG1655. The flu gene encodes Antigen 43, an adhesin 
conserved in most E. coli strains that is involved in biofilm formation and bacterial self-
aggregation (van der Woude and Henderson, 2008) (see Introduction section 3.2.2). Thus, 
these suicide plasmids allowed the replacement of the flu gene in E. coli EcM1 by PN25-SAs 
cassettes generating strains EcM1SAgfp and EcM1SAtir (Fig. 9). 
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Figure 9. Site-specific integration of synthetic adhesin gene in the chromosome of E. coli.  
Scheme showing the integration of a SA gene in the flu locus of E. coli K-12 chromosome. Integration is 
done using a pGEflu-SA suicide plasmid containing the π-dependent R6K origin of replication, a 
kanamycin resistance gene (KmR) and a synthetic adhesin gene cassette of the desired specificity under 
the control of the PN25 constitutive promoter.  The SA gene cassette is flanked by HRs, corresponding to 
the 3'-ends of the yeeP and flu genes, and two I-SceI restriction sites. Homologous recombination of the 
suicide plasmid with the chromosome (Recombination I) leads to  KmR-cointegrants that are later 
resolved by the expression of I-SceI endonuclease from the helper plasmid pACBSR (Table M2).  The 
double strand breaks, generated by cleavage of DNA with I-SceI, are repaired by a second homologous 
recombination (Recombination II) that could either, revert the cointegrant to the wild type situation (not 
shown), or lead to the chromosomal integration of the SA-gene cassette replacing the flu gene (as 
depicted). 
 
In addition, a vector termed pGEflu, having flu HRs and lacking SA gene cassette, was 
constructed to generate the isogenic control strain EcM1Δflu, with a deletion in the flu gene and 
not expressing SAs. Next, EcM1Δflu, EcM1SAgfp and EcM1SAtir strains were tagged with a 
bioluminiscent reporter, the luxCDABE operon of Photorhabdus luminiscens under the control 
of a strong constitutive promoter, named  P2, which was inserted in the matBCDEF operon with 
the suicide vector pGEmat-lux. This operon encodes the meningitis-associated and 
temperature-regulated Mat fimbriae, also termed E. coli common pilus, which are produced by 
most E. coli pathogroups, being involved in early-stage biofilm development and host cell 
recognition (Rendon et al., 2007) (see Introduction section 3.2.1). The final bioluminescent 
strains were named EcM1luxΔflu, EcM1luxSAgfp and EcM1luxSAtir. 
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1.4 Constitutive expression of Synthetic Adhesins. 
Cultures of the bioluminescent strains, grown without any inducer or antibiotic, were analyzed 
by flow cytometry with anti-myc mAb to determine the expression levels of SAs in these strains. 
Data indicates that both SAs were displayed on the bacterial surface of these strains with 
homogeneous levels in the population, being SAgfp expressed at higher levels than SAtir (Fig. 
10). 
 
 
 
1.5 Viability and growth rate of engineered strains. 
To determine whether SAs expression could have an effect on the growth or on the viability of 
the engineered E. coli strains, cultures of the three strains were grown statically in LB media at 
37ºC overnight, serially diluted and plated to calculate the number of viable bacteria per unit of 
optical density at 600nm (OD600nm). The results from these experiments showed nearly identical 
viability of these strains with around 3x108 CFU/OD600nm (Fig. 11A). In addition, strains 
expressing SAs showed an identical growth curve than EcM1luxΔflu in LB media at 37ºC with 
agitation (Fig. 11B). These results demonstrated that bacterial growth and viability were not 
affected by the constitutive expression of SAs. 
Figure 10. Display levels of SAs in 
engineered strains. Flow cytometry analysis 
of E. coli EcM1luxΔflu, EcM1luxSAgfp, or 
EcM1luxSAtir bacteria. Histograms show the 
fluorescence intensity of bacteria stained with 
anti-myc mAb and secondary anti-mouse IgG-
Alexa 488. !
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Figure 11. Effect of SAs expression in bacterial viability and growth rate. (A) Number of viable 
bacterium per OD600 of the indicated strains after overnight growth in LB media at 37ºC. Error bars are 
the standard deviation of bacterial counts from the same culture in three different LB-agar plates. (B) 
Growth curve of the indicated strains at 37ºC in LB media with agitation. 
 
1.6 Stable expression of the introduced gene cassettes. 
EcM1luxSAgfp and EcM1luxSAtir strains were grown at 37oC for 5 days with a daily dilution 
(1:2000) in fresh LB medium lacking antibiotics. Every day an aliquot sample of each culture 
was centrifuged to harvest bacteria. Whole-cell protein extracts from the harvested bacteria 
were prepared and analyzed by Western blot with anti-myc mAb (to detect the SA) and anti-
GroEL mAb, as loading control (Fig. 12A), demonstrating that SAs were stably expressed 
throughout the length of the experiment (ca. 55 bacterial generations), without the need of any 
inducer or antibiotic selective pressure. Similarly, samples from each culture were streaked 
every day on LB-agar plates, incubated at 37ºC for ca. 16 hours and then exposed to a CCD 
camera to detect bioluminescence of the grown colonies (Fig 12B). This experiment 
demonstrated that the expression of the lux operon was also stably maintained along the length 
of the experiment, since all colonies on the plates showed strong bioluminescence signals.  
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Figure 12. Stable expression of SAs and lux gene cassettes. (A) Western blot analysis of the 
expression of SAs in EcM1luxSAgfp and EcM1luxSAtir strains grown in LB cultures for the indicated time 
with a daily dilution (1:2000) with fresh LB medium. SAs were immunodetected with anti-myc mAb. 
Cytoplasmic GroEL chaperone was used as loading control and was detected with anti-GroEL mAb. (B) 
Stability of the bioluminiscence from EcM1luxSAgfp and EcM1luxSAtir strains in the cultures employed in 
panel A. A sample of these cultures from each day was streaked on LB agar plates and white light and 
light emission images from the plates were acquired. 
 
Taken together these results demonstrated that SAs can drive the adhesion of E. coli bacteria 
to target surfaces and that they can be constitutively expressed, together with the lux 
bioluminescent reporter, from the chromosome of E. coli, resulting in a stable and well tolerated 
expression.  
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Chapter 2: The use of SAs to drive the adhesion of engineered strains toward 
mammalian cells expressing cell surface antigens and to characterize the 
adhesion process. 
 
2.1 Generating stable HeLa cell lines with model antigens on their surface. 
Next we investigated the ability of the engineered EcM1luxSAgfp and EcM1luxSAtir strains to 
adhere to in vitro cultured mammalian cells expressing on their surface the target antigen 
recognized by the SAs. To this end, HeLa cells were stably transfected with plasmids pDisplay-
GFP-tm and pDisplay-TirM-tm. These constructions allowed the display of antigens GFP and 
TirM, respectively, on the extracellular side of plasma membrane by means of a N-terminal 
signal peptide and a C-terminal transmembrane (Whitman et al.) domain derived from the 
platelet derived growth factor receptor (PDGFR) (Fig. 8). In addition, pDisplay-TirM-tm 
construction contains the monomeric mWasabi fluorescent protein (Ai et al., 2008) fused to 
TirM. The mWasabi green fluorescent protein was evolved from Clavularia cyan fluorescent 
protein, and its primary sequence differs from that of GFP, avoiding the recognition of mWasabi 
by the VHH anti-GFP of SAgfp (Rothbauer et al., 2008). 
Thus the expression of GFP-tm and TirM-tm fusion proteins on the surface of HeLa cells could 
be monitored by their green fluorescent emission. 
Upon stable transfection, green fluorescent HeLa cells were enriched by fluorescence activated 
cell sorting (FACS) and expanded in vitro. The expanded cell populations, named HeLa-GFP-
tm and HeLa-TirM-tm, contained cells with variable levels of antigens on their surface, including 
some cells with undetectable levels of the antigen, specially in the case of HeLa-TirM-tm cell 
line (Fig. 13). 
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Figure 13. HeLa-GFP-tm and HeLa-TirM-tm cells. (A) Schematic model showing GFP-tm and TirM-tm 
protein fusions in the plasma membrane of stably transfected HeLa-GFP-tm and HeLa-TirM-tm cells, 
respectively. The transmembrane domain (Whitman et al.) from the platelet derived growth factor 
receptor (PDGFR) anchors the fusion proteins in the plasma membrane, displaying on the cell surface 
GFP or mWasabi-TirM protein domains. (B) Flow cytometry analysis of HeLa-GFP-tm and HeLa-TirM-tm 
cells showing fluorescence levels corresponding to the expression of protein fusions GFP-tm and TirM-
tm by these cell populations. Untransfected HeLa cells were used as a negative control. 
 
2.2 In vitro adhesion assays. 
HeLa-GFP-tm and HeLa-TirM-tm cell lines were employed to demonstrate the ability of the 
engineered bacterial strains to adhere to mammalian cells with target antigens on their surface. 
Both cell lines were infected with EcM1luxSAgfp or EcM1luxSAtir bacteria (MOI 300:1). After 
one hour of infection, unbound bacteria were removed washing with PBS, and samples were 
fixed and stained with anti-E. coli polyclonal antibodies. Inspection of the samples by light and 
fluorescence microscopy revealed high numbers of EcM1luxSAgfp or EcM1luxSAtir bacteria 
(red fluorescence) specifically adhered to HeLa cells expressing different levels of the antigens 
GFP or TIrM, respectively (green fluorescence) on their surface. In contrast, EcM1luxSAgfp 
and EcM1luxSAtir bacteria were not bound to HeLa cells expressing the non-recognized 
antigen (i.e. TirM for EcM1luxSAgfp; GFP for EcM1luxSAtir) (Fig. 14). 
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Figure 14. Adhesion of E. coli expressing SAs to target mammalian cells. Light and fluorescence 
microscopy images of HeLa-GFP-tm (A) or HeLa-TirM-tm (B) cell lines grown in culture and infected 
(MOI 300:1) with EcM1luxSAgfp or EcM1luxSAtir as indicated. Expression of the target antigens, GFP 
and TirM, on the surface of these cells is detected by the green fluorescent emission of the fusion 
proteins GFP-tm and TirM-tm respectively. Bacteria were stained with anti-E. coli polyclonal antiserum 
and anti-rabbit IgG-Alexa 594. 
 
The adhesion of the engineered strains to HeLa cells expressing GFP or TirM was also 
assessed by confocal fluorescence microscopy at a higher magnification. This analysis showed 
that target HeLa cells were largely covered by bound bacteria expressing the corresponding SA 
(Video 1 and Fig. 15) while antigen-negative cells that can be found in both cell lines (labeled 
with asterisks in Fig. 15) were free of bound bacteria. These results further demonstrated the 
exquisite specificity that SAs expression provides in bacterial adhesion. 
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Figure 15. Confocal fluorescence microscopy images of engineered strains targeted adhesion. 
High magnification confocal microscopy images of HeLa-GFP-tm cells infected with EcM1luxSAgfp (top 
panels) and HeLa-TirM-tm cells infected with EcM1luxSAtir (bottom panels). Infection and staining were 
carried out as in Figure 9. In addition cell nuclei and bacterial chromosomes were stained with DAPI 
(blue). Selected images contain antigen-negative cells (labeled with asterisks on the merge pictures) to 
show the absence of bacteria bound to them. Scale bars (white lines) showed on the merge pictures 
represent 10 µm. 
 
2.3 Bioluminescence as reporter of bacterial adhesion. 
The possibility of monitoring bacterial adhesion process using the lux operon as bioluminescent 
reporter was addressed. To this end, Hela, Hela-GFP-tm and HeLa-TirM-tm cells were grown in 
a multi-well tissue culture plate and infected as above with EcM1luxΔflu, EcM1luxSAgfp and 
EcM1luxSAtir strains. After one hour of infection the cells were monitored for light emission 
before and after removing unbound bacteria by rinsing the wells with PBS. After washing, 
bioluminescent signals were observed only in those wells in which bacteria expressing SAs 
infected HeLa cells with the recognized antigen on their surface (Fig. 16). 
 
 
Figure 16. Bioluminescence as reporter of bacterial adhesion to target mammalian cells. HeLa, 
HeLa-GFP-tm and HeLa-TirM-tm cells were grown in a tissue culture plate and infected (MOI 300:1) with 
EcM1luxΔflu, EcM1luxSAgfp and EcM1luxSAtir as indicated. After 1 h of infection, the plate was 
monitored for light emission before (left) and after (right) removing unbound bacteria by rinsing the wells 
with PBS, revealing positive bioluminescent signals when the engineered bacterial strain with SAs infects 
its target cell. 
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2.4 Time-lapse live microscopy analysis of bacterial adhesion mediated by SAs. 
To gain further insight into the adhesion process mediated by SAs, we performed time-lapse 
live microscopy recording the interaction of EcM1luxSAgfp bacteria with HeLa-GFP-tm cells. To 
this end, Hela-GFP-tm cells were infected with EcM1luxSAgfp at a MOI of 100:1 to reduce 
bacteria in the medium that could hinder visualization of mammalian cells. In addition, video 
was recorded selecting a field in the microscope that allows us to compare the differential 
behavior of bacteria when they encounter a positive-antigen cell or a negative-antigen cell. 
The result of this experiment (Video 2) revealed that antigen-positive HeLa-GFP-tm cells were 
covered with bacteria in just 5 minutes, whereas almost no bacteria were bound to antigen-
negative cells. In fact, once individual bacterium appears in the recorded field, the adhesion 
event to a GFP-positive cell takes place in a short period of time (<30 sec), after an apparent 
random collision with the surface of the target cell. After this initial contact with the target cell, 
bacteria seems to tumble in close proximity to the surface of mammalian cell, eventually 
establishing a permanent adhesion phenotype and stopping its active motility. In contrast, 
bacteria that contact with antigen-negative cells tumble close to the cell surface, but finally 
swim away from the non-target cell.  
Taken together, these experiments demonstrated that the engineered E. coli strains with 
constitutive of expression of SAs are able to adhere fast, in high numbers and in a highly 
specific manner to mammalian cells expressing on their surface the antigens recognized by the 
SA. 
 
2.5 Influence of the flagellum on bacterial adhesion. 
The above experimental observations suggest that, at least in vitro, active motility plays an 
important role during the adhesion of bacteria to target cells. To investigate this process, the 
SA against GFP was integrated in EcM1Δfli strain (MG1655 ΔfimA-H ΔfliCD) (Majander et al., 
2005). This strain is isogenic to EcM1, with a deletion of fliC and fliD genes, encoding the 
components for the filament and the cap of the flagellum, respectively. Using pGEflu-SAgfp 
vector, a strain termed EcM1ΔfliSAgfp was generated, which displays the SA against GFP and 
is unable to swim. 
Next, we confirmed the expression of the SA against GFP on the surface of EcM1ΔfliSAgfp 
strain with anti-myc mAb. Flow cytometry analysis demonstrated similar expression levels of 
SAgfp in both, EcM1ΔfliSAgfp, and EcM1luxSAgfp strains (Fig. 17). 
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To evaluate the influence of the bacterial flagellum in the adhesion process mediated by SAs, 
HeLa-GFP-tm cells were infected (MOI 300:1) with EcM1ΔfliSAgfp and the control strain 
EcM1luxSAgfp. After 15 and 60 minutes of infection, cells were washed with PBS to remove 
unbound bacteria, fixed and incubated with anti-E. coli polyclonal antibodies and anti-rabbit 
IgG-Alexa-594 for fluorescence microscopy analysis. The results showed that at 15 minutes of 
infection, there were no visible EcM1ΔfliSAgfp bacteria adhered to HeLa-GFP-tm cells, while 
EcM1luxSAgfp bacteria can be easily seen attached to the cells (Fig.18). At 60 minutes post-
infection, EcM1luxSAgfp bacteria were largely covering the surface of HeLa-GFP-tm cells, 
while the level of adhered EcM1ΔfliSAgfp bacteria was significantly lower (Fig. 18). 
 
 
Figure 18. Adhesion of E. coli strains with or without flagella and expressing SAs to target 
mammalian cells. Light and fluorescence microscopy images of HeLa-GFP-tm cells infected with 
EcM1luxSAgfp or EcM1ΔfliSAgfp bacteria (MOI 300:1) for 15 or 60 minutes as indicated. Expression of 
GFP on the surface of HeLa-GFP-tm cells is detected by its green fluorescence emission. Bacteria were 
stained with anti-E. coli polyclonal serum and anti-rabbit IgG-Alexa-594 (red fluorescence). 
Figure 17. Display levels of SAgfp in 
EcM1ΔfliSAgfp and EcM1luxSAgfp 
strains. Flow cytometry analysis of E. coli 
EcM1Δfli, EcM1ΔfliSAgfp or EcM1luxSAgfp 
bacteria. Histograms show the 
fluorescence intensity of bacteria stained 
with anti-myc mAb and secondary anti-
mouse IgG-Alexa 488.!
RESULTS 
 85 
The number of bacteria adhered to HeLa-GFP-tm cells was quantified for both bacterial strains 
by plating. To this end, after 15 minutes and 60 minutes of infection, unbound bacteria were 
removed with PBS and after that, bound bacteria were recovered from infected HeLa-GFP-tm 
cells in a solution of SDS 0,2% (w/v) in PBS and plated on LB-agar plates. As a control, 
untransfected HeLa cells were infected with EcM1luxSAgfp bacteria as a measure of the 
infection background (Fig. 19). 
The quantification of bound bacteria showed that, at 15 minutes post-infection, the number of 
EcM1luxSAgfp bacteria was ca. 12 times higher than that found for EcM1ΔfliSAgfp strain. In 
fact at that time point, the number of adhered EcM1ΔfliSAgfp bacteria was close to the number 
found in the infection of untransfected HeLa cells by EcM1luxSAgfp strain, which represents 
the adhesion background of the experiment. 
After 60 minutes of infection, quantification of bound bacteria for EcM1luxSAgfp and 
EcM1ΔfliSAgfp strains showed a similar difference between both strains, compared to the one 
found after 15 minutes of infection. Interestingly, at this time point the number of bound bacteria 
for EcM1ΔfliSAgfp strain was ca. five times higher than the one found in the control that 
represents the adhesion background (i.e. EcM1luxSAgfp strain infecting untransfected HeLa 
cells), which indicates that an actual adhesion takes place regardless of the lack of motility. 
However, the number of bound bacteria for EcM1ΔfliSAgfp strain after 60 minutes of infection 
was still ca. 3 times lower than the one found for EcM1luxSAgfp after just 15 minutes of 
infection.  Lastly, the number of bound EcM1luxSAgfp bacteria after 60 minutes of infection and 
all the washing steps was ca. 70% of the initial infective dose (i.e. 3x107 CFU) indicating a 
great adhesion efficiency for this strain (Fig. 19).  
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Figure 19. Quantification of adhered bacteria for flagellated and non flagellated E. coli engineered 
strains expressing SAs. The indicated cell lines were infected (MOI 300:1) with EcM1luxSAgfp (SAgfp) 
or EcM1ΔfliSAgfp strains (ΔfliSAgfp). Each bar represents the number of adhered bacteria (Log10 
recovered CFU) found for each bacterial strain after the indicated infection times. Black bars represent 
the background of the experiment, error bars are the standard deviation of bacterial counts obtained on 
LB-Agar platesfrom three different infection assays, and the dashed line represents the initial bacterial 
dose employed in the infections (3x107 CFU). Two tailed P values of t-testare indicated with one asterisk 
(*) when P<0.05 or two asterisks (**) when P<0.01. 
 
Taken together, these results demonstrate that, at least in vitro, active motility mediated by 
flagella is important for a fast and effective adhesion to target cells, especially when short 
infection times are employed. 
 
2.6 Influence of YcgR protein on bacterial adhesion. 
Previous data (Video 2) suggested that bacteria could sense adhesion to the target cell and, in 
response to that, they could stop flagellar rotation. Ycgr protein has been proposed to mediate 
the transition from motile to sessile bacteria in response to c-di-GMP levels, since upon their 
association, the complex Ycgr/c-di-GMP is able to interact with some components of the 
flagellar motor and somehow impair bacterial motility, as a strategy to prepare bacteria for 
sedentary existence (Boehm et al., 2010; Fang and Gomelsky, 2010; Paul et al., 2010). 
However, it is not known whether deficiency in YcgR could induce a reduced adhesion 
phenotype. Hence, to investigate whether YcgR plays a role in the SAs-mediated adhesion, we 
generated a mutant of EcM1luxSAgfp strain with a deletion in ycgR gene using a suicide 
plasmid, termed pGEycgR, with HRs flanking ycgR.  
The motility of EcM1luxSAgfp-ΔycgR and EcM1luxSAgfp strains was evaluated in soft LB-agar 
plates. Cultures of both strains were grown in LB medium at 37ºC and static conditions 
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overnight, and inoculated in motility plates. In addition, as a negative control for motility, 
EcM1Δfli strain was also included in the assay. The experiment showed that, as has been 
previously described (Boehm et al., 2010), ycgR gene deletion does not impair motility, since 
the migration is semi-solid agar plates is similar for EcM1luxSAgfp-ΔycgR and EcM1luxSAgfp 
strains (Fig. 20). 
 
 
Figure 20. Swimming motility assay. EcM1luxSAgfp, EcM1luxSAgfp-ΔycgR and EcM1Δfli strains were 
grown in LB medium overnight, and inoculated as indicated in soft LB-agar plates. The image was taken 
8 hours post-inoculation  
 
Next, we investigated whether EcM1luxSAgfp-ΔycgR bacteria have impaired adhesion to 
mammalian cells. To this end, EcM1luxSAgfp-ΔycgR bacteria were added to HeLa-GFP-tm 
cells (MOI 100:1) and the infection was followed by time-lapse live video microscopy (Video 3). 
This experiment showed that the adhesion behavior of EcM1luxSAgfp-ΔycgR bacteria is similar 
to that one observed for EcM1luxSAgfp (Video 2), since the adhesion to the surface of 
mammalian cells is equally fast and specific for both strains. After the apparent random 
collision of EcM1luxSAgfp-ΔycgR bacteria with the surface of antigen-positive cells bacteria 
stop its active motility and establish a permanent adhesion phenotype similar to EcM1luxSAgfp 
bacteria. 
This result indicates that the lack of YcgR protein does not affect the ability of EcM1luxSAgfp-
ΔycgR bacteria to adhere to HeLa-GFP-tm cells. This suggests that the arrest of flagellar 
rotation upon adhesion is independent of YcgR protein and therefore, additional mechanisms 
may be controlling this arrest of bacterial motility. 
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Chapter 3: Improved tissue specificity and tumor colonization by engineered E. coli 
with SAs. 
 
3.1 Tumor model development.  
During the last decade, several groups have reported that the intravenous administration of 
facultative anaerobic bacteria such as Salmonella and E. coli strains results in the preferential 
bacterial colonization of solid tumors (Forbes, 2010). Subcutaneously implanted tumors in 
immunocompetent or athymic nude mice are efficiently colonized (>90%) with a single dose 
bacterial dose of 5x106 CFU of wild-type E. coli K-12 MG1655 administered systemically 
(Weibel et al., 2008). Three to five days after its intravenous injection, E. coli bacteria were 
recovered in high numbers from the tumor mass (~108 CFU/g), whereas organs such as liver or 
spleen had low bacterial titers (<103 CFU/g). 
To evaluate the functionality of SAs in vivo, we tested whether the engineered bacteria 
exhibited an improved colonization of solids tumors expressing the antigen recognized by the 
SA on the surface of tumor cells. To this end, we established an in vivo tumor xenograft model 
based on HeLa-GFP-tm cells in athymic nude mice. These animals received subcutaneously 
~106 HeLa-GFP-tm cells and developed solid HeLa-GFP-tm tumors of ~200-400 mm3 in about 
10-15 days. 
 
3.2 Systemic administration of 107 CFU. 
Mice bearing HeLa-GFP-tm tumors were divided into two different experimental groups (n=6) 
and received intravenously in their lateral tail vein a single dose of 1x107 CFU of EcM1luxSAgfp 
or EcM1luxSAtir. Live imaging of animals performed four days post-administration showed 
bioluminescent signals in the tumors from both experimental groups and bacteria were found in 
high numbers (~108-109 CFU/g) in all tumors from each group (6/6), as was determined after 
tumor excision, homogenization and plating  (Fig. 21A). Interestingly, non-target organs such 
as liver or spleen did not contain bacteria (detection limit 5x101 CFU/g) or had low bacterial 
titers (<103 CFU/g) (Fig. 21B). 
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Figure 21. In vivo colonization of tumors with high doses of E. coli expressing SAs. (A) Bacterial 
colonization of HeLa-GFP-tm solid tumors by EcM1luxSAtir (SAtir) and EcM1luxSAgfp (SAgfp) strains, 
as indicated, after their intravenous administration with a dose of 1x107 CFU/mouse. Infected tumor-
bearing mice (experimental groups n=6) were euthanized 4-days post-administration and the number of 
CFU in each tumor was determined. Each circle represents the CFU determined per gram of tumor 
(Log10 CFU/g) for each animal in the different experimental groups. The ratio of colonized tumors in each 
group is shown at the bottom.  On the right, bioluminescence live imaging of HeLa-GFP-tm tumor-
bearing mouse infected with 1x107 CFU of EcM1luxSAtir (left image) or EcM1luxSAgfp (right image). 
Images are overlays of photographic white-light and bioluminescence signals from a representative 
tumor-bearing mouse infected with each strain, as indicated on top. The intensities of the 
bioluminescence signals are represented in pseudocolor according to the scale bar. (B) Graphs showing 
bacterial titers in livers (left) and spleens (right) from those animals with a HeLa-GFP-tm tumor colonized 
in A by EcM1luxSAtir (SAtir) or EcM1luxSAgfp (SAgfp) strains. Each circle in the graph represents the 
CFU determined per gram of tissue (Log10 CFU/g).  
 
Importantly, the expression levels of SAs (and the lux operon) were identical in the bacterial 
population administered to mice, and in the tumor-recovered bacterial population, as was 
demonstrated by flow cytometry (Fig. 22A) and Western blot (Fig. 22B) in the case of SAs 
expression, and by bioluminescence imaging in the case of lux expression (Fig. 22C). These 
results demonstrated that the expression of these gene cassettes was stably maintained in vivo 
during all the experiment (4 days). 
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Figure 22. Expression of SAs and bioluminescence in engineered E. coli recovered from 
colonized tumors. (A and B) The expression of SAs in inoculated and tumor-recovered EcM1luxSAtir 
and EcM1luxSAgfp strains, as indicated, was analyzed by flow cytometry (A) and Western blot (B). 
Bacteria were recovered 4-days post-infection from colonized tumors in Figure 16. For flow cytometry, 
bacteria were stained with anti-myc mAb and secondary anti-mouse IgG-Alexa 488. Control strain (black 
line) was EcM1luxΔflu. For Western blot, SA protein fusions were detected with anti-myc mAb and anti-
mouse IgG-POD conjugate. (C) Analysis of bioluminescence of inoculated and tumor-recovered 
EcM1luxSAgfp or EcM1luxSAtir bacteria grown in LB agar plates at 37ºC. Images of white light and light 
emission from the plates were acquired. All individual colonies show strong bioluminescence. 
 
Histological cross-sections of colonized HeLa-GFP-tm tumors stained with anti-E. coli 
antibodies demonstrated the presence of both bacterial strains within HeLa-GFP-tm tumors, 
and revealed that they were localized preferentially at inner regions of the tumor (Fig. 23). A 
similar pattern of bacterial distribution was reported for tumors colonized by wild-type E. coli K-
12 MG1655 strain (Weibel et al., 2008). 
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Figure 23. Bacterial distribution in solid HeLa-GFP-tm tumors. Histological cross-sections of 
colonized HeLa-GFP-tm solid tumors four days post-infection with ~1x107 CFU of EcM1luxSAtir or 
EcM1luxSAgfp strains per mouse, as indicated. Bacteria were stained with anti-E. coli polyclonal 
antibodies and anti-rabbit IgG-Alexa-594 antibodies (red). The green color corresponds to the 
fluorescence of GFP in HeLa-GFP-tm cells. 
 
Therefore, the above data indicated that SAs expression was maintained during all the in vivo 
assay, and that the engineered strains retain their capacity to colonize tumors, since the 
number and distribution of engineered bacteria in solid tumors were similar to those reported 
for wild type E. coli K-12 MG1655 strain (Weibel et al., 2008). However at the bacterial dose 
employed (1x107 CFU) the expression of SAs against the antigen expressed in the tumor, did 
not confer any improvement in tumor colonization, as both, EcM1luxSAgfp and EcM1luxSAtir, 
colonized HeLa-GFP-tm solid tumors. 
 
3.3 Systemic administration of 105 CFU. 
To investigate whether the expression of SAs could favor tumor colonization when low bacterial 
doses are employed, first we determined a bacterial dose that is suboptimal of for the 
colonization of HeLa-GFP-tm tumors by wild-type E. coli MG1655. To this end, nine mice 
bearing HeLa-GFP-tm tumors were infected with 1x105 CFU of the wild-type strain. This 
bacterial dose represents 2% of the dose reported for optimal tumor colonization with wild-type 
E. coli MG1655 (Weibel et al., 2008). Four days after bacterial administration, only one third of 
the mice (3/9) showed tumor colonization by bacteria (Fig. 24A). Interestingly, the tumors that 
were colonized had bacterial titers (~108 CFU/g) similar to those found when a high bacterial 
dose (1x107 CFU) was employed, suggesting that once E. coli succeeded at an early stage of 
tumor colonization, bacteria proliferate reaching a final titer that is independent of the 
administered dose. In contrast, livers and spleens of these animals had undetectable levels of 
bacteria (Fig. 24B). 
Next, the ability of EcM1luxSAgfp and EcM1luxSAtir to colonize HeLa-GFP-tm tumors was 
compared employing a bacterial dose of 1x105 CFU, which was suboptimal for wild-type E. coli 
MG1655. As above, EcM1luxSAgfp or EcM1luxSAtir bacteria were administered intravenously 
to two groups of nude mice (n=9) bearing subcutaneous HeLa-GFP-tm tumors (≥ 200 mm3). 
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Four days post-inoculation, most of the animals (8/9) that were inoculated with EcM1luxSAgfp 
had their tumors colonized with high bacterial titers (≥108 CFU/gr), whereas in the experimental 
group inoculated with EcM1luxSAtir, less that one third of the animals (2/9) had colonized 
tumors. This differential colonization was also detected by live bioluminescence imaging of the 
animals (Fig. 24A). 
As a control to evaluate targeting specificity, a dose of 1x105 CFU of EcM1luxSAgfp was 
administered systemically to a group (n=9) of nude mice bearing tumors derived from un-
transfected HeLa cells. Four days after inoculation, HeLa tumors were colonized with low 
efficiency (2/9) by EcM1luxSAgfp, an identical result to that found with by EcM1luxSAtir in 
HeLa-GFP-tm tumors (Figure 24A). In addition, all animals with colonized tumors showed 
undetectable levels of bacteria in liver and spleen (Figure 24B). 
 
 
Figure 24. In vivo colonization of tumors with low doses of E. coli expressing SAs. (A) Bacterial 
colonization of HeLa-GFP-tm or HeLa tumors, as indicated on top, by the following E. coli strains: wild 
type K-12 (MG1655), EcM1luxSAtir (SAtir) and EcM1luxSAgfp (SAgfp).  Each bacterial strain was 
intravenously administered (1x105 CFU/mouse) to tumor-bearing mice (experimental groups n=9) and 4-
days post-administration the number of CFU in each tumor was determined. Each circle in the graph 
represents the CFU determined per gram of tumor (Log10 CFU/g) for each animal in the different 
experimental groups. The ratio of colonized tumors in each group is shown at the bottom along with the 
statistical analyses between groups connected with lines. Two-tailed P values of Fisher's exact test are 
indicated with one asterisk (*) when P <0.05 or two asterisks (**) when P =0.015.  On the right, 
bioluminescence live imaging of HeLa-GFP-tm tumor-bearing mouse infected with 1x105 CFU of 
EcM1luxSAtir (left image) or EcM1luxSAgfp (right image). Images are overlays of photographic white-
light and bioluminescence signals from a representative tumor-bearing mouse infected with the strains, 
as indicated on top. The intensities of the bioluminescence signals are represented in pseudocolor 
according to the scale bar. (B) Graphs showing bacterial titers in livers (left) and spleens (right) from 
those animals with a HeLa-GFP-tm tumor colonized in A by wild-type K-12 (MG1655), EcM1luxSAtir 
(SAtir), or EcM1luxSAgfp (SAgfp) strains. Each circle in the graph represents the CFU determined per 
gram of tissue (Log10 CFU/g). 
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Taken together, these results demonstrated that engineered E. coli with SAs were able to 
colonize solid tumors expressing a target cell-surface antigen with high efficiency and 
specificity, allowing the use of doses that are suboptimal for wild type E. coli MG1655, or for 
engineered bacteria with SAs against antigens absent on the surface of tumor cells. 
 
3.4 Lower retention of engineered E. coli in non-target tissues. 
We investigated whether, in addition to the improved colonization of target tumors shown 
previously, the engineered strain with SAs and lacking natural adhesins could have a lower 
retention in non-target organs compared with wild type E. coli. To address this question, two 
groups (n=9) of nude mice without implanted tumors received a high dose (1x107 CFU) of wild 
type E. coli MG1655 or EcM1luxSAgfp strains, and 4, 24 or 48 hours post-inoculation, three 
mice of each group were euthanized to determine bacterial titers in livers and spleens (Fig. 25). 
 
 
Figure 25. Low retention of the engineered E. coli strain in non-target organs. Bacterial titers (Log10 
CFU/g) recovered from livers (left) and spleens (right) of tumor-less nude mice at 4, 24 and 48 h after 
intravenous administration of 1x107 CFU of wild type E. coli K-12 (MG1655) or EcM1luxSAgfp, as 
indicated. Each bar represents the average CFU/g with standard deviation determined from three mice 
from each group at the indicated time post-inoculation. 
 
The experiment revealed that, at all time points analyzed, the titers of the engineered E. coli 
strain in these organs were lower than those obtained in the case of wild type E. coli. The 
difference is especially remarkable in liver were the titers of engineered bacteria were ~10 to 30 
times lower than those found for wild type E. coli, whereas in spleen the difference is around ~2 
to 4 times.  
Therefore, these data indicated that the engineered bacteria exhibit a lower retention in non-
target organs that the wild type E. coli strain. 
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Chapter 4:  Development and validation of a SA against tumor cells expressing EGFR, a 
therapeutically relevant marker. 
 
4.1 Construction of a SA binding EGFR.  
The modular architecture of SAs makes possible the modification of their specificity by an 
exchange of the VHH sequence. Thus, we decided to create SAs against clinically relevant 
tumor-associated antigens, such as the human Epidermal Growth Factor Receptor (EGFR). 
EGFR has been shown to be a valid target for antibody-based cancer therapy as its expression 
is upregulated in many tumors, especially those from epithelial origin, such as those found in 
the gastrointestinal tract (Cohen et al., 2006) or the urinary tract (Neal et al., 1990). Indeed, 
several anti-hEGFR monoclonal antibodies such as cetuximab or matuzumab are currently in 
use (Vacchelli et al., 2014). In addition, a VHH library has been created by immunization of 
llamas (Llama glama) with human tumor cells termed A431 that are derived from a cervix 
squamous cell carcinoma and overexpress EGFR (Roovers et al., 2007). Hence, the sequence 
coding for a VHH termed EGa1, which binds the extracellular domain of EGFR, was selected 
from the above-mentioned repertoire and cloned in the pGE suicide vector to create pGEflu-
SAega plasmid. Integration of this construction in EcM1lux chromosome leads to the 
generation of EcM1luxSAega strain. Flow cytometry analysis demonstrated that SA against 
EGFR is displayed on the bacterial surface at levels close to the ones found for the SA against 
GFP (Fig. 26) 
 
 
 
4.2 Specific adhesion of the engineered strain to EGFR-positive tumor cells.  
The ability of EcM1luxSAega bacteria to adhere specifically to tumor cells expressing EGFR on 
their surface was evaluated. To this end, two isogenic cell lines derived from the mouse 
fibroblast stable cell line NIH 3T3, termed 3T3#2.2 and Her14, were employed. 3T3#2.2 cells 
Figure 26. Display levels of the SA against 
EGFR. Flow cytometry analysis of E. coli 
EcM1luxSAega bacteria. EcM1luxΔflu and 
EcM1luxSAgfp strains were also analyzed as 
negative and positive controls for SAs 
expression, respectively. Histograms show 
the fluorescence intensity of bacteria stained 
with anti-myc mAb and secondary anti-
mouse IgG-Alexa 488. !
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are devoid of endogenous mouse EGFR expression, while Her14 cells are stable transfectants 
of 3T3#2.2 cells expressing human EGFR on their surface (Honegger et al., 1987). In addition, 
the cell line employed to immunize llamas for the VHH library construction (i.e. A431) was also 
tested. 
Subsequently, in vitro adhesion assays with EcM1luxSAega strain (MOI 300:1) to 3T3#2.2, 
Her14 and A431 cells were performed as follows. After one hour of infection unbound bacteria 
were washed with PBS and samples were fixed and stained with anti-EGFR mAb, anti-E. coli 
polyclonal serum and DAPI. Images of the adhesion assay showed that cells positive for EGFR 
surface expression (i.e. Her14 and A431) (green fluorescence) were largely covered by 
EcM1luxSAega bacteria (red fluorescence), while in cells negative for EGFR expression (i.e. 
3T3#2.2) no bound bacteria were detected (Fig. 27). 
 
 
Figure 27. Anti-EGFR SAs drive the specific adhesion of engineered E. coli cells to EGFR positive 
cell lines. Confocal microscopy images of 3T3#2.2, Her14 and A431 cells infected with EcM1luxSAega 
strain. Bacteria were stained with anti-E. coli polyclonal serum and anti-rabbit IgG-Alexa-594 (red), 
EGFR was stained with anti-EGFR mAb and anti-mouse IgG-Alexa-488 (green), cell nuclei and bacterial 
chromosomes were stained with DAPI (blue). Scale bars (white lines) showed on the merge pictures 
represent 10 µm. 
 
Therefore, these data demonstrate that SAs can target E. coli to tumor cells expressing on their 
surface EGFR, a therapeutically relevant tyrosine kinase receptor overexpressed on the cell 
surface of many human cancers of epithelial origin (Cohen et al., 2006; Neal et al., 1990).  
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Chapter 5: Transcriptional response of E. coli upon adhesion mediated by Synthetic 
Adhesins. 
 
5.1 Experimental design. 
The transcriptional response of E. coli upon adhesion to surfaces has been widely studied 
(Beloin et al., 2003; Bhomkar et al., 2010; Domka et al., 2007; Hancock and Klemm, 2007; Ren 
et al., 2004; Schembri et al., 2003). However, all these studies analyzed transcriptional 
changes that take place in E. coli after several hours or even days upon bacterial adhesion, 
which makes difficult to ensure that the transcriptional profile observed is developed in 
response to adhesion rather than in response to sessile life adaptation or even biofilm 
development. The extremely fast adhesion mediated by SAs could allow the study of those 
transcriptional changes that take place immediately upon adhesion. Moreover, SAs-mediated 
adhesion would also allow to perform a transcriptomic analysis of a more coordinated bacterial 
population, since all analyzed bacteria would have adhered in a short window of time, as 
opposed to the above-mentioned studies. In addition, our experimental model based on SAs-
mediated adhesion to mammalian cells would allow to describe, for the first time, the 
transcriptional changes of E. coli upon adhesion to cells, instead of adhesion to abiotic surfaces. 
Hence, our objective was to test whether the binding mediated by SAs induces changes in the 
transcriptional profile of E. coli bacteria at a short time just after bacterial adhesion to target 
cells. We selected SAs-mediated adhesion to cells expressing GFP and EGFR on their surface, 
and 15 minutes as the time point after adhesion in which the transcriptional response would be 
analyzed. 
Before performing the transcriptomic studies, we tested whether at the infection time selected 
(15 min) most of the adhered bacteria remain extracellular and therefore are under similar 
environmental stimuli. 
To address this question we carried out in vitro adhesion assays of Her14 and HeLa-GFP-tm 
cells infected (MOI 100:1) with EcM1luxSAega and EcM1luxSAgfp bacteria, respectively. After 
15 min of infection, unbound bacteria were removed with PBS and samples were subjected to a 
double staining of bacteria before and after permeablization of the tumor cell plasma 
membrane, that allowed to distinguish between intracellular and extracellular bacteria. 
Inspection of Her14 cells samples by confocal microscopy revealed that in most cells, all bound 
EcM1luxSAega bacteria remained extracellular (Fig. 28A). Exceptionally, we could detect some 
intracellular bacteria (ca. 1-2 per cell) in a small percentage of the Her14cells inspected (ca. 
5%) (Fig. 28B). Similar results were obtained with HeLa-GFP-tm cells infected with 
EcM1luxSAgfp bacteria (Fig. 28CD).  
Hence, in both experimental models (EGFR and GFP) most bacteria (>99%) remained 
extracellular at the time analyzed (15 min). 
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Figure 28. Bacterial internalization rate at the conditions determined for RNA extraction. Confocal 
microscopy images of Her14 cells infected with EcM1luxSAega (A and B) and HeLa-GFP-tm cells 
infected with EcM1luxSAgfp (C and D). A and C panels represent the situation found in most of the cells 
analyzed, whereas B and D panels show cells with internalized bacteria (marked with arrows) that were 
exceptionally found. Infections were carried out at a MOI 100:1 for 15 minutes. Prior to Triton-mediated 
membrane permeablization, external bacteria were stained with anti-E. coli polyclonal serum and anti-
rabbit IgG-Alexa-594 (red). After triton-mediated permeablization total bacteria were stained with anti-E. 
coli polyclonal serum and anti-rabbit IgG-Alexa-488 (green) in A and B or with anti-E. coli polyclonal 
serum and anti-rabbit IgG-Alexa-647 (dark blue) in C and D. Cell nuclei and bacterial chromosomes were 
stained with DAPI (white). EGFR was stained with anti-EGFR mAb and anti-mouse IgG-Alexa-647 (dark 
blue) in A and B, while GFP was detected by its green fluorescent emission in C and D. Scale bars 
(white lines) showed on total bacteria pictures represent 10 µm. 
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5.2 Experimental conditions and samples for the transcriptomic analysis. 
We performed in vitro adhesion assays in two different models involving bacterial adhesion to 
mammalian cells expressing EGFR and GFP-tm on their surface. After 15 min of infection 
adhered bacteria (i.e. EcM1luxSAega infecting Her14 cells, and EcM1luxSAgfp infecting HeLa-
GFP-tm cells) and non-adhered bacteria (i.e. EcM1luxSAega bacteria infecting 3T3#2.2 cells 
and EcM1luxSAgfp bacteria infecting HeLa cells) were collected to isolate bacterial RNA. This 
experimental setup allowed us to compare the transcriptomic profile of one bacterial strain (i.e. 
EcM1luxSAega or EcM1luxSAgfp) under two different physiological states (i.e. adhered or non-
adhered). The RNA samples were isolated from four independent in vitro adhesion assays for 
each bacterial strain. 
After removal of ribosomal RNA (rRNA) each bacterial RNA sample was used to construct a 
cDNA library, which was massively sequenced by RNAseq, a sequencing based method that 
allows the entire transcriptome to be surveyed in a very high-throughput and quantitative 
manner (Wang et al., 2009). In this technique the number of reads for a given transcript is 
directly related with the number of mRNA molecules present at the isolation time point. The 
construction of cDNA libraries as well as the subsequent massive sequencing and statistical 
analyses of data were carried out at the Genopole platform from Institut Pasteur (France). 
 
5.3 Genes upregulated upon adhesion to target mammalian cells. 
According to the RNAseq data, adhesion of EcM1luxSAega bacteria to Her14 cells upregulated 
a set of 136 genes (p ≤ 0.05) (original excel file available in the CD). Among them, 21 genes 
were upregulated more than two-fold (Table 1). On the other hand, adhesion of EcM1luxSAgfp 
bacteria to HeLa-GFP-tm cells upregulated a set of 58 genes (p ≤ 0.05) (original excel file 
available in the CD), being 12 of them upregulated two-fold or more (Table 1). 
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Table 1. List of genes upregulated upon adhesion more than two-fold in at least one bacterial 
strain. RNA from EcM1luxSAega and EcM1luxSAgfp bacteria was isolated at two different physiological 
states (i.e. adhered and non-adhered) and massively sequenced. In the list are showed those bacterial 
genes in which the number of reads at sequencing was at least 2 times higher for the adhered condition 
than for the non-adhered condition (Fold change) in at least one of the indicated strains. NSS is indicated 
when no statistically significant data was obtained for a gene when comparing adhered vs. non-adhered 
conditions. 
 
Classification into functional categories revealed that most of the genes whose expression is 
upregulated upon adhesion are involved in the transport and metabolism of amino acids, 
carbohydrates and inorganic ions. However, the function of a significant number of upregulated 
genes remain to be elucidated and were therefore assigned to the unknown function functional 
category (Fig. 29).  
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Figure 29. Functional categories of genes upregulated upon SAs-mediated adhesion to target 
cells. The figure summarizes the data showed in Table 1. The 25 genes were classified according to the 
cluster of orthologous  groups (COG) functional categories annotation system. 
 
Remarkably, we found that a set of eight genes showed an upregulation on their expression 
upon bacterial adhesion higher than two-fold in both, EcM1luxSAega and EcM1luxSAgfp 
strains, suggesting that the transcriptional change in response to adhesion was triggered 
regardless of the cellular receptor recognized (Table 2). The genes that are upregulated in 
common to both strains upon adhesion are mainly involved in sulfur uptake and metabolism. 
To validate RNAseq data with a different technology, we performed a microarray analysis 
(Schena et al., 1995) with mRNA samples obtained from adhered and non-adhered 
EcM1luxSAega bacteria. The mRNA samples were used to synthesize two cDNA libraries 
labeled with two different fluorophores. Subsequently, the labeled cDNAs were mixed in equal 
proportions and hybridized on a chip containing complementary oligonucleotides probes 
corresponding to most E. coli ORFs (Agilent Microarray Design ID 020097). The fluorescence 
level of each fluorophore was determined in all the spots of the chip, providing a quantitative 
measure of how differentially expressed is a given gene (fold change) under the two conditions 
investigated (adhered vs. non-adhered). Hybrydization of the chip, as well as data recording 
and statistical analysis of the data, were carried out at the CNB-CSIC Genomic Platform.  
Remarkably, the expression of seven out of the eight genes found upregulated by RNAseq 
analysis was also found upregulated according to the microarray analysis. (Table 2) 
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Table 2. List of genes upregulated upon adhesion common to both, EcM1luxSAega and 
EcM1luxSAgfp strains. The list shows the genes whose expression was upregulated at least two-fold in 
both strains. The table includes microarray data obtained for EcM1luxSAega strain. NSS is indicated 
when no statistically significant difference was obtained for a gene when its expression level was 
compared at the adhered and the non-adhered conditions. 
 
5.4 Genes downregulated upon adhesion to target mammalian cells. 
We also scrutinize transcriptomic data for those genes whose expression was repressed 
(downregulated) in the adhered condition. RNAseq data indicated that EcM1luxSAega bacteria 
downregulated a set of 125 genes (p ≤ 0.05) after binding to Her14 cells (original excel file 
available in the CD), being 22 of them highly repressed (more than two-fold) Adhesion of 
EcM1luxSAgfp bacteria to HeLa-GFP-tm cells downregulated the expression of 85 genes (p ≤ 
0.05) (original excel file available in the CD) and 38 of them showed a repression higher than 
two-fold (Table 3). 
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Table 3. List of genes downregulated upon adhesion more than two-fold in at least one bacterial 
strain. In the list are showed those bacterial genes in which the number of reads by RNAseq at least two 
times higher for the non-adhered condition than for the adhered condition (Fold change) in at least one of 
the indicated strains. NSS is indicated when no statistically significant difference was obtained the 
expression of a gene when comparing adhered vs. non-adhered conditions.  
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Analysis of the functional categories in which the downregulated genes were classified showed 
that most of these genes are involved in energy production and conversion and transcription 
and carbohydrate transport and metabolism in a lesser extent. However, again a significant 
number of downregulated genes were assigned to the unknown function functional category 
(Fig. 30).  
 
 
Figure 30. Functional categories of genes downregulated upon SAs-mediated adhesion to target 
cells. The figure summarizes the data showed in Table 3. The 37 protein-coding genes were classified 
according to the cluster of orthologous  groups (COG) functional categories annotation system. 
 
As shown in Table 3, the expression of 12 genes was highly repressed (fold change <-2) upon 
adhesion to the target cell in both strains, suggesting a programmed genetic repression profile 
in response to adhesion that is independent of the antigen that is recognized. The 
transcriptional downregulation of six of these genes was also validated for EcM1luxSAega 
bacteria by microarray analysis (Table 4).  
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Table 4. List of genes downregulated upon adhesion common to both, EcM1luxSAega and 
EcM1luxSAgfp strains. In the list are showed the genes that are downregulated upon adhesion in both 
strains, at least two times. Results were validated by microarray for EcM1luxSAega strain. NSS is 
indicated when no statistically significant difference was obtained when the expression level of that gene 
was compared at the adhered and the non-adhered situations. NPA is indicated when in the chip no 
probe was available for that gene. 
 
The above data showed that upon adhesion both strains mainly repress the transcription of 
genes involved in the transport of some carbohydrates (e.g. D-ribose, citrate etc.) and genes 
involved in the transport and synthesis of tryptophane.  
 
5.5 Adhesion-dependent promoters. 
The finding that the expression of certain genes is upregulated upon the adhesion of E. coli to 
mammalian cells mediated by SAs, prompted us to investigate whether the activation of these 
promoters could be used as a signal of bacterial adhesion. This will allow the coupling of a 
stimulus (i.e. adhesion to a target cell) to a response (i.e. production of a reporter or therapeutic 
protein) 
To this end, we amplified 500 bp DNA fragments containing the promoter and the upstream 
region of cysP, cysD, yeeE, ydjN, ldhA and fruB genes, whose expression was found 
upregulated upon adhesion in both, EcM1luxSAega and EcM1luxSAgfp strains (Table 2).  
These promoter regions were cloned in pGE suicide plasmids upstream of the Shine-Dalgarno 
and coding sequence of mCherry fluorescent protein (Fig. 31) (Shaner et al., 2004). The 
resulting suicide plasmids were used to transform EcM1luxSAega strain. Interestingly, co-
integrants obtained after transformation of these plasmids in EcM1luxSAega strain, showed a 
duplication of the corresponding promoter region, in which one copy drives the expression of 
the natural gene, whereas the other regulates the expression of mCherry gene (Fig. 31). 
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Figure 31. Constructions to test adhesion-dependent promoters. Schematic representation of yeeE 
promoter as an example of the constructions generated to test adhesion-dependent promoters. mCherry 
gene was cloned between the promoter region of yeeE gene, and the lambda t0 derived transcriptional 
termination region, in the pGE suicide vector (left). Chromosomal integration takes place by homologous 
recombination in the yeeE gene promoter region present in both EcM1luxSAega chromosome and 
pGEPyeeECherryT0 plasmid. Cointegrants selected by Kanamycin resistance, have two copies of the 
yeeE promoter, one that controls yeeE gene transcription and other that controls mCherry gene 
transcription 
 
Following this strategy, we generated six reporter strains that have mCherry gene under the 
control of cysP, cysD, yeeE, ydjN, ldhA or fruB promoter regions. Next their activation was 
tested in vitro by infecting Her14 and control 3T3#2.2 cells with the reporter strains (MOI 100:1). 
After 15 minutes of infection (identical time that the one of RNA isolation), Her14 cells were 
washed to remove unbound bacteria and then incubated for 2 additional hours at 37ºC to leave 
enough time for mCherry protein translation, maturation and accumulation. On the other hand, 
3T3#2.2 cells were infected for 2 hours, and after that, the medium in which the infection took 
place was collected and centrifuged to obtain non-adhered bacteria that were fixed and 
prepared for microscopy visualization. Inspection of the samples by light and fluorescence 
microscopy revealed that most reporter strains did not express detectable levels of mCherry 
protein (red fluorescence) neither at the non-adhered condition, nor at the adhered situation 
(Fig. 32, cysD gene promoter as example). 
Interestingly, the reporter strain used to test the yeeE gene promoter expressed detectable 
levels of mCherry protein when it was incubated with Her14 cells and not with 3T3#2.2 cells. 
However, the expression of mCherry protein in response to adhesion was not homogeneous 
across the entire bacterial population, and only some of the adhered bacteria expressed 
mCherry protein upon binding to target cells (Fig. 32). Taken together these results indicated 
that the yeeE gene promoter acts as an adhesion-responsive promoter in at least some 
bacteria adhered to the target cell. 
 ! !
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Figure 32. Adhesion-dependent promoters. The indicated reporter strains derived from 
EcM1luxSAega strain were used to infect Her14 cells (adhered panels), and 3T3#2.2 cells (non-adhered 
panels). After 15 minutes of infection, Her14 cells were washed to remove unbound bacteria and then 
incubated for 2 hours before fixation. Infection of 3T3#2.2 cells was carried out for two hours and after 
that bacteria in media were collected and fixed. Samples were analyzed by light (brightfield panels) and 
fluorescence microscopy (mCherry panels) to test whether an upregulation in mCherry expression take 
place upon adhesion.  
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Chapter 6:  SAs to drive the adhesion of minicells. 
 
6.1 Minicells producer strains generation. 
Nano-sized vehicles have attracted the attention of researchers as tools for the specific delivery 
of therapeutic compounds to target cells (Malam et al., 2009). We wanted to test whether SAs 
could drive the adhesion of non-live bacterial nanoparticles derived from E. coli, termed 
minicells or nanocells. These minicells are bacterial-derived anucleate nanoparticles produced 
as a result of inactivating the minCD genes that control septum positioning during bacterial cell 
division (Adler et al., 1967). Minicells obtained from Salmonella enterica serovar Typhimurium 
have been used as nano-vehicles for the in vivo delivery of chemotherapeutic agents, cell-cycle 
inhibitors and vectors encoding for siRNAs (MacDiarmid et al., 2009; MacDiarmid et al., 2007a; 
MacDiarmid et al., 2007b). To date, targeting of minicells to specific cell-types (i.e. tumor cells) 
has been achieved using bispecific antibodies, in which one arm recognizes a component of 
the minicell surface (i.e. LPS), and the other a cell surface receptor specific for the targeted 
mammalian cell (i.e. EGFR). However, this system suffers an important limitation because 
bispecific antibodies have to be designed, expressed, purified and chemically linked to the 
minicells, which leads to a time consuming and expensive procedure.  
These reports prompted us to investigate whether the expression of SAs could be maintained 
on the surface of E. coli minicells. In addition, we wanted to generate minicell producer strains 
with reduced immunogenicity, in order to create safer minicells for therapeutic purposes. To this 
end, we selected the EcM1Δfli strain as minicell-producer strain, since it is deficient for the 
expression of FimH and flagellar proteins FliC (flagellin) and FliD (flagellar cap protein), which 
are major inducers of innate immunity against bacteria through the activation of Toll-like 
receptors 4 (FimH) (Mossman et al., 2008) and 5 (FliC) (Hayashi et al., 2001). To further 
reduce immunogenicity, we also deleted the msbB (lpxM) gene from the chromosome of 
EcM1Δfli strain, using the suicide plasmid pGEmsbB. Inactivation of msbB (lpxM) gene results 
in the synthesis of an altered LPS with a penta-acylated lipid A that has a reduced ability to 
stimulate innate immunity through the activation of Toll like receptor 4 (Somerville et al., 1999). 
The msbB (lpxM) gene deletion in EcM1Δfli bacteria generated a strain termed in EcM1Δfli 
ΔmsbB. Subsequently, the acylation pattern found in the lipid A of purified LPS samples from 
EcM1Δfli ΔmsbB and EcM1Δfli strains was compared by mass spectrometry (Fig. 33). Results 
showed a decrease in the mass of lipid A purified from EcM1Δfli ΔmsbB strain, compatible with 
the predicted penta-acylated lipid A caused by msbB (lpxM) gene deletion, instead of the hexa-
acylated lipid A found in EcM1Δfli bacteria. Mass spectrometry analyses were carried out in 
collaboration with the group of Prof. Jose Antonio Bengoechea at the Fundación Caubet-
Cimera, Mallorca, Spain. 
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Figure 33. Mass spectrometry analysis of purified lipid A from EcM1Δfli and EcM1Δfli ΔmsbB  
strains. Negative ion MALDI-TOF mass spectrometry spectra of lipid A purified from the indicated strains. 
The results are representative of three independent lipid A extractions. 
 
To obtain a minicell-producer strain, the genes minCD were deleted from the chromosome of 
EcM1Δfli ΔmsbB strain using the suicide vector pGEminCD-AmpFRT. The minC and minD 
genes together with minE, whose deletion results lethal for E. coli, conform the Min system, 
which drives the position of the Z ring at midcell, inhibiting the formation of division septum 
away from there (Lutkenhaus, 2007). The minicell-producer strain derived from of EcM1Δfli 
ΔmsbB bacteria was termed EcMini. In addition, the plasmid pGEminCD-AmpFRT was also 
recombined in wildtype E. coli MG1655 to generate the strain EcMini-WT. 
 
6.2 Purification of minicells and expression of SAs on their surface. 
SAs binding GFP and EGFR were integrated in the chromosome of the minicell-producer strain 
EcMini, using vectors pGEflu-SAgfp and pGEflu-SAega respectively. The final minicell-
producer strains that constitutively produce SAs against GFP or EGFR were named EcMini-
SAgfp and EcMini-SAega, respectively. 
Minicells were purified from cultures of EcMini-WT, EcMini-SAgfp and EcMini-SAega strains by 
mean of procedure consisting mainly in several differential centrifugations and density gradient 
centrifugations that isolate minicells (Fig. 34A), followed by a short gentamicin treatment to kill 
any residual bacteria.  
Purified minicells were free of viable bacteria as no CFU was detected after plating purified 
minicell samples (data not shown). Importantly, minicells purified from EcMini-SAgfp and 
EcMini-SAega strains maintained the expression of SAs on their surface, as was demonstrated 
by immunofluorescence with anti-myc mAb and anti-mouse IgG-Alexa 488 (Fig. 34B). 
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Figure 34. Purification of minicells displaying SAs on their surface. (A) Density gradient 
centrifugation of a minicell enriched culture of EcMini-SAega. The fraction containing minicells is marked 
with a red circle. (B) Brightfield and fluorescence images of purified minicells Mini-WT, Mini-SAgfp and 
Mini-SAega purified minicells. After their purification minicells were stained with anti-myc mAb and anti-
mouse IgG-Alexa488 to demonstrate the expression of SAs on their surface. 
 
Minicell purifications from EcMini-WT and EcMini-SAgfp cultures were analyzed by 
transmission electron microscopy (TEM). Inspection of the samples revealed the massive 
presence of fimbrial and flagellar contaminants in the minicells obtained from EcMini-WT strain, 
whereas minicells obtained from EcMini-SAgfp strain were free of fimbriae and flagellar debris 
(Fig. 35). 
 
 
Figure 35. TEM images of Mini-WT and Mini-SAgfp minicells. Purified minicells from EcMini-WT (left) 
and EcMini-SAgfp (right) bacterial strains were mounted in copper-collodion grids and stained with 
phosphotungstic acid for TEM. 
 
6.3 Adhesion of engineered minicells to target tumor cells. 
We tested whether SAs expressed on minicells could drive their adhesion to target tumor cells 
expressing on their surface the antigen recognized by the SA. To this end, we performed in 
vitro assays, in which Her14 cells (EGFR positive) were incubated with Mini-SAega or Mini-
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SAgfp minicells (MOI 1000:1). After 4 h of incubation at 37 ºC, unbound minicells were washed 
with PBS and samples were fixed and stained with anti-E. coli polyclonal antibodies, anti-EGFR 
mAb, and DAPI for its visualization by fluorescence microscopy. The experiment showed high 
numbers of Mini-SAega minicells (red fluorescence) adhered to Her14 cells expressing human 
EGFR (green fluorescence), whereas only few Mini-SAgfp minicells were visualized on the 
surface of these cells (Fig. 36A). 
Additionally, as a control for specificity 3T3#2.2 cells (negative for EGFR) were incubated as 
above with Mini-SAega minicells. Inspection of the sample revealed few minicells (red 
fluorescence) on the surface of 3T3#2.2 cells (Fig. 36B). 
 
Figure 36. Specific adhesion of minicells expressing SAs to target tumor cells. (A) Confocal 
microscopy images of Her14 cells incubated for 4 h at 37 ºC with Mini-SAega (top panels) or Mini-SAgfp 
(bottom panels) (MOI 1000:1). Minicells were stained with anti-E. coli polyclonal serum and anti-rabbit 
IgG-Alexa594 (red), EGFR was stained with anti-EGFR mAb and anti-mouse IgG-Alexa-488 (green), cell 
nuclei and bacterial chromosomes were stained with DAPI (blue). (B) Confocal microscopy images of 
3T3 #2.2 cells incubated with Mini-SAega minicells and stained as in A. Scale bars (white lines) showed 
on merge pictures represent 10 µm. 
 
Taken together, these results demonstrated that minicells purified expressing functional SAs on 
their surface are able to adhere to target tumor cells. 
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Bacterial adhesion mediated by SAs. 
Programming adhesion capacities of engineered microorganisms is an important aspect for 
synthetic biology (Moe-Behrens et al., 2013). In this work we took advantage of the fact that 
antibodies and bacterial adhesins share a common folding structure based on Ig domains 
(Bodelon et al., 2012) to anchor antibody fragments to the surface of E. coli as SAs. Antibody 
surface display has been employed to create and adhesion module that directs E. coli adhesion 
at will, and fulfills most of the desirable conditions for a genetic module or device (Porcar et al., 
2011). 
We have engineered a stable and specific adhesion of E. coli bacteria with SAs based on the β-
domain of Intimin (Fairman et al., 2012) and the Ig-domain from VHHs (Muyldermans, 2013). 
Importantly constitutive expression of SAs from the chromosome did not affect growth and 
viability of the engineered E. coli strain, being stably maintained and inherited through multiple 
bacterial generations without selection pressure. In addition the modular architecture of SAs 
makes possible a simple modification of their specificity by an exchange of the VHH sequence, 
which can be selected from repertoires employing phage and cell display technologies in E. coli 
(Muyldermans, 2013; Salema et al., 2013). This allows the generation of SAs against virtually 
any antigen of interest, enabling the design of a programmable E. coli adhesion to any chosen 
surface or cell. Previous works have displayed antibody fragments on the surface of E. coli with 
various systems (Bodelon et al., 2012) such as lipoprotein fusions (Francisco et al., 1993) or β-
domains of autotransporters (Marin et al., 2010) with the objective of screening libraries of 
antibody-fragments and the subsequent identification of high affinity clones against an antigen 
of interest. Nevertheless, programmable adhesion of E. coli bacteria to target surfaces or cells 
has not been reported with those systems. Lipoprotein fusions severely disturb the integrity of 
bacterial OM causing significant leakiness that threat bacterial viability (Georgiou et al., 1996), 
whereas β-domains of autotransporters are prone to proteolysis as part of their secretion 
system. In contrast, the expression of SAs reported in this work is well-tolerated by E. coli 
through multiple generations and the components selected for SAs construction (i.e. β-domain 
of Intimin and VHHs) are resistant to proteases and denaturant agents (e.g. SDS, urea, 
temperature) (Bodelon et al., 2009; Muyldermans, 2013). Altogether these properties make 
SAs extremely robust, inducing the stable attachment of a great number of E. coli bacteria to 
the targeted surface or cell.  
Adhesion mediated by SAs is a fast and effective process that in most cases takes place in less 
than 30 s from the initial contact of a swimming bacterium with the target cell. After this contact, 
bacteria move and tumble close to the target cell surface, which resembles a “scanning” 
process, until active movement is stopped and a phenotype of permanent attachment to the cell 
DISCUSSION 
 116 
is established. In contrast, when the initial contact is made with a non-target cell, the scanning 
process ends with the bacterium swimming in a different direction away from the cell.  
Interestingly, the bacterial behavior observed upon SAs-mediated adhesion to target cells 
suggests that engineered bacteria are able to sense the productive adhesion and transduce 
that signal to stop flagella, mimicking what happens in natural adhesion processes. It is clear 
that motility and adhesion are mutually exclusive events. Although the mechanism by which 
microbes sense and respond to the contact with a cell or surface are poorly understood, it is 
widely accepted that transition from motile to sessile bacteria is a fast process, that therefore is 
probably mediated by post-translational mechanisms. In fact c-di-GMP, a global second 
messenger in bacteria, has been proposed as a key factor in the switching between motile to 
sessile lifestyles (Boyd and O'Toole, 2012). Current hypothesis propose that enzymes that 
maintain steady state levels of c-di-GMP somehow sense that bacteria are in close proximity to 
a cell or surface, which leads to an increase in intracellular c-di-GMP levels and impairment of 
flagellar rotation mediated by YcgR bound to c-di-GMP. Several studies have tried to determine 
the exact flagellar component that interacts with YcgR, and how this interaction affects motility 
(Boehm et al., 2010; Fang and Gomelsky, 2010; Paul et al., 2010). However the role of the 
interaction between YcgR and flagellar components in the development of a stable adhesive 
phenotype has not been demonstrated. We hypothesized that a strain lacking ycgR gene might 
show an impaired adhesion, since although it would sense proximity to target cells, it might be 
unable to stop flagella. However, our data showed that adhesion to target cells of E. coli 
expressing SAs but lacking YcgR is not impaired, suggesting that, at least in E. coli, other 
proteins should be involved in the arrest of bacterial motility upon adhesion. Indeed, it has been 
demonstrated that, at least in Salmonella, the cellulose synthesized by BcsA protein interfere 
with flagellum functionality through steric hindrance in a c-di-GMP dependent manner 
(Zorraquino et al., 2013), given that BcsA together with YcgR seems to be the only proteins 
found in enterobacteria that have a conserved c-di-GMP binding domain (i.e. PilZ) (Amikam 
and Galperin, 2006). However this second mechanism inhibiting flagellar motility in the 
transition between motile and sessile lifestyles it is likely to need more time to be effective than 
that observed in our experiments. Therefore we believe that additional mechanisms might be 
controlling the initial bacterial response to adhesion and the arrest of motility.  
The fast and efficient adhesive phenotype conferred by SAs expression was also used to 
evaluate the influence that active motility has during the adhesion of bacteria to target cells. 
Our data indicated that active motility dramatically improves the adhesive phenotype of 
engineered bacteria. The number of bacteria adhered to target cells was determined for two 
isogenic E. coli strains that only differs in the expression of FliC and FliD flagellar components. 
Engineered E. coli strain lacking FliC and FliD showed a reduced adhesion to target cells 
compared with the isogenic E. coli strain producing functional flagella. Since our experiment 
DISCUSSION 
 117 
was carried out under static conditions the differences found could be assignable to a positive 
effect of motility for contacting a target cell. However a study of bacterial adhesion to glass 
surfaces under continuous flow conditions, which ensured similar scanned area for both motile 
and non-motile bacteria, revealed that non-motile bacteria adhered in a rate five times slower 
than the one found for motile bacteria (McClaine and Ford, 2002). These data suggest that 
active bacterial motility mediated by flagellar rotation may have a positive role in the 
development of an efficient adhesion phenotype, not only by increasing the possibilities to find 
a target, but also by strengthening the interaction between bacteria and target cell. 
 
Tumor targeting capabilities improved by SAs expression. 
We have demonstrated the functionality of SAs to drive the adhesion of E. coli to antigen-
coated surfaces and mammalian cells in vitro. Further, we have demonstrated the functionality 
of SAs in vivo showing that the engineered E. coli strain with SAs colonizes more efficiently 
solid tumors expressing a target cell surface antigen. Interestingly, in our study a clear 
improvement in tumor colonization was observed when bacteria are administered at low doses 
(i.e. 105 CFU) and carry SAs against antigens present on the surface of tumor cells. However, 4 
days post-infection all tumors that were colonized by bacteria, irrespective of the dose or the 
administered strain, showed similar bacterial titers and intra-tumoral distribution. These data 
suggest that bacteria expressing SAs have and advantage to colonize tumors at the initial 
stages of colonization, likely by adhering to tumor cells, but once bacteria succeed at this early 
stage of colonization SAs appear to have less influence in the replication and intra-tumoral 
distribution of bacteria at later stages of colonization. 
The natural ability of bacteria for tumor colonization has encouraged the development of 
several bacterial therapies to treat tumors (Lee, 2012). Indeed, an attenuated Salmonella strain 
termed VNP-2009, was administered sistemically to treat melanoma patients in a phase I 
clinical trial (Toso et al., 2002). Unfortunately, the study highlighted the trade-off between safe 
and effective dose, since at the highest dose that was well tolerated, less than 20% of patients 
showed tumor colonization by VNP-2009, whereas the use of higher doses was associated with 
side-effects such as anemia, hyperbilirubinemia, thrombocytopenia, diarrhea and nausea 
among others. In our work, the higher efficiency in tumor colonization showed by bacteria 
expressing SAs allowed a significant reduction (ca. two-orders of magnitude) of the bacterial 
dose needed for optimal tumor colonization in vivo. In addition, we have found that the 
engineered E. coli strain is retained at lower levels than the wild-type strain in non-target 
organs such as liver or spleen. This phenotype might be due to due to the deletion of natural 
adhesins in the engineered strain (i.e. Type 1 fimbriae, Antigen 43 and Mat fimbriae) that have 
the potential to bind receptors (e.g. glycan residues) widely expressed on the surface of several 
host tissues (Kline et al., 2009). Hence, expression of SAs into an E. coli chassis lacking a set 
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of natural adhesins generates engineered bacteria with selective adhesion to target tissues and 
lower adhesion to healthy non-target organs. This approach could solve some limitations in 
terms of biosafety and tumor colonization effectiveness that came up in clinical trials with 
Salmonella strains. In addition, other bacterial-based therapeutic approaches for tumor therapy 
could benefit from SAs, such as the expression of therapeutic proteins within the tumor (Ganai 
et al., 2009), the localized conversion of prodrugs to drugs (Cheng et al., 2008), or the delivery 
of plasmids for gene therapy (Xiang et al., 2006). We think that although intravenous 
administration of bacteria to treat tumors has reached clinical trials, other routes of bacterial 
administration could be more suitable to carry out an effective cancer therapy, such as oral 
administration for gastrointestinal tumors or urethral administration for bladder cancer. The 
utility of SAs in bacteria administered in any of these ways probably overcomes the one 
showed for intravenous administration since without blood flux, active adhesion seems to be a 
key factor for tumor colonization.  
Currently, intra-vesicle administration of BCG bacteria is approved as an standard treatment for 
high-grade, non-muscle invasive bladder cancer (Gandhi et al., 2013). Apparently, the 
presence of BCG in bladder triggers a strong local immunological response leading to tumor 
cells destruction. However, BCG therapy is not free of undesired side-effects ranging from 
discomfort, ache, fever and hematuria to life-threatening by fatal sepsis (Lamm et al., 1992). It 
is likely that a more targeted therapy based on SAs against specific markers on bladder tumor 
cells could improve current treatment of bladder cancer. 
Tumor cells often deregulate the expression and/or post-translational modification of cell 
surface proteins (e.g. growth factor receptors, mucins) (Hanahan and Weinberg, 2011), 
allowing their use as specific targets for therapeutic antibodies (Vacchelli et al., 2014). Hence, 
SAs could be constructed against these validated targets in order to improve the colonization of 
specific tumors by engineered E. coli strains. 
During the development of this work, a modified Salmonella strain termed AT-Salmonella 
displaying a VHH against CD20 antigen marker of lymphomas was reported (Massa et al., 
2013). The strain also expressed HSV-TK in order to locally convert ganciclovir into a GTP 
analogue that induces apoptosis once it is incorporated in DNA. It should be mentioned the 
VHH against CD20 was obtained from a naïve library (i.e. constructed from non-immunized 
animals) (Monegal et al., 2009), without any step of affinity maturation, which resulted in the 
isolation of a clone that binds CD20 with low affinity as can be inferred from the weak bacterial 
adhesion observed in in vitro adhesion assays to target cells. In addition, the display of the 
VHH molecule was achieved by fusion to a truncated version of OprL lipoprotein, lacking the 
characteristic stability whole β-barrels OMPs. The reported toxicity exerted by the expression of 
this truncated lipoprotein (Cote-Sierra et al., 1998), could be responsible of the diminished 
ability of AT-Salmonella-CD20 strain to adhere and invade non-target cells in vitro, compared to 
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the parental AT-Salmonella strain. Lastly, expression of both VHH-lipoprotein and HSV-TK was 
controlled from inducible plasmids that could be lost during in vivo experiments. In spite of all 
these limitations, AT-Salmonella-CD20 strain expressing HSV-TK was quite successful in 
mediating significant reduction in tumor volume when coadministered with ganciclovir. 
Therefore, it is likely that a better targeting based on SAs might improve this therapy.  
 
Short-term transcriptional response of E. coli upon adhesion mediated by SAs. 
We also investigated the global transcriptional response of E. coli in the transition from motile to 
sessile lifestyle in a model of adhesion to tumor cells. In addition to the basic interest for 
understanding bacterial adhesion to mammalian cells our study could be of interest for 
biotechnological applications (e.g. specific activation of therapeutic or reporter genes in the 
bacteria upon specific cell contact). We took advantage of the fast, specific and efficient 
adhesive phenotype exhibited by bacteria expressing SAs to analyze which transcriptional 
changes take place immediately after adhesion of E. coli bacteria to target tumor cells. 
Several groups have studied long-term transcriptional response upon bacterial adhesion, in 
order to understand bacterial adaptation to biofilm development (Beloin et al., 2003; Domka et 
al., 2007; Hancock and Klemm, 2007; Ren et al., 2004; Schembri et al., 2003). However, to our 
best knowledge only a single study had addressed the short-term impact that E. coli adhesion 
mediated by Type 1 fimbriae has in global gene regulation, using as substrate for adhesion 
agarose beads coated with mannose and setting 1 hour as the time-point analyzed (Bhomkar 
et al., 2010). 
In our study we analyzed the transcriptional response of E. coli bacteria after infecting 
mammalian cells for 15 minutes. The time point selected for the analysis allows to measure 
early transcriptional responses related with adhesion rather than with first stages of biofilm 
development. This short time may also help to obtain a more homogeneous transcriptional 
response in the bacterial population. Given the massive adhesion phenotype of E. coli with SAs 
we employed a lower MOI (i.e. 100:1) to minimize transcriptional changes in response to 
bacterial density instead of adhesion. 
In our study, analysis of the transcriptional response of bacteria was performed in two different 
experimental models involving adhesion to mammalian cells that express human EGFR (i.e. 
Her14 cell line) or GFP-tm (i.e. HeLa-GFP-tm cells) on their surface. The combination of both 
models allowed the finding of the transcriptional program that bacteria activate upon binding, 
independently of the recognized receptor or the origin of the mammalian cell line (murine or 
human). 
Our data showed that most of the genes that are upregulated upon binding are common to both 
experimental models, supporting the existence of a genetic program that is activated upon 
binding independently of the target. Most of the upregulated genes (i.e. cysP, cysD, yeeE) are 
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involved in the assimilatory reduction of sulfate, which probably leads to an increased 
production of the amino acid cysteine. Production of the tripeptide glutathione (γ−glutamyl-
cysteine-glycine) is limited by the availability of its three amino acids components. Glutathione 
is essential to maintain the redox balance of the bacteria since glutaredoxin use reduced 
glutathione (GSH) as cofactor to reduce oxidized proteins. Thus, it seems that adhesion to 
target cells triggers a state of oxidative stress in bacteria that is balanced through the 
overexpression of genes involved in Glutathione biosynthesis. Interestingly, expression of gene 
encoding for glutaredoxin 1 (grxA) was also upregulated in the model involving adhesion to 
EGFR, and this upregulation was also found in the DNA microarray validation (data not shown). 
No statistical significant data was obtained for this gene in the model involving adhesion to GFP. 
Glutaredoxin 1 catalyzes the reduction of oxidized proteins in a Glutathione dependent manner 
and its expression is regulated by the OxyR cysteine-based redox sensor. Therefore 
upregulation of grxA gene agrees with the oxidative stress that seems to take place upon 
bacterial adhesion. Actually, it is known that E. coli as well as many other bacteria have 
mechanosensitive channels that adopt distinct conformational states in response to applied 
tension in the membrane (Busscher and van der Mei, 2012). In fact, it has been proposed that 
bacterial adhesion leads to a membrane stress that triggers a switch from the close to the open 
conformational state of mechanosensitive channels, allowing in that way the flow of solutes 
across the membrane in a tension-dependent manner (Haswell et al., 2011). Thus, it is likely 
that this transitory flow of solutes could disbalance the bacterial redox state of bacteria, which 
could explain the transcriptional changes observed in E. coli upon adhesion. Alternatively, the 
fact that tumor cells have increased levels of reactive oxygen species (ROS) (Nogueira and 
Hay, 2013) might also explain the oxidative stress that seems to take place in E. coli upon 
adhesion to target tumor cells. However, this second hypothesis seems less feasible since 
bacterial adhesion to mannose-coated agarose beads instead of tumor cells also induce the 
upregulation of genes involved in the assimilatory reduction of sulfate (i.e. cysD, yeeE) and 
reduction of oxidized proteins (i.e. grxA) (Bhomkar et al., 2010).  
Our data also showed that the expression of some genes is inhibited upon contact, however 
this downregulation in gene expression does not seem to be as homogenous as the 
upregulation is, since both experimental models show modest overlapping. Among the genes 
whose expression appear to be downregulated in response to adhesion independently of the 
experimental model analyzed, we found genes involved in tryptophan synthesis and transport, 
as well as genes encoding for IM transporters of several carbohydrates, such as glycerol, 
ribose, citrate and C4 dicarboxilic acids. dctA gene encodes for a transporter protein that 
mediates the uptake of orotate, an intermediary metabolite of the pyrimidines synthesis 
pathway, as well as citrate and several C4 dicarboxilic acids (i.e. malate, fumarate) that could 
act as intermediary metabolites of the Krebs cycle. dctA gene product mediates transport of 
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these molecules under aerobic conditions since an alternative transport system termed Dcu is 
employed under anaerobic conditions (Davies et al., 1999). Ugp operon includes genes 
involved in the uptake of glycerol-3-phosphate (G3P) and glycerophosphodiesters that can be 
later degrade to G3P an essential precursor for de novo synthesis of glycerophospholipids that 
constitute membranes (Ohshima et al., 2008). rbsA gene encodes for a ATPase that transports 
ribose across the IM (Lopilato et al., 1984).  
Interestingly, most of the genes whose expression is altered upon adhesion to mammalian cells 
are associated with metabolic activities rather than with cell surface or cell structure 
composition. This might be explained by the fact that bacterial adhesion involves loss of cell 
mobility and a reduction in the bacterial surface area available to interact with the environment. 
Together, these 2 events, that are inherent to bacterial adhesion, limit bacterial capacity to 
uptake oxygen and nutrients, which may exert a pressure to modify some metabolic pathways.  
Congruently with our vision of synthetic biology and bacterial engineering, we wanted to test 
whether the identified promoters responding to adhesion may help us to develop a genetic 
circuit able to program bacterial behavior in response to adhesion. Common inducible 
promoters respond to nutrients (e.g. PBAD by Arabinose) (Guzman et al., 1995), nutrient 
analogues (Ptac/Plac by IPTG) (de Boer et al., 1983), antibiotics analogues (Ptet by 
anhydrotetracycline) (Skerra, 1994) or small molecules (Psal by salycilate) (Royo et al., 2007). 
However it is noticeably the lack of promoters that are induced by a switch in the physiological 
state of bacteria as for instance, the transition from motile to sessile bacteria. Promoters 
upregulated in the adhered bacteria could represent the basis for the generation of a genetic 
circuit responding to this transition. We constructed six strains carrying SAs against EGFR and 
having the mCherry gene cloned downstream the promoter regions of six genes whose 
expression was found upregulated upon adhesion (i.e. ldhA, yeeE, cysP, cysD, fruB and ydjN). 
The strategy followed allowed site-specific integration of the reporter gene, maintaining a wild 
type copy of the gene. One of the reporter strains constructed (i.e. yeeE gene promoter 
reporter strain) showed an specific induction of mCherry gene expression upon adhesion to 
mammalian cells, although the induction was detectable only in a small percentage of bacteria. 
The rest of the reporter strains did not show any detectable expression of mCherry upon 
adhesion. Despite these data, it cannot be discarded that an induction of mCherry expression is 
taking place upon adhesion, since the selected promoters could be controlling the expression 
of genes that are naturally transcribed at low rates. An increased transcription from these 
promoters after adhesion, may lead to the generation of an insufficient number of mCherry 
molecules to obtain a detectable fluorescent signal. The reporter strain carrying the genetic 
fusion PyeeE::mCherry show an adhesion-dependent increase of red fluorescence. However 
the behavior was not homogenous in all bacterial population, as only a small percentage of 
adhered bacteria showed red fluorescence. These data might be revealing a major limitation of 
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massive transcriptional analysis such as RNAseq or microarrays since both techniques 
provides a huge amount of data that represents the mean of all analyzed bacteria. 
Upregulations or downregulations in gene expression found by these techniques, explain the 
global behavior of the whole bacterial population, missing valuable information about 
heterogeneity in bacterial responses.  
 
Minicells adhesion directed by SAs. 
We have demonstrated that SAs are also effective to drive the adhesion of non-live 
nanoparticles derived from bacteria (i.e. minicells) toward target cells. Previously, minicells 
derived from Salmonella enterica serovar typhimurium were used for the localized delivery of 
chemotherapeutics (MacDiarmid et al., 2007b), cell cycle inhibitors (MacDiarmid et al., 2007a), 
or siRNAs (MacDiarmid et al., 2009) to tumor target cells. The Australian company EnGeneIC 
(http://www.engeneic.com/index.html) has recently completed a Phase I first-in-man clinical trial 
that proved the safety of minicells as therapy vehicles. A weak point in the development of 
these minicells is that the tumor targeting was carried out using bispecific antibodies, in which 
one arm recognize the surface of the minicell and the other an antigen expressed on the 
surface of the tumor cell. This requires a complex composition, with at least three molecular 
entities that should be combined, which turns the production into a costly and difficult process.  
In our work we have improved the production of minicells generated from an E. coli strain 
devoid of major immunogenic components (i.e. Type 1 fimbriae, flagellin, hexa-acylated lipid A) 
that is endogenously expressing SAs against EGFR on the surface. Minicells purified from this 
strain are free of major bacterial components causing immunogenic response in patients and in 
addition carry functional SAs that bind tumor cells expressing EGFR. However, although an 
effective targeting of EGFR+ tumor cells was achieved with minicells, it required the use of 
longer infection times (4 h) and higher infective dose (MOI 1000:1) than those used with live 
bacteria. Likely this limitation is related with the non-motile phenotype of minicells that limits the 
possibilities to contact with a target cell. In fact this low level adhesion phenotype was also 
observed with non-motile live bacteria, as discussed above. 
 
To conclude, in this work we have designed SAs that drive the adhesion of live E. coli and 
derived nanoparticles at will. Additionally, we have characterized the transcriptomic response of 
E. coli in response to adhesion. Given the modularity of SAs and the possibility of generate 
VHHs against different targets (De Meyer et al., 2014; Vincke et al., 2012), this technology 
offers multiple potential applications beyond the improved tumor targeting that has been 
demonstrated in vivo. 
For instance, SAs could help in the localized delivery of antigens to specific immune cells or 
tissues (Owen et al., 2013) for more effective vaccines based on bacterial vectors (Bolhassani 
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and Zahedifard, 2012). Tailored probiotics could be constructed with SAs, facilitating the 
therapeutic intervention of bacteria (Sartor, 2005). In addition SAs could be targeted to antigens 
expressed by viral and bacterial pathogens on their own surface or on the surface of infected 
cells, facilitating the intervention of engineered bacteria against pathogens (Hwang et al., 2013).  
Industrial applications could be also envisioned for SAs technology, such as the generation of 
defined bacterial consortia for certain industrial processes (Minty et al., 2013). In addition 
adhesion of bacteria to metal plastics and other abiotic surfaces could improve the 
development of biosensors (Park et al., 2013), as well as more efficient bioreactors retaining 
bacterial biomass (Kalyanpur, 2002). 
Given the conservation of cellular machineries used for folding and insertion of β-barrel OM 
proteins (Noinaj et al., 2013), it is likely that SAs could be functional in other Gram-negative 
bacterial species, including alternative non-pathogenic bacterial chassis commonly used in 
synthetic biology such as Pseudomonas putida (Martinez-Garcia and de Lorenzo, 2011). In 
conclusion, future work on SAs technology should expand its use in E. coli and other bacterial 
chassis for specialized biomedical, industrial and environmental applications. 
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1- Synthetic Adhesins that are able to drive an effective and specific adhesion of E. coli 
bacteria to a target surface or cell, can be constructed as protein fusions between the outer 
membrane anchoring β-domain of Intimin, residues 1 to 659 of wild type Intimin from EHEC, 
and one adhesive Ig domain based on VHHs from camelid heavy-chain antibodies 
recognizing a specific antigen on the target surface or cell. The modular structure of the 
SAs enables to program the adhesion of E. coli toward different target surfaces or cells by 
the simple exchange of the VHH sequence, which can be selected with the desired 
specificity from large VHH repertoires cloned in E. coli. 
 
2- Constitutive expression of SAs from the chromosome of E. coli does not affect bacterial 
growth or viability, being stable maintained through multiple bacterial generations. The 
expression of SAs in an E. coli strain having deletions in several major natural adhesins 
(i.e. Type 1 fimbriae, Antigen 43 and Mat fimbriae) allows the specific adhesion of E. coli 
bacteria to target cells expressing a specific protein antigen on their surface.  
  
3- Adhesion of E. coli mediated by SAs is a fast and very effective process that, at least in 
vitro, is enhanced by the presence of active bacterial motility. We have observed that, 
immediately upon contact with the target cell surface, the active motility mediated by 
flagella is stopped by an uncharacterized signaling mechanism that does not require the 
presence of YcgR protein.  
 
4- Functionality of SAs in vivo was demonstrated by testing the efficiency of E. coli wild type 
strain and engineered strains expressing SAs, in the colonization of solid tumors implanted 
subcutaneously in mice. After systemic administration of different bacterial doses in tumor-
bearing mice, we showed that the engineered E. coli strain, lacking major natural adhesins 
and expressing SAs, efficiently colonized solid tumors expressing on the surface of the 
tumor cells an antigen recognized by the SA. Significant lower doses of the engineered 
strain were required to colonize >90% of the target tumors (i.e. 2% of the dose required for 
the same level of tumor colonization with wild type E. coli strain or an engineered strain 
expressing a control SA that does not recognize the tumor cell). 
 
5- The engineered E. coli strain expressing SAs and lacking natural adhesins is retained at 
lower levels in non-target organs such as liver and spleen, increasing the specificity and 
biosafety of its systemic administration.  
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6- The fast and specific adhesion of engineered E. coli bacteria expressing SAs allowed us to 
characterize by RNAseq the global transcriptomic changes taking place in E. coli after 15 
min of adhesion to target tumor cells, which revealed a common transcriptional response 
independently of the recognized target. We found that genes related to sulfur uptake and 
its metabolism (e.g. cysD, yeeE etc) are upregulated upon bacterial adhesion, whereas 
genes encoding transporters of amino acids (i.e. mtr), of carbohydrates (i.e. ugpE, rbsA 
etc) and of intermediary metabolites of the Krebs cycle (i.e. dctA) are downregulated. 
 
7- Gene fusion between the mCherry reporter gene and the promoter region of yeeE gene, 
integrated in the chromosome of E. coli, allowed us to confirm the activation of this 
promoter upon bacterial adhesion to target tumor cells. Activation of this promoter upon 
adhesion could provide the basis for the generation of an E. coli genetic circuit responding 
to specific adhesion. 
 
8- We have produced and purified non live bacterial nanoparticles termed minicells, derived 
from an E. coli minCD mutant strain lacking major immunogenic antigens (i.e. Type 1 
fimbriae, flagellar filament and hexa-acylated lipid A), which express functional SAs on 
their surface. SAs against a relevant therapeutic target (i.e. EGFR) allowed the specific 
adhesion of these nanoparticles to target tumor cells.  
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1- Adhesinas sintéticas capaces de dirigir de manera efectiva y específica la adhesión de E. 
coli hacia superficies o células diana, pueden ser construidas como proteínas de fusión 
entre el dominio β de anclaje a membrana externa de Intimina (aminoácidos 1-659 de la 
secuencia nativa de Intimina en EHEC) y un dominio Ig adhesivo basado en moléculas 
VHH, presentes en los anticuerpos de cadena pesada de los camélidos, que reconozcan 
de manera específica un antígeno presente en la superficie o célula diana. La estructura 
modular de las adhesinas sintéticas permite programar la adhesión de E. coli a diferentes 
superficies o células diana mediante el intercambio de secuencias VHH, que pueden ser 
seleccionadas con la especificidad deseada desde repertorios de VHH clonados en E. coli. 
 
2- La expresión constitutiva de adhesinas sintéticas desde el cromosoma de E. coli no afecta 
el crecimiento bacteriano ni su viabilidad, y se mantiene estable durante múltiples 
generaciones bacterianas. La expresión de las adhesinas sintéticas en una cepa de E. coli 
que carece de varias adhesinas naturales conservadas (fimbrias tipo 1, Antígeno 43 y 
fimbrias Mat) permite la adhesión específica de esta cepa a células  diana que expresan 
en su superficie un antígeno proteico específico.  
 
3- La adhesión de E. coli mediada por adhesinas sintéticas es un proceso muy rápido y 
efectivo que, al menos in vitro, se ve potenciado por la presencia de un sistema de 
motilidad bacteriana activo. Además hemos observado que inmediatamente después del 
contacto con la superficie de una célula diana, la motilidad bacteriana mediada por el 
flagelo se detiene mediante un mecanismo de señalización no caracterizado, que no 
requiere la presencia de la proteína YcgR. 
 
4- La funcionalidad in vivo de las adhesinas sintéticas fue demostrada comparando la 
eficiencia de la cepa silvestre y las cepas modificadas de E. coli, en la colonización de 
tumores sólidos implantados subcutáneamente en ratones. Tras la administración 
sistémica de distintas dosis bacterianas a ratones portadores de tumores comprobamos 
que la cepa modificada de E. coli, carente de muchas de las principales adhesinas 
naturales y que expresaba adhesinas sintéticas, colonizaba de modo muy eficiente 
tumores sólidos que expresaban en la superficie de sus células el antígeno reconocido por 
la adhesina sintética.  Para obtener una colonización efectiva en mas del 90% de los 
tumores se requirió una dosis bacteriana de la cepa modificada significativamente menor 
(2%) que la requerida para alcanzar un eficiencia similar de colonización con la cepa 
silvestre de E. coli o con una cepa control que expresaba adhesinas sintéticas frente a otro 
antígeno no expresado por el tumor. 
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5- La cepa de E. coli modificada, carente de las principales adhesinas naturales y que 
expresa las adhesinas sintéticas, presenta in vivo una menor tasa de retención en órganos 
no diana como el hígado o el bazo, incrementando de este modo la especificidad y la 
bioseguridad de su administración sistémica. 
 
6- La rápida y específica adhesión mostrada por las cepas modificas de E. coli que 
expresaban adhesinas sintéticas, nos permitió caracterizar mediante secuenciación 
masiva de ARN los cambios transcripcionales que ocurren en E. coli tras 15 minutos de 
adhesión a células tumorales diana, revelando una respuesta trancripcional común, 
independientemente del receptor reconocido. Encontramos que genes relacionados con  
la asimilación y el metabolismo del sulfato (p.ej. cysD, yeeE. etc.) se sobreexpresan en 
respuesta a la adhesión, mientras que la expresión de genes que codifican para 
transportadores de aminoácidos (mtr), de carbohidratos (ugpE, rbsA) y de intermediarios 
del ciclo de Krebs (dctA) se ve reducida tras la adhesión. 
 
7- La fusión entre el gen de la proteína roja fluorescente mCherry y la región promotora del 
gen yeeE integrada en el cromosoma de E. coli, nos permitió confirmar la activación de 
este promotor tras la adhesión bacteriana a células tumorales diana. La activación de este 
promotor tras la adhesión puede suponer el punto de partida para la generación de un 
circuito genético en E. coli que responda específicamente a la adhesión. 
 
8- Hemos producido y purificado nanopartículas bacterianas no vivas llamadas minicélulas 
desde una cepa de E. coli mutante para los genes minCD y carente de los principales 
antígenos que desencadenan una respuesta inmunológica (fimbrias tipo 1, el filamento 
flagelar, y el lípido A hexa-acilado), que expresan adhesinas sintéticas funcionales en su 
superficie. Las adhesinas sintéticas frente un marcador terapéuticamente relevante 
(EGFR), permitieron la adhesión específica de estas nanopartículas a células tumorales 
diana. 
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